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ABSTRACT 
 
New Synthetic Derivatives of Triterpenoids in the 
Treatment of Cancer. (December 2008) 
Sabitha Papineni, B.V.Sc & AH, College of Veterinary Science, India 
Chair of Advisory Committee: Dr. Stephen H. Safe 
 
Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (β-CDODA-Me) and 
methyl 2-cyano-3,11-dioxo-18α-olean-1,12-dien-30-oate (α-CDODA-Me ) isomers are 
synthetic analogs of the naturally occurring triterpenoid glycyrrhetinic acid. The activity 
of these compounds as selective peroxisome proliferator-activated receptor γ (PPARγ) 
agonists and as cytotoxic anticancer agents has been investigated in colon, prostate and 
pancreatic cancer cells. In colon cancer cells β-CDODA-Me arrested the growth at 
G2/M and this was accompanied by decreased expression of Sp1, Sp3 and Sp4 protein 
and mRNA and several Sp-dependent genes including survivin, vascular endothelial 
growth factor (VEGF), and VEGF receptor 1 (VEGFR1 or Flt-1).  β-CDODA-Me also 
inhibited tumor growth in athymic nude mice bearing RKO cells as xenografts.  β-
CDODA-Me decreased expression of microRNA-27a (miR-27a), and this was 
accompanied by increased expression of two miR-27a-regulated mRNAs, namely 
ZBTB10 (an Sp repressor) and Myt-1 which catalyzes phosphorylation of cdc2 to inhibit 
progression of cells through G2/M.    
In LNCaP prostate cancer cells induction of two proapoptotic proteins namely 
 iv
nonsteroidal anti-inflammatory drug- activated gene-1 (NAG-1) and activating 
transcription factor-3 (ATF-3) was PPARγ independent and required activation of 
kinases. β-CDODA-Me also decreased the levels of androgen receptor (AR) and 
prostate-specific antigen (PSA) mRNA and protein levels. Thus the cytotoxicity of β-
CDODA-Me involved multiple pathways that selectively activate growth inhibitory and 
proapoptotic responses.  
Betulinic acid (BA), an inhibitor of melanoma  is a pentacyclic triterpenoid 
natural product that  induces apoptosis and antiangiogenic responses in tumors derived 
from multiple tissues. However, the underlying mechanism of action of BA is unknown.  
In LNCaP prostate cancer cells, BA acts as a novel anticancer agent by inducing 
proteasome-dependent repression of Sp proteins and Sp- dependent genes. The 
anticancer activity of the 2-cyano substituted analogs of BA, CN-BA and its methyl 
ester, CN-BA-Me was also investigated in colon and pancreatic cancer cells.  Both CN-
BA and CN-BA-Me were highly cytotoxic and activated PPARγ and induced several 
receptor-mediated responses. The results clearly demonstrated that both the PPARγ 
agonist activities of CN-BA and CN-BA-Me were structure-, response-/gene- and cell 
context-dependent suggesting that these compounds are a novel class of selective PPARγ 
modulators with potential for clinical treatment of prostate, colon and pancreatic cancer. 
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CHAPTER I 
INTRODUCTION 
CANCER 
Cancer is a devastating disease and Celsus, a Roman encyclopedist translated 
the term “carcinos” described by Greek Physician Hippocrates, the father of Medicine 
into a Latin term “cancer”. Over 565,650 Americans are expected to die of cancer and 
about 1,437,180 new cancer cases will be diagnosed this year (1). Under normal 
conditions, cells in the body divide in a controlled and regulated manner, however; cells 
that lose this regulation divide continuously without control and may develop into 
cancer. The pathogenesis of cancer is not fully characterized and depending on the type 
of cancer, differs widely in etiology and biology. Cancer is caused by both external 
factors such as exposure to chemicals, UV radiation and infectious agents and internal 
factors which include hormones for breast cancer and prostate cancer, inherited 
mutations/genetic abnormalities and a compromised immune system.  Irrespective of the 
type of cancer, all known cancers are characterized by abnormalities in the genetic 
material that results in abnormal expression of genes and proteins leading to the 
development of cancer. Most importantly, cancer develops when genetic changes affect 
two classes of genes namely, oncogenes and tumor suppressor genes. The first 
oncogenes identified were of viral origin with cellular functions ranging from functional 
roles as transmembrane protein receptors to nuclear transcription factors.  
____________ 
This dissertation follows the style of Cancer Research. 
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These proto-oncogenes are constituitive or normal genes that are activated by mutations 
and enhance cell proliferation and transformation. Tumor suppressor genes regulate cell 
division or apoptosis and are downregulated or repressed in cancer cells.  
Carcinogenesis 
Carcinogenesis, the process of cancer development, is complex and can be 
categorized into five main stages: initiation, promotion, progression, invasion and 
metastases (Fig. 1.1). The first stage of initiation involves accumulation of genetic 
changes or hits in a single cell as suggested by Knudson (2) and Nowell (3). The genetic 
changes or DNA damage can be initiated by ionizing radiation such as X-rays, chemical 
carcinogens such as nitrosamines or viruses like papillomavirus and Epstein-Barr virus.  
Epidemiological studies based on age-dependent cancer incidence suggested that rate of 
tumor development is proportional to  the fourth to sixth power of lifetime indicating 
that four to six independent genetic hits or events are necessary for the development of a 
tumor (4).The association of lung cancer with smoking demonstrated by Cairns et al (5) 
is a well-characterized case illustrating  that the frequency of the tumors in humans is 
proportional to the first or second power of cigarettes per day and to the sixth power of 
the duration of smoking. Several different models have been put forward to characterize 
the process of carcinogenesis including a well-characterized  mouse skin tumor 
promotion model. A single sub-threshold dose of a carcinogen such as 7, 12-
dimethylbenz[a]anthracene administration is followed by the repetitive application of a 
tumor promoter such as 12-O-tetradecanoylphorbol-13-acetate. Benign squamous 
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papillomas generally develop within 10 weeks and contain Ha-ras mutations (6). Only 
few of these papillomas develop into malignant squamous  
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Fig. 1.1.  Five stages of carcinogenesis (7). 
 
cell carcinomas (SCC). The progression of papillomas to SCC has been characterized 
phenotypically by inappropriate expression of certain membrane receptor/adhesion 
molecules (8, 9), keratins (10-13), growth factors (14-16) and cyclins/cyclin-dependent 
kinases(17, 18) and genotypically with respect to alterations in p53 and further 
alterations in Ha-ras (19-23). However cancer cells contain thousands of mutations and 
this finding  has led to the proposal of  a new hypothesis by Loeb called “mutator 
phenotype hypothesis” suggesting that the normal rate of mutations doesn’t correlate 
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with the number of mutations observed in the cancer cells (24, 25). According to this 
hypothesis mutations in the genes involved in the regulation of DNA synthesis, DNA 
repair or in the genes regulating the cell cycle or apoptosis will amplify the basal 
mutation rate and promote the tumor initiation/promotion model to a multihit model of 
carcinogenesis. 
Tumor promotion is the second stage of carcinogenesis, during which a single 
initiatied cell with genetic changes expands clonally and is dependent on the favourable 
conditions  for cellular growth such as interactions between tumor cells and stroma, 
growth factor availability, vascularization, O2 partial pressure and many other factors.  
However DNA damage check points or apoptosis pathways may be induced by genetic 
events resulting from the initiation phase. Fifty percent of human cancers are defective 
in these pathways due to mutations in tumor suppressor genes or genes encoding pro-
apoptotic proteins such as p53 or RB or INK4 locus; and  cancer cells  continue to divide 
(26). There are number of tumor promoting agents such as phorbol esters, phenobarbitol, 
peroxisome proliferators, and biphenyls, many of which  reversibly inhibit the gap 
junctions (27, 28). 
 The third stage of carcinogenesis is tumor progression and a classical example of 
this stage was described by Vogelstein and his colleagues in colorectal carcinogenesis 
which involves successive waves of clonal selection (29). According to this model, 
mutations occur randomly in the genome and selection of major mutated genes results 
from clonal proliferation; and since these cells grow rapidly even  a small growth 
advantage will result in  progeny (30).This stage is characterized by genetic alterations 
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that produce permanent genetic instability with a higher rate of chromosomal or base 
modifications resulting in gross morphological and karyotypic changes that transform  
pre-neoplastic cells into neoplastic cells (Fig. 1.1). In colorectal cancers, there is a good  
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Fig. 1.2. Hallmarks of tumor cells (30). 
 
 
correlation between the allelic imbalance at several loci such as loss of chromosomes 8p 
and 18q and the aggressiveness of the disease measured by disease-free survival at five 
years after surgery (31). 
Invasion is the fourth stage of carcinogenesis and involves progression of 
neoplastic cells to malignant cells; and this is associated with additional gentic and 
epigenetic changes in the tumors and more aggressive characteristics with time. The 
invasion and metastases phenotype of tumor cells is characterized by the ability of these 
cells to attach to  host cells and this may involve extracellular matrix (ECM)  factors. 
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These cells also have the  ability to secrete proteases to lyse barriers such as basement 
membranes in host cells and they can  facilitate tumor angiogenesis in distal sites (32, 
33). To date, the genes involved in this stage of  tumor invasion and metastasis are not 
well defined, however, there is evidence that loss of E-cadherin, a tumor suppressor 
gene, results in rapid progression of gastric adenomas into invasive poorly differentiated 
metastatic carcinomas (34). According to Hanahan and Weinberg (30) there are six 
charactertics or hallmarks that tumor cells acquire during the process of carcinogenesis 
which dictate the fate of the tumor. The hallmarks include self-sufficiency in growth 
signals, insensitivity to anti-growth factors, evasion of  apoptosis, limitless replicative 
potential, sustained angiogenesis and tissue invasion and metastases (Fig. 1.2). 
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Fig. 1.3. Estimated U.S cancer deaths and new cases in 2008 (1). 
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Tumors are classified based on the tissue of origin; in 2008 the American Cancer 
Society (ACS) estimates prostate cancer in men and breast cancer in women will be 
among the leading causes of cancer deaths, second only to lung cancer (Fig. 1.3) (ACS).  
Treatment of cancer 
  The most common types of treatment for cancer include surgery, radiation and 
chemotherapy which can be used either alone or in combination with other therapies. 
The initial treatments given to the patient are called first-line therapy and  treatments 
given after the first line therapy are called adjuvant therapy. Neo-adjuvant therapy is 
given prior to the first-line therapy and this often involves decreasing the tumor size. 
Surgery involves removal of the cancerous tissue and it is the primary treatment for most 
cancers, particularly solid tumors. It is also used as a diagnostic tool to confirm a 
diagnosis and determine the extent and spread of the tumor. Radiation therapy uses high 
energy X-rays to shrink the tumor. Radiation is mostly used in conjunction with surgery 
or chemotherapy or as neoadjuvant therapy to aid in surgery by reducing the size of the 
tumor. and is considered local treatment since it affects only the tumor region. 
Chemotherapy uses chemicals or drugs to kill cancer cells and the effects are systemic. 
There are several different classes of anticancer drugs based on the mechanism of action 
and these include the following: a)  alkylating agents which damage DNA; b) 
antimetabolites that replace the normal building blocks of RNA and DNA; c)  antibiotics 
that interfere with the enzymes involved in DNA replication; d) topoisomerase inhibitors 
that inhibit either topoisomerase I or II which are the enzymes involved in unwinding  
DNA during replication and transcription; e) mitotic inhibitors that inhibit mitosis and  
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cell division; f) corticosteroids which are used  for the treatment of cancer and  to relieve 
the side effects from other drugs; and g) other miscellaneous drugs such as L-
asparaginase, an enzyme used in the treatment of acute lymphocytic leukemia and the 
proteosome inhibitor bortezomib (Velcade)(Table 1.1). Chemotherapy is also used as an 
adjuvant therapy alone or in combination with other treatments. Hormone therapy is 
used for the treatment of endocrine or reproductive related cancers like prostate, breast 
and testicular cancers which develop in part due to dysregulated hormone signals. For 
example Tamoxifen (Nolvadex) is an antiestrogen used for treatment of hormone 
responsive breast cancers.  
 Cytotoxic anticancer drugs attack all rapidly dividing cells in the body, and this 
includes not only cancer cells but also other dividing normal cells such as hair follicles, 
gastric epithelium, and blood cells. Because of these non-specific effects, chemotherapy 
is associated with side effects such as hair loss, nausea, vomiting, fatigue, increased 
sensitivity to infectious diseases and loss of appetite. Hence several new approaches are 
under development to increase the specificity of cancer treatment and some of these 
include biological therapies and targeted therapies. Immunotherapies utilize the body’s 
defense mechanisms by stimulating the immune response against cancer cells. 
Monoclonal antibodies (mAbs) against antigens or specific molecules expressed on the 
surface of cancer cells have been developed and cancer vaccines that make immune cells 
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Table 1.1. Different classes of anticancer drugs 
 
Chemotherapeutic Drugs 
Alkylating agents 
 
      Nitrogen mustards:    Cyclophosphamide (Cytoxan), melphalan, clorambucil,  
                                          mechlorethamine 
 
               Nitrosoureas:     Streptozocin, carmustine (BCNU), and lomustine. 
 
          Alkyl sulfonates:     Busulfan 
 
                      Triazines:     Dacarbazine (DTIC), and temozolomide (Temodar). 
 
              Ethylenimines:    Thiotepa and altretamine (hexamethylmelamine). 
 
            Platinum drugs:   Cisplatin, carboplatin, and oxaliplatin. 
   
 
Antimetabolites      5-Fluorouracil (5-FU), capecitabine (Xeloda), 6-  
                                         mercaptopurine (6-MP), methotrexate,             
                                         gemcitabine (Gemzar), cytarabine (Ara- C), fludarabine, and   
                                         pemetrexed (Alimta). 
Antitumor antibiotics 
 
          Anthracyclines:     Daunorubicin, doxorubicin (Adriamycin), epirubicin, and 
                                        Idarubicin 
 
        Other antibiotic       Actinomycin-D, bleomycin, and mitomycin-C. 
                         drugs:  
 
Topoisomerase inhibitors 
 
      Topoisomerase I       Topotecan and irinotecan 
                inhibitors:    
      Topoisomerase II      Etoposide (VP-16) and teniposide 
                inhibitors: 
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Table 1.1 Continued 
 
 
Mitotic inhibitors 
 
            The Taxanes:       Paclitaxel (Taxol), docetaxel (Taxotere). 
             Epothilones:       Ixabepilone (Ixempra). 
                The Vinca         Vinblastine (Velban), Vincristine(Oncovin), 
                  alkaloids:        and vinorelbine (Navelbine). 
                                            
 Estramustine (Emcyt). 
 
Corticosteroids                 Prednisone, methylprednisone(Solumedrol), and             
                                         dexamethasoneDecadron. 
 
Others                              L-asparaginase and proteosome inhibitor        
                                         bortezomib(Velcade). 
 
 
 
 
recognize cancer cells and kill them are examples of biological treatments. Targeted 
therapies selectively target cancer cells but not normal cells, and this greatly reduces the 
side effects associated with chemotherapy. Targeted therapies include antiangiogenic 
drugs, various enzyme inhibitors, antisense and gene therapy. This approach has been 
expanding to include drugs that are highly specialized and are only effective in treating a 
narrow range of tumors. For example, the tyrosine kinase inhibitor, geftinib, which 
blocks EGFR signaling, is effective only in lung cancer patients that express the 
mutations in the tyrosone kinase domain of EGFR gene (35). Our laboratory has focused  
on  development of such specific molecules which are synthetic derivatives of natural 
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products and these  include betulinic acid, a hydrolysed product of betulin derived from 
birch bark and methyl 2-cyano-3,11-dioxo-18βolean-1,12-dien-30-oate (CDODA-Me), a 
synthetic derivative of glycyrrhetinic acid, a triterpenoid derived from licorice root 
extract. In order to investigate the mechanism of action of these mechanism-based drugs  
in different cell and organ contexts,  four different cancer cell models have been selected 
and are discussed in another section. The cancer models include prostate cancer, a 
reproductive and hormone related cancer in males, colorectal and pancreatic cancer 
which are gastroinstestinal related cancers and esophageal cancer, an aggressive disease 
in which the incidence rate has been increasing significantly in recent years. 
PROSTATE CANCER 
Incidence 
It is  estimated that there will be  186,320 new cases of prostate cancer and about 
28,660 prostate cancer deaths in the US in 2008 (1). The number of cases and deaths 
have significantly increased from 1988-1992 and declined sharply from 1992-1995 and 
have been relatively constant since 1995. For unknown reasons incidence rates are 
higher among African American and Jamaican men when compared to Caucascians. 
Worldwide, the disease is common in Northern America and northwestern Europe, but 
less common in Asia and South America (1). 
 Both benign prostatic hypertrophy (BPH) and prostate cancer incidence rates are 
negligible or not detected in eunuchs and have been linked to the presence of testes and 
androgen function (36, 37). Autopsy studies indicate that approximately 70% of  men 
  
 
12
who died of other diseases had prostate cancer at the time of their death but most of 
these cancers were clinically insignificant (38). 
Development of prostate gland 
The prostate gland is a male specific reproductive organ that develops before 
birth and continues to grow until the end of puberty. Growth and development of the 
prostate gland is androgen dependent (39) and androgens elicit their effects on the 
prostate via binding to the androgen receptor (AR), present in the fetal urogenital sinus 
mesenchyme (UGM). Mesenchymal and epithelial interactions play a critical role in the 
prostatic development.  UGM induces ductal morphogenesis, expression of the epithelial 
AR, regulates epithelial proliferation, and induces the expression of prostatic lobe-
specific secretory proteins (40-46). Although prostate development and function are 
androgen dependent, several other growth factors, cytokines and  hormones  such as 
insulin like growth factor-1 ( IGF-1),  fibroblast growth factors (FGFs), and 
prostaglandins are associated with the development, growth and differentiation of the 
epithelium and stroma of the prostate (47).  
Tumorigenesis of prostate gland 
 Nearly all-prostate cancers arise from glandular cells and are called 
adenocarcinomas. Prostate cancers can initially develop when men are  20-30 years of 
age or older and the incidence increases with age (48, 49) . Multiple genetic and 
epigenetic abnormalities have been associated with prostate cancer. Initially the process 
of prostate tumorigenesis  begins with dysplasia associated with proliferative 
inflammatory atrophy (PIA), which further leads to prostatic intraepithelial neoplasia 
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(PIN) and then to carcinoma in few cases (50). During the process of premalignant 
lesion formation and the  progression to primary  and  metastatic cancer and to 
androgen-independent cancer, genetic changes continue to accumulate in the cells and 
these are illustrated in Figure 1.4 (50-52). Added to these alterations in the genome, 
androgenic hormones promote further cancer cell growth and proliferation.  
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Fig. 1.4. Cellular changes in development of metastatic prostate cancer (53). 
 
Testesterone is converted to an active metabolite, dihydrotestosterone (DHT) in 
the prostate cells by the enzyme 5α-reductase.  Binding of DHT to the AR results in 
formation of a phosphorylated homodimer which is then translocated to the nucleus and 
activates transcription of androgen-responsive genes related to growth and proliferation 
(54, 55). The work of Chinnaiyan and collegues (56-59) suggests that the TMPRSS2, a 
prostate-specific androgen regulated gene when fused to ETS family of transcription 
factors  leads to overexpression of an androgen-responsive oncoprotein. This process has 
been identified as one of the most common somatic rearrangements in  prostate cancer,  
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is associated with an  invasive phenotype, and appears to be an important early step in 
the  tumorigenesis (60). In most  prostate cancers, chromosomal abnormalities with loss 
of chromosomes 6q, 7q, 8p, 10q, 13q, 16q, 17q, and 18q have been identified (61).   
NKx-3.1 is a homeobox gene located on human chromosome 8p21, a region that 
undergoes frequent loss of heterozygosity in prostate tumors. Loss of  NKx-3.1 
expression along with phosphatase and tensin homolog (PTEN) hetrozygosity,  which  
inhibits phosphoinositol-3-kinase (PI3K) signaling has also been associated with prostate 
tumorigenesis (62). In addition, hypermethylation of enzymes such as glutathione S-
transferase 1 and O6-methylguanine DNA methyltransferase have also been observed 
(62). 
Grading of prostate cancer 
Grading of prostate carcinomas is based on histologic patterns which are scored  
using the Gleason grading system (63). Prostate cancers with a Gleason score of 5-7 are 
considered to be of intermediate grade or moderately differentiated and cancers with a 
score of 8-10 are considered to be of high grade or poorly differentiated, which predicts 
resistance to treatment and a low rate of patient survival. 
Diagnosis of prostate cancer 
 Prostate cancer is diagnosed by elevated levels of prostate specific antigen 
(PSA) in blood and abnormal digital rectal examination (DRE). PSA is a serine protease 
produced by normal epithelial cells of the prostate gland and the physiological role of 
PSA is to liquefy seminal fluid. It is produced in small quantities in the normal prostate 
gland but is consistently elevated in prostate cancer and other disorders of the prostate 
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such as infection, inflammation and benign prostatic hyperplasia (BPH). Both for initial 
diagnosis of the disease and to monitor the treatment response, PSA levels are widely 
used as a biomarker for prostate cancer. The upper limit for normal levels of PSA  has 
been set at 4.0 ng/ml and higher levels  in patients usually results in prostate biopsies for 
tumors (64). With  increased screening for PSA levels, most cancers are detected at early 
stages where they are localized to the gland itself and this can result in over-diagnosis of 
clinically insignificant or irrelevant prostate cancers (65-69).  
Treatment of prostate cancer  
Prostate cancer treatment is based on the specific type, location and stage of the 
cancer. Radical prostectomy is used to surgically remove the cancer when it has not 
spread from the gland. The major risks associated with surgery include urinary 
incontinence and impotence. Radiation is also used for low grade cancers that are 
confined to the gland itself or have spread only to the nearby tissue. Radiation is used 
alone or performed in combination with surgery and  side effects such as bowel 
problems accompany radiation (1). Cryosurgery or cryotherapy which reduces the size 
of localized tumors by freezing is also being used for the treatment of prostate cancer. 
Hormone therapy 
Androgens are required for the prostate cell growth and play a role not only 
during prostate development but also during tumorigenesis. The major objective of 
hormone therapy is to lower male hormone or androgen levels and thereby minimize 
tumor growth. It is used in patients who are not good subjects for surgery or radiation or 
the combination of surgery with radiation. In most cases of prolonged hormone 
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treatment, tumors become resistant to hormone therapy and there is a poor prognosis for 
disease-free survival. In order to overcome this problem, therapy is used on an “on-again 
and off –again” approach (1). 
Types of hormone therapy 
 Orchiectomy. Surgical removal of testes eliminates the source of androgen 
synthesis however; therapy though simple to perform is accompanied by severe side 
effects. 
 Luteinizing hormone-releasing hormone (LHRH) analogs. LHRH is a 
hormone produced by the hypothalamus, which stimulates the pituitary gland to produce 
luteinizing hormone (LH). LH then stimulates testicles to produce testosterone. 
Treatment with LHRH analogs initially increases levels of testosterone but due to a 
negative feedback loop, androgen levels decrease and slow the process of tumor growth. 
Leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex), and triptorelin (Trelstar) are 
the major LHRH analogs being used for hormone therapy (70-72). Side effects from 
using LHRH analogs are similar to those observed after orchiectomy and related to low 
testosterone levels. Abarelix ( Plenaxis) is an LHRH antagonist that works like an 
agonist and rapidly reduces   testosterone levels but is accompanied by less severe side 
effects (1). 
Antiandrogens. Antiandrogens work by blocking the action of androgens in the 
body and thus inhibit their effects. Flutamide (Eulexin), bicalutamide (Casodex), and 
nilutamide (Nilandron) are some  antiandrogen drugs currently used for the treatment of 
prostate cancer (70-72). Usually antiandrogens are used in combined androgen blockade 
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(CAB) along with orchiectomy for total inhibition of androgen activity.  Compared to 
orchiectomy or treatment with LHRH agonists, antiandrogens when used alone have 
fewer side effects on sexual competency (1). 
5-alpha reductase inhibitors. Finasteride (Proscar, Propecia) or dutasteride 
(Avodart) inhibit enzyme 5-alpha reductase and this results in decreased conversion of 
testosterone to its active moiety DHT resulting in the  inhibition of prostate tumor 
growth (73).  
Others. Estrogens were once used to suppress the action of testosterone as an 
alternative to orchiectomy. Because of possible serious estrogenic side-effects of breast 
enlargement and blood clot formation estrogens have largely been replaced by 
antiandrogens and LHRH analogs. They are used in some situations if the patient is not 
responding to other treatments. Antifungal compound Ketoconazole (Nizoral)  also  
inhibits production of androgens and is sometimes used for treatment of prostate cancer 
(74). 
Chemotherapy for prostate cancer 
Cytotoxic drugs are used for prostate cancer therapy when other treatments fail. 
Combination treatment with docetaxel and prednisone prolongs survival and has been 
extensively used for treating prostate cancer (75, 76). Other drugs used to treat prostate 
cancer include mitoxantrone (Novantrone), estramustine (Emcyt), doxorubicin 
(Adriamycin), etoposide (VP-16), vinblastine (Velban), paclitaxel (Taxol), carboplatin 
(Paraplatin), vinorelbine (Navelbine) (1). Mitoxantrone plus low-dose prednisone 
treatment showed improvement in the quality of life when compared to the  prednisone 
  
 
18
treatment alone  and this finding led to a subsequent phase III study TAX 327 by 
Tannock et al  (77, 78) comparing docetaxel plus daily prednisone  with mitoxantrone 
plus prednisone given either every three weeks or weekly. In this study, docetaxel plus 
prednisone showed significant improvement in the survival and response rate when 
compared to the mitoxantrone plus prednisone treatment (75).       
COLON CANCER 
Incidence 
 
Colon cancer is the third most common cancer diagnosed both in men and 
women in the United States excluding skin cancers. Risk factors for developing colon 
cancer include age, history both personal and family, inherited syndromes and lifestyle 
factors (1). 
The risk of developing colon cancer is higher in people older than 50 years but it can be 
observed even in the younger population. People with history of adenomatous polyps 
and any bowel diseases such as inflammatory bowel disease are also at an increased risk. 
People with the family history of colorectal cancer are also at an increased risk of 
developing cancer but accounts only up to 20%.  Most of the people who are diagnosed 
with colon cancer do not have a family history of colon cancer incidence, and only about 
5 % of colon cancer patients have inherited genetic abnormalities (1).  
The most common inherited syndromes that pose a risk of developing colon 
cancer include familial adenomatous polyposis (FAP) and hereditary non-polyposis 
colon cancer (HNPCC). FAP is observed because of mutations in the adenomatous 
polyposis coli (APC) gene and this syndrome accounts to about 1% of of all colorectal 
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cancers diagnosed. This is a syndrome observed in young populations characterized by 
thousands of polyps in the colon and rectum (1). HNPCC, also known as Lynch 
syndrome accounts for about 3-4% of all the colon cancers. It is caused by mutations in 
genes involved in DNA repair which include hMLH1, hMLH2 and hMLH6 (79-81) 
When compared to FAP,  HNPCC is observed in younger populations like FAP but, 
unlike FAP patients, have very few polyps in their gut.  
Other polyposis syndromes that increase the incidence of colorectal cancer 
include Peutz Jegher's syndrome, familial juvenile polyposis, and hereditary mixed 
polyposis syndrome.  These syndromes are linked to mutations in LKB1, STK11, 
SMAD4, PTEN, E-cadherin, cyclin D1, and transforming growth factor β receptors (82).   
Racial and ethnic background 
African Americans in the United States and Jews of Eastern European descent 
(Ashkenazi Jews) in the world have the highest colorectal cancer incidence and several 
mutations in genes that increase the risk of colorectal cancer have been observed in 
Ashkenai jews (1). The colon cancer incidence rate is very low in Asian countries 
especially in India (83) and the increase in incidence of this disease in migrants from 
Asian countries to Western countries suggests that environmental factors related to diet 
contribute to  development of colon cancer (84, 85). 
Environment and lifestyle factors 
 Obesity, physical inactivity, smoking, alcohol intake and diets high in red or 
processed meats and low in fiber (i.e. low intake of fruits and nuts) are some of the 
possible risk factors for colorectal cancer. Fruits, nuts and vegetables contain diverse 
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anticarcinogenic phytochemicals; however, epidemiological studies and particularly 
prospective studies do not strongly correlate high consumption of these foods with 
decreased incidence of colon cancer (86-88).  Several reports suggest that folate intake 
may be protective for colon cancer (89, 90) and in a  study of colorectal cancer cases and 
controls, there was a decrease in colon cancer risk in individuals that express a 677 T–C 
mutation in 5,10-methylenetetrahydrofolate reductase (91).  This decreased enzyme 
activity results in increased levels of 5-10-methylenetetrahydrofolate that plays an 
integral role in DNA synthesis. 
Types of colon cancers 
Most colon cancers (about 90%) develop in the gland cells that form mucus to 
lubricate the inner lining of the gut hence called adenocarcinomas. Other type of tumors 
are less common and these include carcinoid tumors that develop from cells that  
produce hormones, gastrointestinal stromal tumors (GISTs) which develop from 
“interstitial cells of Cajal” and lymphomas-which develop from the immune cells of the 
lymph glands in the colon or rectum (1). 
Diagnosis of colorectal cancer 
Colorectal cancer is diagnosed as soon as the symptoms appear and this results in 
a complete physical examination  along with blood tests to check for any tumor 
biomarkers such as carcinoembryonic antigen (CEA) and CA 19-9, which are produced 
by the cancer and released into the blood. Levels of these markers are not specific to 
colorectal cancer and may be high for other diseases of the gut such as ulcerative colitis; 
sometimes smoking  increases levels of CEA. If the physical examination and symptoms 
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are suggestive of cancer, additional tests are carried out; and these include endoscopic 
tests such as sigmoidoscopy or colonoscopy or imaging such as barium enema, 
computed tomography (CT) colonoscopy. Once cancer is diagnosed, a biopsy is 
performed to confirm the diagnosis (1). 
Stages of colorectal cancer 
      The wall of the intestine is made up of different layers. Colorectal cancer starts in the 
innermost lining also called epithelium. Cancer usually begins as a non-cancerous polyp 
on the innermost layer of the colon or rectum.  
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Fig. 1.5. Genetic progression model of colorectal adenocarcinoma (92). 
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These polyps may or may not transform into malignant tumors and their transformation 
depends on several other factors and the type of polyp (Fig. 1.5) (92). There are two 
kinds of polyps; one is adenomatous polyps that have a higher risk of developing into 
cancer and the second type hyperplastic polyps and inflammatory polyps, which are 
usually not cancerous. Dysplasia is a different type of condition where the cells of the 
colon and rectum look abnormal and have the potential to transform into cancer cells. 
AJCC (TNM) staging system 
TNM is the most common staging method used. This system is focused on three 
elements of the tumor: T for the extent of spreading of the primary tumor into the wall of 
the intestine and N for the extent of the spread of the tumor to the adjacent lymph nodes. 
M stands for metastases and measures the extent of tumor spreading to other organs of 
the body or not (1). Numbers or letters appear after T, N, and M to provide more detailed 
information related to the tumor and the numbers 0 through 4 indicate increasing 
severity. The letter “X” indicates that the tumor cannot be assessed. The letters “is” 
indicates  “in situ carcinoma ” indicating that the  tumor is contained within the top 
layers of the duct and has not invaded deeper into the duct (1). 
Treatment for colorectal cancer 
Depending on the stage of the cancer, any one of the following treatment options 
are available. Colectomy or laparoscopic–assisted colectomy is performed during early 
stages when the cancer is limited to the colon itself. Rectal surgery is performed if the 
cancer is localized in the rectum itself. Sometimes high-energy radiowaves are used to 
destroy the cancer cells and is called radiofrequency ablation (93, 94). Percutaneous 
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injection of ethanol into the tumors is also an option called ethanol ablation; and 
cryosurgery can be used for destroying the larger tumors by freezing (95). Radiation is 
usually performed to destroy any cancer cells that are remaining after surgery. External-
beam and internal radiation therapy or brachytherapy are the two types of radiation to 
destroy cancer cells after surgery, however, here are several side effects such as sexual 
problems, bowel incontinence, etc associated with this method (96). 
Chemotherapy for colorectal cancer 
For treatment of colon cancer, chemotherapy is used as an adjuvant therapy after 
surgery to increase patient survival rates. It is also in use as a neoadjuvant therapy prior 
to the surgery to shrink the tumor and facilitate its removal during surgery. Colon cancer 
chemotherapy usually involves drug combinations. 5-FU has been used for about 50 
years and is given in combination with folinic acid drug leucovorin to increase its 
efficacy. 5-FU is a pyrimidine analogue which is incorporated into DNA and RNA to 
inhibit the cell cycle in S-phase and induces apoptosis (97). Leucovorin is metabolized 
in the cell into polyglutamated 5, 10 methylnetetrahydrofolate and stabilizes the binding 
of 5-FU with thymidylate synthase (98). Capecitabine (Xeloda) is a prodrug that is 
converted into 5-FU in the tissues, and Irinotecan (Camptosar) is a structural analogue of 
camptothecin which is a topoisomerase I inhibitor. Irinotecan is used in combination 
with 5-FU and leucovorin as a first line chemotherapy in the FOLFIRI regimen for 
treatment of advanced colorectal cancers. Topoisomerases are  enzymes that catalyze  
DNA to unwind from its supercoiled topology and to aid in transcription or replication. 
Irinotecan is a topoisomerase I inhibitor which is hydrolysed into an active metabolite 
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SN-38 which inhibits DNA replication and transcription, tumor growth. Major side 
effects with this drug include severe diarrhea and immunosuppression. 
Oxaliplatin (Eloxatin) is a platinum based drug used in combination with 5-FU in 
FOLFOX therapy and in combination with capecitabine in CapeOX therapy (99). This   
is a cisplatin drug with increased efficacy when compared to its counterparts; however, 
the mechanism of action of oxaliplatin is not known. Major side-effects include 
neuropathy, GI problems, neutropenia, and ototoxicity. Many of these therapies use non-
specific cytotoxic agents, which induce undesirable adverse effects, and there is an 
increasing need to develop alternative drugs that target specific pathways to inhibit 
tumor growth, progression, and metastasis and to induce apoptosis.   
PANCREATIC CANCER 
Incidence 
 
 According to ACS, there will be about 37,680 new cases diagnosed and about 
34,290 deaths because of pancreatic cancer this year in US, making it a fourth leading 
cause of cancer deaths (1). 
Risk Factors 
The incidence rates for pancreatic cancer in tobacco smokers is two times higher 
than in nonsmokers (100-105). Men tend to have higher risk when compared to women 
but the differences have decreased; and this has been attributed to increased smoking in 
women.  Obesity, diabetes, cirrhosis and chronic pancreatitis are also risk factors for 
pancreatic cancer. Diets high in fat content also increase the risk for pancreatic cancer. 
About 10% of pancreatic cancer patients have a family history of this disease and 
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germline mutations in genes such as familial atypical multiple melanoma (FAMM), 
BRCA2, PRSS1, Lynch syndrome, Peutz-Jeghers syndrome are associated with 
increased risk of pancreatic cancer. In addition to these germline mutations several 
acquired gene mutations have also been identified in pancreatic tumors and these include 
mutations in oncogenes, tumor suppressors and DNA repair genes (Fig. 1.6) (106-117). 
The K-ras oncogene  mutated in codon 12 is expressed in more than 90% of pancreatic 
cancers; this constitutively active form of ras increases cell proliferation (118). 
Mutations in the tumor suppressor gene p53, cyclin dependent kinase inhibitor p16 and 
SMAD4, the downstream target of transforming growth factor β (TGFβ), are also 
frequently observed in pancreatic tumors (107, 108);  vascular endothelial growth factor 
(VEGF) and Erb2/neu are overexpressed in pancreatic tumors (110, 119, 120). Using 
microarrays, many genes that are differentially expressed in pancreatic adenocarcinoma 
have been identified and further research on these targets for pancreatic cancer 
chemoprevention and chemotherapy is needed (121, 122) . 
Tumorigenesis of pancreas 
The pancreas is composed mainly of two different types of glands – exocrine and 
endocrine. The exocrine part of pancreas secretes pancreatic juice, which contains 
enzymes that help in digestion of the food that enters the duodenum from the stomach. 
The endocrine part of pancreas accounts for a smaller portion of pancreatic mass  and is 
arranged in the form of clusters called Islets of Langerhans, which produce two different 
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types of hormones, namely insulin and glucagon, which are important for maintaining 
glucose levels in the body. Endocrine pancreatic tumors are rare and most pancreatic 
tumors originate from the exocrine part and are adenocarcinomas arising in 
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Fig. 1.6. Genetic progression model of pancreatic adenocarcinoma (123). 
 
 
the ducts of glands or acinar cells and account for 85-90% of all pancreatic tumors (123, 
124). A stepwise pattern of pancreatic adenocarcinoma progression has been described 
by studying the molecular and pathological features of pancreatic intraepithelial 
neoplasias (PanINs) (Fig. 1.6). Mutations in K-ras, ERBB2, and EGFR are associated 
with the transition from normal ductal cells to PanIN-1 stage cells which are 
characterized by elongated morphology and mucin production. Loss of the tumor 
suppressor CDKN2A due to mutations, deletions or hypermethylation of the promoter is 
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observed in 80-95% of the sporadic pancreatic adenocarcinomas. CDKN2A is located at 
the 9q21 gene locus which encodes for two tumor suppressor genes namely INK4A and 
ARF. INK4A inhibits phophorylation of retinoblastoma (RB) and prevent the entry of 
cells into S phase of cell cycle and ARF inhibits MDM2-depedent proteolysis which 
stabilizes p53. These genetic changes are observed in PanIN-2 lesions and are 
characterized by cells with enlarged nuclei and other abnormalities. Other genetic 
alterations that are associated with pancreatic cancer progression of PanIN-2 to PanIN-3 
and adenocarcinoma include mutations in tumor suprressor genes, TP53, 
SMAD4/DPC4, and BRAC2. Moreover chromosomal and microsatellite instability are 
also frequently detected at the late stages of PanIN lesions (Fig. 1.6)  (123). 
Diagnosis of pancreatic cancer 
 Only 7% of pancreatic cancers are detected in their early stages since there are 
not any effective diagnostic methods for early detection.The disease is usually 
asymptomatic until it metastasizes to other organs (125, 126). CA 19-9 is a substance 
produced by pancreatic cancer cells and released into the blood, however, by the time  
blood levels of CA 19-9 are  detectable, the disease is no longer in its early stages. Thus 
the CA19-9 test is  used during treatment but not for detection of pancreatic cancer . 
Once the disease is advanced, patients exhibit signs and symptoms such as jaundice, 
abdominal pain, weight loss, poor appetite, digestive problems, and further tests are 
required to confirm the diagnosis. Imaging tests such as CT scan, positron emission 
tomography (PET) scan, ultrasonography, mangnetic resonance imaging (MRI), 
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endoscopic Retrograde Cholangiopancreatography are used and a biopsy ultimately 
confirms the presence and stage of the cancer (1). 
Staging of pancreatic cancer 
Staging of pancreatic cancer is also done according to the AJCC –TNM system as 
described under colorectal cancer. 
Treatment of pancreatic cancer 
Although surgery is considered as a potential treatment option for pancreatic 
cancer, only 15% of the patients are good surgical subjects.Two types of surgeries are 
performed depending on the stage of cancer. Based on the imaging tests, if they suggest 
that the cancer is not that widespread and can be removed completely, potential curative 
surgery is performed. However, if the imaging tests suggest that the tumor is widespread 
and cannot be removed completely, palliative surgery is done to prevent the 
complications such as blockage of bile ducts or intestine by the cancer and to relieve the 
symptoms. External beam radiation therapy is the most common type of radiation used 
for treating pancreatic cancer (125). 
Chemotherapy for pancreatic cancer 
Gemcitabine is the drug most commonly used for the treatment of pancreatic 
cancer. Gemcitabine replaces cytidine, one of the building blocks of nucleic acids during 
DNA replication and this inhibits cell cycle progression. 5-FU is also used for treatment 
alone or in combination with Gemcitabine. Several clinical trials are underway testing 
the combination of 5-FU and gemcitabine with other chemotherapies that include 
cisplatin, oxaliplatin, docetaxel, irinotecan (125). 
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ESOPHAGEAL CANCER 
The esophagus is a muscular tube connecting throat to the stomach,  and cancer 
of esophagus can arise anywhere along the lining of the tube. Although the incidence of 
cancer is relatively rare accounting for 1% of US cancer incidence, has been increasing 
(1). 
Risk factors 
The risk of esophageal cancer increases with age with 80% diagnosed in people 
between 55 and 85 years old. African Americans have twice the risk as whites for 
developing esophageal cancer. Tobacco and obesity are major risk factors for developing 
esophageal cancer (127). Males have a higher risk than females and this is attributed to 
tobacco use.  People with gastro-esophageal reflux disease (GERD) and with Barrett 
esophagus are also at higher risk. Diets low in fruits, vegetables and vitamins have 
increased risk for esophageal cancer (128, 129) . Various genetic alterations are 
associated with esophageal cancer progression including allelic loss of chromosomes 
17p, 13q, 9p21-22 and mutations in p53 and p16 genes (130, 131). Studies using cDNA 
microarrays have identified differential patterns of gene expression involved in the 
regulation of squamous cell proliferation and differentiation. Genes involved in 
differentiation were downregulated and these include transglutaminase (TGM) 3 and its 
substrates including small proline-rich proteins (SPRRs), calcium binding S100 proteins 
(S100A8 and S100A9), annexin I, epithelial membrane protein (EMP) 1 and cystatin A 
(132-135). All these proteins are expressed in the cell envelope (CE) which functions as 
a barrier and results in impaired CE and accumulation of toxic substances. SPRRs and 
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calcium binding S100 proteins constitutes the epidermal differentiation complex (EDC) 
involved in the terminal differentiation of epithelial cells (134). KRT4, KRT13, and 
KRT15 are cytokeratins involved in epithelial differentiation and these genes were also 
downregulated in contrast to increased expression of KRT16 and KRT17 in esophageal 
cancer (136) . Studies with KRT4-/- mice demonstrated abnormal proliferation and 
improper terminal differention of the epithelial cells (137). Genes involved in 
transcription including gut enriched kruppel-like factor (GKLF), and eukaryotic 
translation elongation factor 1 alpha -1 (EEF1A1) which regulates the cell cycle by 
modulating microtubules were also downregulated (138). Genes that play a role in 
metastasis were differentially expressed including upregulation of proteases such as 
cathepsin B  that degrade ECM and downregulation of  protease inhibitors such as 
cystatin A, cystastin B and serine proteinase inhibitor. However, the role of these genes 
in the progression of esophageal cancer is not well characterized and needs to be 
investigated. 
Diagnosis of esophageal cancer 
Symptoms of esophageal cancer do not appear until the disease has advanced. 
The most common symptom as the tumor grows is difficulty in swallowing and it can 
also cause chest pain or burning. Endoscopy and barium swallow tests are used to 
diagnose esophageal cancer. 
Treatment of esophageal cancer 
Surgery when combined with other treatments can help ease the symptoms and 
improve the quality of life. Esophagectomy is the first line of treatment and is performed 
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if the tumor is localized in the esophagus and has not been spread to the regional lymph 
nodes. If the tumor spreads to other organs and regional lymph nodes, radiation and 
chemotherapy are used. In locally advanced cancer, concurrent cisplatin-based 
chemoradiotherapy or surgery result in 60-90% disease control rate and 20-40% 5-year 
disease free survival rate (139-145). Neoadjuvant chemoradiotherapy after 
esophagectomy is extensively used because of its beneficial effects in the treatment of 
esophageal adenocarcinoma. More than 50% of patients are diagnosed with metastatic or 
unresctable esophageal cancer and chemotherapy  provides improvement in the quality 
of life relieving  symptoms such as dysphagia in 60-80% of the patients (146-148). 
Drugs that are used in esophageal cancer chemotherapy include 5-FU, platinum 
based drugs such as cisplatin, caboplatin, and antibiotics such as bleomycin, 
anthracycline antibiotic doxorubicin, mitotic inhibitors paclitaxel, topoisomerase 
inhibitors irenotecan, topotecan.  
Photodynamic therapy, use drugs that make the precancerous and cancerous cells 
sensitive to light and when light is inserted into the esophagus using endoscope 
cancerous tissues are burned. This is usually used for treatment of Barrett’s esophagus 
and has now been extended to esophageal cancer. 
NEW TARGET MECHANISM BASED DRUGS 
Targeted therapies for treatment of cancer derived from multiple tissues/organs 
are highly promising for future  treatments since these agents are usually more tumor-
specific and are accompanied by fewer adverse side-effects (149-153). Targeted 
therapies include drugs such as kinase inhibitors, antibodies that block various signaling 
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pathways, immunotherapies, and genomic therapies that involve re-expression of tumor 
suppressor genes or specific gene knockdown technologies (including RNA 
interference).  The application of these targeted drugs may be highly tumor-specific or 
specific for only a sub-class of tumors such as the highly effective treatment of non-
small lung cancer patients with specific EGF receptor mutations with the EGF receptor 
inhibitors erlotinib and gefitinib (35, 154). 
Targeted therapies for prostate cancer 
With the increasing knowledge of the genes that play a role in the progression of 
prostate cancer there is  scope for  development of new drugs for  treatment of metastatic 
or hormone-refractory prostate cancer with increased specificity. Recent developments 
in the treatment of prostate cancer are discussed below. 
Drugs that target signal transduction pathways    
Several mechanisms are involved in the transformation of androgen  responsive 
prostate cancer to an androgen  refractory prostate cancer (155) and some of these 
pathways include i) amplification of AR and hypersensitivity to  low levels of DHT; ii) 
decreased specificity of the AR so that it responds  to other growth signals or hormones ; 
iii) activation of AR through kinase-dependent phosphorylation and ; iv) activation of 
AR independent growth pathways (Fig. 1.7) (38). Agents that target growth factors 
involved in androgen independent cancer include rapamycin analogs that inhibit 
Akt/PI3/mTOR, monoclonal antibodies and inhibitors of HER-2/3, IGF-R, IL-6R, and 
platelet-derived growth factor receptor (PDGFR). The Akt/PI3K pathway regulates 
various processes including cell proliferation, growth, apoptosis and cytosketal 
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rearrangement. PI3Ks are heterodimers with different regulatory and catalytic subunits. 
P85 is the regulatory subunit and acts as a substrate for many cytoplasmic and receptor 
tyrosine kinases that bind its SH2 domain to the phosphotyrosine residues of the kinases. 
There are three classes of PI3Ks and classIA PI3Ks are strongly associated with 
oncogenesis. PI3K activation by receptor tyrosine kinases results in generation of PIP3 
which acts as a second messenger for downstream effects involving AKT and other  
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Fig. 1.7. Mechanisms of androgen independence (155). 
 
proteins. The increasing emphasis on the role of Akt/PI3K pathway and its associated 
proteins in survival, differentiation and apoptosis has lead to the identification of the 
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expression and alterations of these genes in the progression of many human cancers. 
Amplification and several mutations of the catalytic and regulatory subunits of PI3K and 
AKT been identified in many human cancers (117, 119). 
In most prostate cancers there is a loss of tumor suppressor gene PTEN which 
results in  activation of Akt/PI3K pathway and  increased cell proliferation and tumor 
growth (156, 157). Loss of PTEN and activation of Akt  is associated with hormonal 
resistance, chemoresistance and increased tumor growth (158, 159). Rapamycin analogs  
inhibit this pathway in mouse models of PTEN loss or Akt activation (159, 160).Three  
rapamycin analogs are currently being investigated, namely rapamycin, CCI-779 
(Temsirolimus), and RAD001 (Everolimus) (161-163). Everolimus in combination with 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib and 
docetaxel is in phase II clinical trials. EGFR inhibitors, geftinib and trastuzumab, have 
not been successful for treating metastatic prostate cancer. Recent studies showed that 
EGFR and HER-2 are not  causal determinants in prostate cancer (164-166) and  HER-3, 
IGF-R, TGF-β, IL-6 and other growth factors were shown to be important. Drugs that 
target HER- 3 include neuregulin and pertuzumab, monoclonal antibody (Omnitarg) and 
lapatinib, an intracellular inhibitor (GlaxoSmithkline) of HER-2/HER-3 signaling  (167, 
168).  
Drugs that target the endothelin axis 
 Endothelin (ET) is an important paracrine signaling molecule  that plays a role 
in the mediation of bone-prostate cancer crosstalk (155). ET is a vasoconstrictive agent 
which also regulates mitogenic pathways in prostate cancer cells and osteoblasts and is 
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associated with the aggressive behavior of the hormone refractory prostate cancer (169). 
Atrasetan (Xinlay) is a potent antagonist of the ET-A receptor and Phase III trials using 
this drug resulted in a statistically insignificant outcome (170). Another ET-A receptor 
antagonist, ZD4054 (Astra Zeneca) is also in Phase II clinical trials. 
Drugs that target platelet-derived growth factor receptor (PDGFR)  
 Prostate cancer cells express higher levels of PDGFR; and this receptor 
enhances  PI3 kinase/Akt signaling and  results in prostate cancer progression (171).The 
efficacy of Imatinib (Gleevac), an inhibitor of PDGFR tyrosine kinase alone or  in 
combination with docetaxel, is being investigated for prostate cancer chemotherapy. 
Drugs that target stem cells 
 Elements of the Hedgehog (Hh) signaling pathway, human telomerase and 
CD133 have been  identified  in  stem cells and are overexpressed in prostate cancer 
(172-175). A prolonged period of prostate cancer relapse was observed after inhibiting 
the Hh signaling pathway in xenograft models  of androgen insensitive prostate cancer 
(PC-3) cells (175). Cyclopamine analogs are hedgehog (Hh) antagonists that are being 
investigated in pre-clinical drug development. Human telomerase is a reverse 
transcriptase enzyme that maintains the stability and length of the chromosome by 
protecting the ends of chromosomes also called telomeres (176). Telomeres get shorter 
with each DNA replication and when they  are critically short, cells stop dividing and 
die, this phenomenon of limited cellular division is called the  “Hayflick limit”. However 
some cells such as germ cells, stem cells, hair follicles and cancer cells overcome this 
limit and aquire indefinite replicative ability by overexpressing telomerase which aids in 
  
 
36
telomere repair. Normal prostate lacks telomerase activity but the enzyme is 
overexpressed in prostate tumors. Drugs targeting telomerase are also underdevelopment 
for treatment of prostate cancer (174). 
Drugs that target angiogenesis 
Angiogenesis plays an important role in physiological processes and also in 
tumor growth and metastasis; inhibition of angiogenesis has become an attractive 
therapeutic strategy. In 1971, Judah Folkman and his colleagues first proposed that 
vascularization is essential for the growth of clinically invasive tumors (Fig. 1.8).  
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Fig. 1.8.  Angiogenesis and cancer (177). 
 
There are several pro- and anti-angiogenic factors that regulate angiogenesis, and 
these include VEGF, basic FGF (bFGF), interleukin-8, placenta-like growth factor 
(PlGF), angiopoeitin-2 TGF, PDEGF, pleiotrophin, and others (178, 179). VEGF is the 
most potent pro-angiogenic factor and has been well characterized as  an important 
regulator of angiogenesis (180). The VEGF family of angiogenic factors include VEGF-
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A, VEGF-B,VEGF-C,VEGF-D, and PlGF (181, 182). VEGF-A, also referred to as 
VEGF, is the major mediator of tumor angiogenesis and binds to two main receptors, 
namely fms like tyrosine kinase (Flt-1) or VEGFR-1and flk-1/ kinase domain region 
(KDR) or VEGFR-2, which are expressed at higher levels by endothelial cells and by 
circulating bone marrow-derived endothelial progenitor cells (Fig. 1.9)(180).  
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Fig. 1.9. The family of VEGF molecules and receptors (183). 
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Angiogenic factors stimulate angiogenesis by two mechanisms. Firstly, they bind 
locally to cognate receptors on the peritumoral vascular endothelial cells and this results 
in budding of new capillaries that supply blood to tumors from the existing host blood 
vessels. The second mechanism involves binding of angiogenic factors to distant 
receptors on bone marrow cells to mobilize them into the circulation and into the tumor 
to promote vacularization in cooperation with  additional angiogenic factors. VEGF 
binding to VEGFR-2 is critical in the former mechanism since it activates endothelial 
cell proliferation and survival whereas PlGF binding to VEGFR-1 recruits macrophages 
and other proangiogenic cells derived from bone marrow and plays an important role in 
the latter mechanism (184). Anti PlGF antibodies inhibited tumor growth, angiogenesis 
and recruitment of macrophages in mouse models of cancer. In contrast antibodies 
against VEGFR-2 inhibited tumor growth and angiogenesis but did not inhibit the 
recruitment of macrophages suggesting different mechanism of actions mediated by 
these two receptors and their ligands (185). Combination therapy with the two antibodies 
resulted in greater inhibition when compared to individual treatments. This preclinical 
data with anti-PlGF antibodies constitutes a significant improvement that will be further 
evaluated in clinical trials of antiangiogenic therapy for human cancers. Hypoxia-
inducible factor-1(HIF-1) mediates the transcription of angiogenic genes and is induced 
in response to reduced levels of oxygen; is also overexpressed in many tumors (186). 
Endothelial and stromal interactions are not only critical for organogenesis but also for 
tumorigenesis and tumor progression. Stroma with respect to tumor constitutes ECM and 
mesenchymal cells such as endothelial cells, fibroblasts, vascular smooth muscle cells 
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and pericytes (187). Interaction of endothelial cells with ECM proteins is mediated 
through cell surface  integrins that are expressed on the surface such as α1β1, α2β1 and 
α3β1, all of which bind collagen and laminin; α6β1, which binds laminin; α4β1 and α5β1, 
which bind fibronectin and fibrin; and αvβ3 and αvβ5, which variously bind vitronectin, 
fibronectin, fibrin and laminin (188). 
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Fig. 1.10. Tumor angiogenesis signaling cascade and endothelial stromal interactions 
(177). 
 
During angiogenesis endothelial cells mainly interact with integrin αvβ3 and 
results in VEGFR-2/αvβ3 complex formation. VEGF-A activated VEGFR-2 recruits c-
src and PI3K, which then phosphorylates cytosolic domain of β3 integrin and thus 
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results in the formation of VEGFR-2/ αvβ3 complex (189-192). A recent study using 
knock-in mice expressing a β3-/- mutant was not able to form a complex with VEGFR-2 
and had impaired tumor angiogenesis (191). Degradation and remodeling of the ECM is 
critical in the formation of new capillaries from existing ones. Endothelial cells produce 
matrix metalloproteinases (MMPs) that degrade the basement membrane and mobilize 
endothelial cells and growth factors such as VEGF from the matrix towards new vessel 
formation; and pericytes are recruited to form new capillary wall (Fig. 1.10). Knock 
down of a membrane bound MMP, MT1-MMP using RNAinterference mechanism 
impaired lumen formation in an in vitro assay emphasizing its importance in 
angiogenesis (193). Gene deletion methods have shown that MMP2 and MMP9 play a 
significant role in angiogenesis (194). MMPs also cause the release of the antiangiogenic 
factors  angiostatin and tumstatin. Surgical removal of a primary tumor initiates 
secondary tumor development or metastasis. Systemic administration of angiostatin 
inhibited secondary tumor formation and neovascularization after  removal of the 
primary tumor emphasizing the role of angiostatin as an antiangiogenic factor produced 
by tumor cells (195, 196). VEGF has been targeted by various strategies including 
monoclonal antibodies (mAbs), inhibitors of endothelial cell-receptor tyrosine kinase 
activity and antisense oligonucleotides. Bevacizumab (Avastin) is the most well-
characterized recombinant humanized mAb against VEGF. It binds to all isoforms of 
human VEGF and prevents its binding to cognate receptors (197). Bevacizumab is the 
first anti-angiogenesis therapy approved by the U.S. Food and Drug Administration 
(FDA) and is currently approved for  treatment of two of the three largest cancer killers 
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in the U.S. (198).  A Phase II study demonstrated safety and efficacy of combination 
therapy with drugs including docetaxel, estramustine, and bevacizumab for the treatment 
of hormonerefractory prostate cancer which  lead to a phase III study, CALGB 90401 to 
compare docetaxel  and  bevacizumab in combination with prednisone for the treatment 
of hormonerefractory prostate cancer. 
There are multiple receptor tyrosine kinase inhibitors (RTKIs)  that target EGFR 
tyrosine kinase (cetuximab, erlotinib, geftinib, ZD6474,CI1033 or PKI1666), VEGFR 
tyrosine kinase (Sorafenib/BAY-43-9006, PTK787, ZD6474, Sutent/SU6668/SU11248), 
PDGF tyrosine kinase (PTK787 or SU11248),  HER-2/Neu receptor (trastuzumab), and 
interferon (IFN)-α receptor. VEGFR tyrosine kinase inhibitors, sorafenib and sutent 
(SU11248), and thalidomide analogs, revlimid and actimid that inhibit VEGF, T-cell 
costimulatory function, TNF-α inhibition and decrease IL-6 levels, are in Phase II and 
Phase III studies clinical trials for the treatment of prostate cancer (199-201). A Phase II 
trial with docetaxel in combination with thalidomide resulted in  significantly decreased 
PSA levels, time to disease progression and disease free survival but was accompanied 
by severe side effects (202). 
There are number of other drugs that target angiogenesis by inhibiting basement 
membrane degradation, endothelial cell proliferation, migration, tube formation, 
neovascularization and inducing apoptosis in endothelial cells. For example, NM-3, an 
isocumarin inhibitor of VEGF blocks combretastatin, induces rearrangement of the actin 
cytoskeleton, and induces early membrane blebbing in endothelial cells (179, 203-205).  
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In addition, there are a number of endogenous antiangiogenic factors which include 
angiostatin, angiomotin, arrestan, canstatin, endostatin, tumstatin, and thrombospondin. 
Agents that induce differentiation and apoptosis 
Epidemiological data suggest a  link between Vitamin D deficiency and prostate 
cancer progression indicating that the  vitamin D receptor (VDR) may be a potential 
target for  development of new anticancer drugs (206). Calcitriol, the active form of 
vitamin D found in the body exhibits proapoptotic, growth inhibitory and differentiation- 
inducing properties  in prostate cancer cells and is currently being evaluated in clinical 
trials (207, 208). Histone deacetylase (HDAC) and DNA methyltransferase inhibitors are 
also being evaluated for the treatment of prostate cancer. HDAC and DNA 
methyltransferase enzymes play a role in epigenetic silencing of  gene expression; and 
inhibition of these enzymes induces apoptosis,  p21 signaling and  inhibition of tumor 
growth (209). SAHA (Merck) is an orally bioavailable HDAC inhibitor currently 
undergoing clinical trials for treatment of androgen-independent prostate cancer. 
Abnormal hypermethylation and gene silencing of the antioxidant enzyme GST-II and 
the tumor suppressor p21 is observed in prostate cancer (210). Antisense Bcl-2, 
oblimersen sodium (Genasense) and the proteasome inhibitor, bortezomib (Velcade) are  
two drugs that target Bcl-2, an anti-apoptotic protein that is overexpressed in metastatic 
hormonerefractory prostate cancer (211). 
Vaccination strategies 
 Provenge, a prostate acid posphatase (PAP)-activated dendriticcellbased 
vaccine, and Prosate GVAX, a wholecell allogeneic vaccine are  being developed for 
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treatment of prostate cancer in combination with docetaxel (212). Provenge is a process 
of antigen delivery to activated antigen-presenting cells that are collected from patients 
and stimulated by fusing cells with PAP-GMCSF protein and then administered 
intradermally to the patients. Prostate GVAX immunotherapy uses whole–cell allogenic 
PC-3 and LNCaP prostate cancer cells  that are virally transduced to express GM-CSF 
an immune adjuvant which is lethally irradiated and injected into patients intradermally 
(213-215). Two other vaccines that are in early phases of testing include Prostvac-VF 
recombinant vaccinia-fowlpox PSA vaccine (TRICOM) and the BLP25MUC1 liposomal 
vaccine MUC-1 (216, 217). 
Novel cytotoxic drugs 
The limitations of Docetaxel therapy are related to the toxicity associated with 
current dosing regimens and there is a need for development of novel cytotoxic drugs 
with fewer toxic sideeffects. Satraplatin, a platinum-based agent exhibited a favourable 
outcome in a Phase- III clinical trial (218). Epithilones are a new class of  cytotoxic 
drugs that target microtubules but pose an advantage over taxanes since they are not 
susceptible to P-glycoprotein induced drug efflux (219). Monoclonal antibodies tagged 
to cytotoxic agents are also an attractive therapeutic approach, for example MLN2704 is 
a prostate-specific membrane antigen conjugated to a toxic substance maytansinoid  and 
this conjugate is in clinical trials for the treatment of androgen independent prostate 
cancer (220). Radioimmunotherapy is also emerging as a novel therapeutic approach 
where specific mAbs are conjugated to radioactive molecules (220-223). 
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Targeted therapies for colon cancer 
Several targeted therapies have already been approved for the treatment of 
colorectal cancer and they include bevacizumab, cetuximab (Erbitux), and panitumumab 
(Vectibix). Bevacizumab is given in combination with intravenous (IV) 5-fluorouracil 
(FU) as first- or second-line treatment in patients with metastatic carcinoma of the colon 
or rectum. Cetuximab (IgG1) and Panitumumab (IgG2) are the mAbs with different 
isotypes that target EGFR. Several other therapies are being developed, and two of these 
include various cyclooxygenase (COX) inhibitors and peroxisome proliferator-activated 
receptor γ (PPARγ) agonists.  These are discussed in the following two subsections. 
PPARγ Agonists 
PPAR is a member of the nuclear receptor (NR) family of transcription factors 
(224-228), and the three members of this subfamily (Fig. 1.11 ) serve as regulators of 
lipid and carbohydrate metabolism and play a critical role in multiple diseases including 
diabetes, atherosclerosis and cancer. Ligand activation of PPARγ results in formation of 
a DNA-bound heterodimer with the retinoic acid X receptor (RXR) (Fig. 1.12 ); and 
after recruitment of the appropriate cofactors, transcriptional activation of target gene 
expression is observed.  The assembly of a transcriptionally-active PPAR/RXR complex 
may be highly variable and depends on expression of coregulatory proteins; and this may 
dictate, in part, the tissue-specific and ligand structure-dependent activation of PPAR-
mediated gene expression and responses.    
PPARγ and cancer 
The proliferation advantage of cancer cells over their normal counterparts is 
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Fig. 1.11. General structure of PPARs. Schematic representation of the domain structure 
of PPARs. The numbers within each domain corresponds to the percentage of aminoacid 
sequence identity of human PPARb and PPARg relative to PPARa. Two transcription 
activation functions (AFs) have been described, a constitutively active AF-1 in 
region A/B and a ligand inducible AF-2 in region E and a DNA binding domain in 
region C. 
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Fig. 1.12. Regulation of PPAR-mediated gene expression. 
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atleast, in part, due to their inability to undergo terminal differentiation, remain in a 
proliferative state and continue to grow. The potential uses of PPARγ agonists for cancer 
chemotherapy were based on results showing that PPARγ ligands inhibited cell 
proliferation while inducing adipocyte differentiation. Moreover PPARγ is 
overexpressed in most tumor samples and cancer cells lines. PPARγ agonists inhibit 
proliferation of transformed cells mainly by inducing cell cycle arrest or differentiation 
and/or apoptosis. 
Cell cycle. Studies in several tumor cell lines have suggested a role for 
PPARγ in cell cycle arrest. It was initially observed that ligand activation of PPARγ 
induces cell cycle withdrawal of preadipocytes via suppression of the transcriptional 
activity of E2F/DP DNA-binding complex. Decreased E2F/DP activity is in part 
mediated by PPARγ through down-regulation of the protein phosphotase 2A (PP2A). 
E2F/DP activity can also be inhibited by activation of retinoblastoma protein 
(RB) and PPARγ ligands inhibit phosphorylation of RB in vascular smooth muscle 
cells, therefore maintaining RB in its hypophosphorylated form  abrogating the G1 to 
S phase transition. Morrison and Farmer have suggested a role for PPARγ in up-
regulating the cyclin-dependent kinase inhibitors (CDKIs) p18 and p21 during 
adipogenesis (229). Thus PPARγ ligands control genes involved in inhibition of normal 
cell cycle progression and similar responses were also observed in pancreatic cancer cell 
lines (230). However, the specific growth regulatory pathways that are affected by 
PPARγ agonists are highly variable even among cells derived from a common tumor 
type. The most widely used synthetic PPARγ agonists are the thiazolidinedione (TZD) 
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class of antidiabetic drugs, also referred to as glitazones and these include ciglitazone, 
troglitazone (TGZ) (Rezulin), pioglitazone((Actos), rosiglitazone (Avandia)  and 
LY171.833 (Fig. 1.13). Pioglitazone, rosiglitazone and TGZ  sensitize patients to insulin 
and lower blood glucose levels and have been used clinically to treat type 2 diabetes 
(231). 
Troglitazone was recently removed from the market due to idiosyncratic 
hepatotoxicity, which resulted in liver failure in extreme cases. Several other 
structurally distinct ligands, such as the derivative of 2,3-disubstituted indole-5- 
acetic acid called GW0207 or non-thiazolidinedione tyrosine based compounds are 
potent and selective PPARγ agonists (232).  
Non-steroidal anti-inflammatory drugs such as indomethacin, ibuprofen, 
fenoprofen and fulfenamic acid are also PPARγ agonists, and this might explain the anti-
inflammatory effects of these drugs at concentrations that are substantially higher than 
those required to inhibit prostanoid synthesis (233). The synthetic triterpenoid 2-cyano- 
3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO) binds PPARγ, induces 
Differentiation, inhibits proliferation of a variety of cancer cells, and also 
exhibits anti-inflammatory activity (234). 
TGZ inhibited growth of six of nine pancreatic cancer cell lines by G1 phase cell 
cycle arrest through the up-regulation of p21 mRNA and protein expression (230). In the 
Panc-1 pancreatic cancer cell line, TZD-dependent growth inhibition of G1 phase arrest  
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was accompanied by increased expression of p27 but not p21 (230, 235). A dose- 
dependent cytostatic effect of TZD and G0 to G1 cell cycle arrest was observed in 
different hepatoma cell lines including HLF, HuH-7, HAK-1B, and HAK-5 cells, and 
was related to alterations in p21 protein expression. HLF hepatoma cells, which are 
deficient in RB, responded more profoundly to TGZ, which induced expression of p21, 
p27 and p18  suggesting that these CDKIs may be involved in TGZ-induced cell cycle 
arrest in human hepatoma cell lines (236). 
Hupfeld and Weiss reported that TZDs inhibit vascular smooth muscle cell 
growth by decreasing cyclin D1 and cyclin E levels, suggesting another possible 
mechanism for TZD action (237). MCF-7 breast cancer cell growth and G1-S phase 
progression was inhibited by troglitazone treatment, and cells accumulated in the G1 
phase by modulating RB phosphorylation and decreasing cyclin D1 expression (238). 
CDK-dependent activity which was also decreased by troglitazone and overexpression 
of cyclin D1 and partially rescued MCF-7 cells from troglitazone mediated G1 cell cycle 
arrest (238). PPARγ activation inhibits proliferation of several other malignant cells 
from carcinoma (239-241), non-small cell lung carcinoma (242), bladder cancer cells 
(243) and gastric carcinoma cells (244). 
Differentiation. PPARγ induces differentiation pathways beyond adipocytes, 
and overexpression of PPARγ induces differentiation of hepatocytes, myoblasts and 
several other cell types including mammary and colon epithelium (245). Furthermore, 
treatment of human primary liposarcoma cells with pioglitazone induced terminal 
differentiation (246). PPARγ agonists induce upregulation of several differentiation 
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markers such as carcinoembryogenic antigen, E-cadherin and alkaline phosphotase in 
pancreatic cancer cell lines (247). Ligand-dependent activation of PPARγ induced 
apoptosis in different malignant  lineages such as liposarcoma (248), prostate carcinoma 
(249), colorectal carcinoma (239-241), non-small cell lung carcinoma (242),bladder 
cancer cells (243) and gastric carcinoma cells (244). 
In the colon, levels of PPARγ mRNA are nearly equivalent to that found in 
adipocytes (250) with the highest levels of receptor expressed in the post-mitotic, 
differentiated epithelial cells facing the lumen (251). Consistent with this expression 
pattern, exposure of human colon cancer cells to PPARγ agonists inhibits growth, arrests 
cells in G1 phase, increase  several markers of differentiation including caveolin-1 and 
caveolin-2, which exhibit tumor suppressor activity, and also some members of the 
keratin and CEA families (239, 252, 253). Levels of caveolin-1 and 2 also increase 
during differentiation of pre-adipocytes to adipocytes (254, 255). Breast adenocarcinoma 
and colon adenocarcinoma cells, where caveolin expression is normally downregulated, 
express a functional PPARγ with transcriptional activity (251). These cells undergo 
differentiation in vitro upon treatment with PPARγ agonists (240, 248, 256). The ability 
of PPARγ to promote lineage-specific differentiation and the fact that caveolins are 
characteristic markers for terminally differentiated cells raised the hypothesis that 
PPARγ transcriptionally regulates caveolin expression. Burgermeister et al. have shown 
that PPARγ induces caveolin gene expression in human adenocarcinoma cells and this 
may have important applications in the context of cancer differentiation therapy (257). 
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Fig. 1.13 Chemical structures of different synthetic PPARγ ligands (258). 
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Apoptosis. PPARγ ligands induce apoptotic cell death in a wide variety of 
experimental cancer models both in vitro and in vivo (259-261) including ER negative 
MDA-MB-231 and ER positive MCF-7 breast cancer cells (262). Treatment of MCF-7 
cells with troglitazone irreversibly inhibited growth and induced apoptosis; and this 
was accompanied by a dramatic decrease of the anti apoptotic bcl-2 protein (263). 
Inhibition of RNA or protein synthesis abrogates apoptosis induced by 15d-PGJ2 in 
breast cancer cells. Additionally, 15d-PGJ2-induced caspase activation is inhibited by 
caspase inhibitors, showing that de novo gene transcription was necessary for induction 
of apoptosis in breast cancer cells (264). 
PPARγ ligands such as 15d-PGJ2, LY171 833 and ciglitazone inhibited 
proliferation and induced cell death in human (U87MG and A172) and rat (C6) glioma 
cell lines. This cell death was characterized by DNA fragmentation and nuclear 
condensation which are the hallmarks of apoptosis. In contrast, primary murine 
astrocytes were not affected by treatment with ciglitazone (265). PPARγ ligand-induced 
apoptotic cell death in glioma cells was accompanied by transient upregulation of 
proapoptotic proteins Bax and Bad. Upregulated expression of Bad and Bax induces 
apoptosis by enhanced release of mitochondrial cytochrome C and subsequent activation 
of several effector caspases. In addition, inhibition of Bax expression by specific 
antisense oligonucleotides protected glioma cells against PPARγ mediated apoptosis, 
indicating an essential role of Bax in this process (265). PPARγ activation by 
troglitazone also leads to increased caspase 3 activity in human liver cancer cells (266) 
and in human malignant astrocytoma cell lines (267). 
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Shimada and coworkers noted that troglitazone-induced cell death in colon 
cancer cells was inhibited by pan-caspase inhibitors (268). Furthermore, ciglitazone-
induced apoptosis in human pancreatic cell lines is blocked by the pan-caspase inhibitor 
ZVAD-FMK but not by a specific caspase-3 inhibitor  (269). Moreover, treatment of 
human liver cancer cell lines (266) and human thyroid carcinoma cells (270) with 
PPARγ agonists did not increase levels of Bax protein, suggesting that PPARγ agonists 
induce several different apoptotic pathways. TNF-related apoptosis inducing ligand 
(TRAIL) is a member of TNF family of cytokines that induces apoptosis and both 
natural and synthetic PPARγ agonists sensitize tumor cells but not normal cells to 
induction of apoptosis by TRAIL. PPARγ ligands selectively decrease levels of FLICE-
inhibitory protein (FLIP), an apoptosis-suppressing protein that blocks early events in 
TRAIL/TNF family death receptor signaling. PPARγ ligands induced ubiquitination and 
proteasome-dependent degradation of FLIP, without concomitant decreases in FLIP 
mRNA (271). 
PPARγ-independent actions. PPARγ agonists inhibit proliferation of several 
types of cancer cells, however, the role of PPARγ remains controversial; and in many 
cases the compounds induce receptor-independent effects. The sensitivity of cancer cell 
lines growth inhibition by PPARγ agonist does not correlate with levels of PPARγ 
protein in these cells. For example glitazone resistance occurs even in tumors with high 
PPARγ concentrations (e.g., breast-tumor cells) (272). Homologous recombination was 
used to create embryonic stem cells with a null mutation for PPARγ and these stem cells 
could be differentiated into macrophages when treated with glitazones (273). 
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Troglitazone-induced cell cycle arrest and subsequent cell death; and this was associated 
with downregulation of c-myc, c-myb and cyclin D2 expression. These genes lack a 
PPRE in their promoter regions, indicating that these responses were not directly 
mediated through PPARγ (274). Similar results were observed in the human leukemia 
cell line (KU812) suggesting that troglitazone-mediated growth suppression was 
PPARγ-independent and was associated with decreased cyclin E levels and 
hyperphosphorylation of RB (275). 
In human glioblastoma T98G cells, TZD induced cell cycle arrest and apoptosis, 
and the fomer response was associated with increased p27 levels, whereas apoptosis was 
mediated by downregulation of anti-apoptotic Bcl2 and upregulation of pro-apoptotic 
Bax and caspase-3 activation. None of these responses were blocked in cells treated with 
a specific PPARγ antagonist (276). The mechanisms by which PPARγ agonists induce 
glioma cell toxicity were also investigated in another study using rosiglitazone and 
ciglitazone. The rapidity of the mitochondrial damage caused by PPARγ agonists and the 
failure to reverse the cytotoxic effects using the specific PPARγ antagonist GW9662 
suggested a receptor-independent action (277). 
Troglitazone inhibited growth of HCT-116 colon cancer cells by induction of 
NAG-1, most likely via direct activation of the transcription factor early growth 
response-1 (EGR-1) (278). Induction was not blocked by a PPARγ antagonist, thus 
indicating another mechanism by which TZD can cause growth inhibition. In MCF-7 
breast cancer cell lines, troglitazone- induced apoptosis was dependent upon GADD45 
expression. Regulation of GADD45 by troglitazone occurred at the transcriptional level 
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and was associated with MAPK activation. In the same studies neither rosiglitazone nor 
pioglitazone induced GADD45 expression indicating a receptor-independent response 
(279). 
The triterpenoid CDDO inhibits the growth of ovarian cancer cells that express 
PPARγ, but the effects of CDDO were not blocked after co-treatment with the PPARγ 
antagonist T007, suggesting that  growth inhibition was  PPARγ independent 
(280). Another group of PPARγ agonists, 1, 1-bis (3'-indolyl)-1-(p-substituted phenyl) 
methanes inhibited the G0/G1-S phase progression in MCF-7 and several cancer cell 
lines by downregulation of cyclin D1. The PPARγ inhibitor T007 did not affect 
downregulation of cyclin D1 indicating that this response was also PPARγ independent 
(281). More direct evidence of PPARγ independent effects comes from receptor 
knockout studies. Embryonic stem cell induced tumor growth was inhibited by 
troglitazone and ciglitazone in both PPARγ (-/-) and PPARγ (+/+) mice, confirming the 
receptor-independent actions of PPARγ agonists. These compounds blocked the G1/S 
phase transition by inhibiting translation initiation as a consequence of partial depletion 
of intracellular calcium stores. This resulted in activation of PKR, a kinase that 
phosphorylates the alpha subunit of eukaryotic initiation factor 2, thus rendering it 
inactive (282). 
Indirect and direct evidence suggest that many of the anticancer activities of 
PPARγ ligands are PPARγ-independent, however the mechanisms of receptor-
independent pathways warrant further study. Although PPARγ is well characterized, 
there are still numerous challenges before modulators of this receptor will be adopted for 
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therapeutic applications in treating cancer. This will require development of selective 
PPARγ modulators with minimal side effects and an increased understanding of both 
receptor-dependent and independent pathways. 
PPARγ and colon cancer. PPARγ is overexpressed in multiple tumor-types 
(283), and there is evidence that various structural classes of PPARγ agonists inhibit 
growth and induce apoptosis in colon cancer cells/tumors and other cancer cells/tumors 
(235, 241, 253, 284-302).  There is evidence that PPARγ is overexpressed in human 
colon tumors compared to non-tumor tissues (283); however, results of laboratory 
animal studies have been contradictory (239, 291, 303-308). Sarrat and coworkers 
reported that the TZD troglitazone decreased colon tumor growth and malignancy in 
colon tumor xenografts in nude mice (239); however, two reports showed that 
troglitazone and rosiglitazone enhanced colon tumorigenesis in the APCmin+/- mouse 
model which expresses a nonsense mutation in the APC gene (308, 309).  In contrast, 
subsequent studies demonstrate that TZDs inhibit intestinal polyp formation and 
suppress hyperlipidemia in APC1309 mice which contain a truncation mutation in the 
APC gene and is an animal model for the human genetic mutation that leads to an 
increased incidence of colon cancer (291, 305).  A recent study also demonstrated that 
troglitazone enhances colon tumorigenesis in wild-type and mutant mice (306); and it is 
possible that the effects of troglitazone may be due to the intrinsic (PPARγ-independent) 
properties of the compound which has subsequently been withdrawn as a drug for 
treating Type II diabetes due to toxic side-effects.  Further support for the protective role 
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of PPARγ in colon cancer comes from a study showing that homozygous PPARγ 
deficiency in APCmin+/- mice enhances tumorigenesis (307). 
Research in our laboratory has identified a series of 1,1-bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes (C-DIMs) which contain p-trifluoromethyl (DIM-C-
pPhCF3), p-t-butyl (DIM-C-pPhtBu) and p-phenyl (DIM-C-pPhC6H5) and activate 
PPARγ  (281, 297, 299, 301, 310-313).  These PPARγ-active C-DIMs induce both 
PPARγ-dependent (induction of caveolin-1) and -independent (ER stress, NAG-1) 
proapoptotic and growth inhibitory responses in colon and other cancer cell lines.  The 
antitumor activity of other PPARγ agonists is also due to their activation of receptor-
dependent and -independent pathways.   
Cyclooxygenase (COX) inhibitors 
COX is one of the rate limiting steps in the metabolism of arachidonic acid to 
prostaglandins and thromboxanes, and COX inhibitors which include a broad spectrum 
of NSAIDs are extensively used as anti-inflammatory agents (Fig. 1.14) (314).  COX-2 
is also overexpressed in multiple tumor types including colon cancer;  and both NSAIDs 
and COX inhibitors have been investigated as targets for cancer chemoprevention and 
chemotherapy (314-317).  Several studies show that some COX inhibitors including 
aspirin decrease the incidence and/or mortality rate of human colorectal cancer (318-
320).  The COX-2 inhibitor sulindac has also been successfully used for treating patients 
with familial adenomatous polyposis coli (FAP), a hereditary colon cancer syndrome in 
which there is rapid and early development of polyps and tumors (321-323).  COX-2 
inhibitors are also highly effective chemotherapeutic agents for treating colon cancer in 
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laboratory animals including carcinogen-induced and transgenic rodent models (324-
326).   
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Fig. 1.14. Inhibition of prostaglandin synthesis by COX-inhibitors (327). 
 
 
The mechanisms of COX-2 inhibitor-mediated cancer chemoprevention and 
chemotherapy are complex, and the inhibition of prostaglandin/thromboxane production 
(e.g. prostaglandin E2) contributes to these effects (314-317).  However, it is also clear 
that COX-2 inhibitors can be effective in cells with minimal COX-2 expression and 
many cell growth inhibitory responses induced by these compounds are COX-2-
independent (328-330).  For example, sulindac sulfone induces apoptosis in Caco-2  
cells by decreasing polyamine levels through activation of PPARγ-dependent induction 
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of spermidine/spermine N-acetyltransferase gene expression.  
The cancer chemotherapeutic actions of COX-2 inhibitors have also been linked 
to their antiangiogenic activity and inhibition of VEGF expression (314, 317); and 
studies in this laboratory investigated the effects of the COX-2 inhibitors celecoxib 
(Celebrex), nimesulfide (NM) and NS-398 on colon cancer cell growth and expression 
of the key angiogenesis protein VEGF (331).  Treatment of SW-480 colon cancer cells 
with Celebrex, NS-398 or NM decreased vascular endothelial growth factor (VEGF) 
mRNA and immunoreactive protein expression.  This was also accompanied by 
decreased transactivation in cells transfected with constructs containing VEGF gene 
promoter inserts.  Deletion analysis of the VEGF promoter indicated that decreased 
VEGF expression by COX-2 inhibitors was associated with the proximal -131 to -47 
GC-rich region of the VEGF promoter which binds Sp proteins.  Treatment of SW-480 
cells with Cel, NM and NS also decreased Sp1 and Sp4, but not Sp2 or Sp3 protein 
expression.  Similar results were observed in RKO, HT-29 and DLD colon cancer cells 
demonstrating comparable responses in COX-2 expressing and non-expressing colon 
cancer cell lines.  COX-2 inhibitors do not affect Sp1 or Sp4 mRNA levels in SW-480 
cells; however, decreased expression of both proteins was accompanied by increased 
protein ubiquitination and inhibited by the proteasome inhibitor gliotoxin.  These results 
suggest that the antiangiogenic activity of COX-2 inhibitors in colon cancer cells is 
linked to activation of proteasome-dependent degradation of Sp1 and Sp4 protein. 
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Targeted therapies for esophageal cancer 
Table. 1.2. Potential tumor targets for esophageal cancer  (332) 
               
Growth regulation
Epidermal growth factor receptor
HER-2/Neu
Ki-67
Angiogenesis
Vascular endothelial growth factor  
Inflammation
Cyclooxygenase-2
Cell cycle control
p16
p21
Cyclin D1
Apoptosis
p53
bax
bcl-2
Metastatic potential
Tissue inhibitor of metalloproteinase
E-cadherin
Tumor targets
 
 
New drugs that target specific molecules are also being studied for treatment of 
esophageal cancer. Several clinical trials are in progress to test the combination of drugs 
with different mechanism of actions. Potential tumor markers or targets for the 
aggressive esophageal squamous cell carcinoma or gastroesophageal adenocarcinoma 
have been identified and are listed in Table 1.2 (333-335). Earlier these targets were 
understudied as biomarkers to predict the clinical response after chemotherapy or 
chemoradiotherapy but have been now identified as specific molecular targets (333-338). 
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MAbs and signal tranduction/tyrosine kinase inhibitors (TKIs) for EGFR, mAbs for 
HER-2/Neu receptor and VEGF ligand, oral COX-2 inhibitors and many other targeted 
therapies are in Phase I/II clinical trials.    
Drugs that target epidermal growth factor receptor (EGFR) 
 EGFR is a member of ERBB receptor tyrosine kinase family and includes four 
members namely EGFR1 or ERBB1, ERBB2 (HER-2), ERBB3 and ERBB4. EGFR is a 
170 kDa transmembrane glycoprotein having an extracellular domain anchored to the 
plasma membrane and a cytoplasmic component containing a tyrosine kinase domain. 
Upon ligand binding to the extracellular domain, the receptor is activated to form hetero 
-or homodimers resulting in activation of the cytoplasmic tyrosine kinase activity. This 
results in initiation of intracellular signal transduction cascades that regulate cellular 
growth and multiple functions depending on the substrate of the tyrosine kinase (Fig. 
1.15) (339).   
Known ligands for EGFR include EGF and transforming growth factor alpha 
(TGF-α). The Ras-Raf mitogen–activated protein kinase and PI3K/Akt are two of the 
important downstream signaling pathways that regulate the cellular functions for the 
HER /EGFR family (340-343). EGFR and mutant forms of the receptor are 
overexpressed in esophageal and other human cancers; and expression of this receptor is 
positively associated with poor prognosis and aggressiveness of the disease. In order to 
target this receptor monoclonal antibodies and small molecule inhibitors of the tyrosine 
kinase activity of the receptor have been developed.  
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Fig. 1.15. Schematic representation of the EGFR in the transmission of signals 
regulating tumor growth and metastasis (344). 
 
 
EGFR Antibodies 
Cetuximab is a mouse-human chimeric antibody of the IgG1 subclass and binds 
to EGFR or HER-1. The antibody inhibits ligand binding to the EGFR and blocks  
phosphorylation of the tyrosine kinase domain and  inhibits its activity (345). Cetuximab 
also decreases receptor levels by inducing internalization of the receptor which leads to 
receptor degradation and inhibition of activity (346). Cetuximab has been used in 
clinical trials for colorectal and head and neck cancers. There are several clinical trials  
being carried out including a South-West Oncology Group (SWOG) trial of cetuximab 
as second line therapy for patients with metastatic esophageal adenocarcinoma. A 
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Memorial Sloan-Kettering Cancer Center study of cetuximab in irinotecan/cisplatin-
refractory patients with metastatic esophageal cancer and a Dana-Farber Cancer Institute 
preoperative trial with cisplatin, irinotecan, cetuximab and radiation are also underway. 
There are significant improvements in patients in Phase I studies using EGFR-directed 
mAbs and this is accompanied by minimal toxicity. 
EGFR tyrosine kinase inhibitors 
These are small molecules that inhibit the tyrosine kinase activity of EGFR by 
inhibiting the binding of ATP to the tyrosine kinase domain and thus inhibit its 
phosphorylation and  signal transduction (347). Erlotinib (Tarceva) and geftinib (Iressa) 
have been approved as second line therapy for metastatic non-small cell lung cancer 
(NSCLC) and four Phase II clinical trials with these inhibitors are ongoing for treatment 
of  esophageal and gastroesophageal adenocarcinomas. The partial response rates (PR) 
of these inhibitors as single agents  are outlined in  Table 1.3.  In  clinical trials for 
NSCLC only, erlotinib as a single agent showed a survival advantage when compared to 
placebo treated group, although both geftinib and  erlotinib showed significant partial 
response rates (9-19 %), disease control (36-54%) and symptomatic improvement (35-
43%) (348-350). 
Drugs that target HER-2/Neu  
HER-2/Neu, also referred to as ERBB2 is a proto-oncogene localized in 
chromosome 17q. Amplication of this gene is observed in up to 30% of breast cancers 
and is related to the aggressiveness of the tumor (351, 352). Several studies have 
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Table. 1.3. Tyrosine kinase inhibitors: Partial response (PR) rates in metastatic cancers 
(332) 
 
Cancer type                                            Erlotinib (%PR)                     Gefitinib (%PR) 
NSCLC                                                           9-12                                              9-19 
Head and neck squamous cell                           4                                                  11 
Gastric adenocarcinoma                                    0                                                   1 
Esophageal, gastroesophageal junction          9-12                                               12     
 
 
observed overexpression of HER-2/Neu in esophageal squamous cell carcinomas and 
gastroesophageal adenocarcinomas; and this receptor is a potential target for treatment of 
esophageal cancer. Overexpression of this receptor is associated with poor response to 
chemotherapy and invasiveness of the disease (353). Trastuzumab (Herceptin) is a 
humanized IgG1 antibody that targets HER-2/Neu antigen and this drug has been 
approved by FDA for treatment of HER-2/Neu-positive  metastatic breast carcinoma 
(354). Safran and colleagues have used trastuzumab, paclitaxel, cisplatin and radiation in 
a PhaseI/II trial in patients with locally advanced gastroesophageal cancer (355). The 
trial has confirmed the efficacy for addition of trastuzumab with the standard, combined 
modality regimen. Many other clinical trials using this mAb are underway for treatment 
of esophageal cancer. 
Drugs that target angiogenesis  
VEGF is overexpressed in 30-60% of esophageal cancers and is associated with 
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poor survival and clinical response and the VEGF neutralizing antibody bevacizumab 
has been developed as antiangiogenic therapy (356-359). As a monotherapy or in 
combination with other therapies, there are more than 30 clinical trials using 
bevacizumab for treatment of solid tumors and hematologic cancers; and for the 
treatment of esophageal cancer, it is still in the early stage. A Phase II study of 
irinotecan, cisplatin and bevacizumab in patients with metastatic gastroesophageal 
adenocarcinomas yielded positive encouraging results (360). VEGF antibody exhibits a 
radiosensitizing effect in several mouse xenograft models including lung, colon, glioma 
and esophageal cancers suggesting that this antibody gives an enhanced anticancer effect 
when combined with radiation (361-365). 
Drugs that target COX-2 
COX-2 affects many pathways including carcinogenesis, apoptosis, 
inflammation, and regulation of immune system (366, 367). There is increasing evidence 
to link COX-2 with carcinogenesis in Barrett’s esophagus; and the use of COX-2 
inhibitors such as aspirin and NSAID’s reduce the risk for esophageal cancer (368, 369). 
With the use of these COX-2 inhibitors such as Celecoxib (Celebrex) at higher doses, an 
increased risk of thrombosis has been observed; and hence NCI trials with these 
inhibitors were sustained. Several  trials are in progress using COX-2 inhibitors in 
combination with radiotherapy for treatment of esophageal cancer (370). 
P53 gene therapy 
Abnormalities or mutations in the p53 tumor suppressor gene are associated with 
esophageal cancer in 40-60% of the patients (371, 372). P53 genetic analysis is used as a 
  
 
65
prognostic indicator of survival and predictor of response to the treatment for esophageal 
cancer (338, 373-375). Retroviral or adenoviral gene expression mediated p53 gene 
therapy has been evaluated in preclinical tumor models and results from these studies 
revealed its efficacy to maintain drug and radiation sensititvity and induces apoptosis in 
the tumors (376-378). Based on these results Phase I trials with adenovirus-mediated 
wild-type p53 gene transfer in combination with cisplatin  were carried out and were 
revealed to be safe and efficiently induce biological effects in patients with advanced 
lung cancer (379-381). Similar trials in patients with esophageal cancer are in progress. 
Targeted therapies for pancreatic cancer 
Drugs that target epidermal growth factor receptor (EGFR) 
EGFR inhibitors erlotinib and gefitinib  are now being tested against pancreatic 
cancer along with cetuximab  (35, 382). A Phase III clinical trial conducted with 569 
patients with advanced pancreatic cancer randomly received gemcitabine alone or in 
combination with erlotinib and the increased effects of the combined therapy  
resulted in approval of this therapy.  One-year survival rates were higher (24%) in the 
combination therapy group compared to the survival rate (17%) of the group receiving 
gemcitabine alone (383). 
Drugs that target angiogenesis 
Antibodies against angiogenic factors such as bevacizumab are being tested for 
treatment of pancreatic cancer in combination with gemcitabine. Results of a Phase II 
trial with this combination were encouraging and futher confirmatory studies are being 
implemented with gemcitabine plus bevacizumab. 
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Drugs that target K-ras 
Since K-ras mutations are observed in most pancreatic tumors, proteins in the K-
ras pathway are being investigated as drugs targets. Activation of ras and its substrates 
depends on farnesylation or prenylation, a process which adds hydrophobic groups that  
facilitates membrane association of the proteins. Farnesyl transferase is an enzyme 
involved in farnesylation of proteins bearing a CaaX motif, and this includes the Ras 
superfamily of proteins. Farnesyl transferase inhibitors such as tipifarib and lonafarnib 
are being evaluated for treatment of pancreatic cancer  (384). Preliminary results from 
Phase II studies with these inhibitors alone or in combination with 5-FU or gemcitabine 
in patients with advanced pancreatic cancer resulted in a prolonged response. Ongoing 
Phase III trials will determine the clinical activity of these drugs and whether they can be 
used alone or in combination with other cytotoxic drugs. 
Drugs that target matrix metalloproteinases (MMPs) 
Matrix metalloproteinases belong to the family of zinc metalloendopeptidases 
that play a significant role in tissue remodeling by degrading the basement membrane 
and ECM. They are not only required for physiological processes but are also involved 
in tumor invasion, growth, metastasis and angiogenesis. MMPs are divided into five 
groups namely stromelysins, collagenases, gelatinases, membrane type MMPs and other 
MMPs, with about eighteen different subtypes and these are summarized in Table 1.4. 
(385-388). 
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Table. 1.4. Different classes of MMPs (389) 
Family of Matrix Metalloproteinases (MMPs)
Stromelysins
Collagenases
Gelatinases
Membrane-type MMPs
Other MMPs
MMP-3
MMP-7 (Matrily sin)
MMP-10
MMP-12 (Metalloelastase 
MMP-1
MMP-8
MMP-13
MMP-2
MMP-9
MMP-14 (MT-MMP1)
MMP-15 (MT-MMP2)
MMP-16 (MT-MMP3)
MMP-17 (MT-MMP4)
MMP-24 (MT-MMP5)
MMP-18 (Xenopus MMP)
MMP-19
MMP-20 (Enamely sin)
  
 
 
MMPs are produced as propeptides and are autocatalytic cleaved to form active MMPs. 
This activation can be induced using organomercurials such as p-aminophenylmercuric 
acetate which binds in vitro to the conserved cysteine residue in the propeptide and it is 
then released from the covalently bound catalytic zinc iron. In vivo, MMPs are cleaved 
by a wide range of different extracellular proteinases such as plasmin, serine proteases 
and others (390). MMPs are regulated in tissues by endogenous tissue inhibitor of 
metalloproteinases (TIMPs). The specific role of TIMPs is unclear and they may 
promote tumorigenesis by activating MMPs or inhibit MMP activity and exhibit 
antitumor activity. MMPs are upregulated in many tumors including thyroid, prostate, 
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ovarian, gastric, lung, head and neck, pancreatic and colorectal carcinomas; and this 
increased expression correlates with tumor invasiveness of the disease (386, 387). MMP-
2 and MMP-9 play a major role in tumor metastases; and a study by Bramhall and his 
colleagues showed that MMP-2 mRNA was expressed in approximately 93% of tumors 
from pancreatic cancer patients. Northern blot analysis and in situ the  hybridization did 
not detect MMP expression in normal pancreatic tissue specimens (391). MMPs and 
particularly MMP2 and to a lesser extent MMP-9 play an important role in the 
pathogenesis of pancreatic cancer as indicated in Table 1.5, however, the precise 
function of these protein has not  yet been identified (392-394). BB-94 (Batimastat), 
inhibited MMP-2 activity in pancreatic cancer cells and inhibited pancreatic cancer cell 
invasion without affecting cell proliferation and in an orthotopic nude mouse model BB-
94 treated animals formed fewer tumors and exhibited decreased metastases (395-397). 
An enhanced protective effect was observed  in animals cotreated with BB-94 plus 
gemcitabine, the standard drug used as a first line therapy for pancreatic cancer (398). 
BAY12-9566 and BB-2516 (Marimastat) are orally active synthetic inhibitors of matrix 
metalloproteinases and are being investigated in clinical trials for treatment of pancreatic 
cancer (399, 400). A Phase I study with marimastat determined that 100 mg was the 
highest dose that could be used with minimal toxic side- effects and this drug which is 
tumorostatic was evaluated in a chronic dosing study and a series of six subsequent 
Phase I/II trials were carried out in pancreatic, prostate, ovarian, and colorectal cancers. 
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Table. 1.5. MMP expression in pancreatic cancer (389) 
Year Study No. Patients MMP Findings
p
1995 Gress et al.
Koshiba et al.
Kuniyasuet al.
Ito et al.
Gong et al.
Maatta et al.
Ellenrieder et al.
Fukushima et al.
Yamamoto et al.
Correlation with degree of desmoplasia
Correlation with tumor extent, nodal status, 
metastases, and recurrence rate (MMP-2 only )
No correlations
Correlation with survival
Correlation with nodal status
Correlation with degree of desmoplasia
No correlations
Correlation with tumor extent, nodal status, and TNM
classification
Correlation with tumor extent, nodal status, and TNM
Classification and survival
1998
1999
1999
2000
2000
2000
2001
2001
8
33
22
46
15
35
18
70
70
2, 9
2, 9
2, 9
1
2, 9
2, 9, MT-1
2, 9, MT-1, MT-2, MT-3
7
7
MMP, matrix metalloproteinases; MT, membrane-bound; TNM, tumor, node, metastasis.
 
Changes in levels of tumor markers which  include cancer antigen (CA) 19-9 , PSA, 
CA125 and CEA,  respectively, were used as determinants of tumor response over a 28-
day period (401). The studies demonstrated a dose-dependent decrease in levels of serum 
tumor markers and this was accompanied by musculoskeletal side effects in patients who 
received the treatment beyond 28 days (402). Another Phase II study was conducted in 
113 patients with advanced pancreatic cancer using radiological/computed tomography 
response and changes in CA-19-9 levels as tumor response determinants. Approximately 
49% of the patients had stable disease by computed tomography over a 28-day treatment 
period with no difference in disease-free survival whereas decreased levels of serum CA 
19-9 were observed in 30% of the patients with a significant improvement in disease-
free survival. Based on these reports a large multiinstitutional prospective randomized 
trial was conducted with three different doses of marimastat 5, 10, or 25 mg BID or 
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gemcitabine  with survival as a primary end point (400). Survival was not significantly 
different between the groups, but was longer for patients with nonmetastatic disease 
when compared to metastatic disease in the group receiving marimastat alone, and 
slightly longer when compared to the group treated with gemcitabine alone. The 
National Cancer Institute of Canada sponsored a similar trial and compared gemcitabine 
with another oral synthetic MMP inhibitor, BAY12-9566 in patients with advanced 
pancreatic cancer. There was lower survival in the BAY12-9566 treated group compared 
to treatment with gemcitabine alone, the median progression-free survival in the 
gemcitabine treated group was 3.5 months but only 1.8 months for BAY12-9566 
treatment and the trial was terminated (403). 
Additional studies with these inhibitors has focused on localized disease or 
adjuvant therapy; for example, a Phase III study by the British Biotech in patients with 
resected pancreatic cancer observed a potential benefit using marimastat; and this study 
is still ongoing. 
NATURAL PRODUCTS IN THE TREATMENT OF CANCER 
Phytochemicals have been extensively used in traditional medicine by most 
cultures for thousands of years.  Various diseases are treated with crude or refined 
extracts derived from many natural sources, and the current widespread use of many 
nutriceuticals, herbal extracts, and other non-traditional medicines stems from the long 
history of their therapeutic applications (404-410).  Individual natural products from 
various sources have proven to be highly effective for treating many diseases and some 
of the earliest medicines including aspirin, morphine, quinine, digitoxin and pilocarpine 
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were derived from plants  (405, 406, 411).  The discovery of penicillin (412, 413) 
spurred research on natural products or "secondary metabolites" from various 
microorganisms resulting in the discovery and applications of several different structural 
classes of drugs including antibiotics such as penicillins, cephalosporines, streptomycin, 
tetracyclines, and their synthetic analogs (413-416); HMG-CoA reductase inhibitors 
lovastatin and mevastatin and their analogs are now extensively used as antilipidemic 
drugs for preventing and treating cardiovascular disease (417-419).  Natural products 
and their synthetic derivatives are also important drugs for cancer chemotherapy and are 
further discussed in this section.  Although newer high-throughput screening techniques 
and the development of chemical libraries have facilitated discovery of many new 
synthetic drugs (410), the overall percentage of new drugs derived from natural products 
or their synthetic analogs is approximately 25% (420-422). 
The root extract of mayapple, Podophyllum peltatum has been used for treating 
skin cancers and venereal warts by American Indians. The active ingredient in that root 
extract was identified to be podophyllotoxin which is the forerunner of today’s 
anticancer drugs etoposide and teniposide. Catharanthus roseus also called vinca rosea 
was used in Asian countries as a hypoglycemic agent, but not until 1958 was it found to 
have cytotoxic properties. The cytotoxicity of the plant has been attributed to two main 
ingredients, namely vinblastine and vincristine. In the modern world these compounds 
play a major role as anticancer drugs in treating childhood leukemias, testicular cancer, 
hodgkin’s lymphoma. Several structural analogs of these compounds are also in clinical 
use. Paclitaxel (Taxol), a compound purified from the bark of the plant Pacific yew 
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Taxus brevifolia has become one of the most important anticancer drugs and in contrast 
to the vinca alkaloids  paclitaxel stabilizes the microtubules during cell division (423). 
Camptothecin, a specific inhibitor of topoisomerase I enzyme is derived from 
Chinese ornamental tree Camptotheca accuminata. In order to overcome the bladder 
toxicity observed with camptothecin,  two structural analogs namely topotecan 
(Hycamptin) and irinotecan (Camptosar) were synthesized (424). Topoisomerase I is an 
enzyme that unwinds the DNA double helix during transcription and replication and 
camptothecin and its structural analogs  inhibit this enzyme which results in inhibition of  
transcription and replication  leading to cell death (425). 
There are several molecules derived from plants that are under investigation and 
show promise for treating different cancers. Polyphenols are antioxidant molecules 
found in the skin and seeds of grapes and also from tea leaves. These compounds are 
usually produced by plants as a defense mechanism. Polyphenols have antioxidant 
properties and thus counteract the effects of free radicals which are implicated as a 
causal factor in cancer progression. Resveratrol is a phytoalexin found abundantly in red 
wine and also in grapes, raspberries and other plants. It has also been shown to reduce 
tumor growth and decrease inflammation by inhibiting  nuclear factor κB (NFκB) (426-
429). 
 Epidemiological studies have indicated that nutrition plays a major role in 
carcinogensis. Adjustment of diets can reduce tumor formation (327, 430, 431) and  
epidemiological studies indicate that fruits, vegetables, herbs and spices contain 
compounds associated with cancer chemoprevention (432-435). Tea which is an 
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important source of anticarcinogenic polyphenols is the second largest drink consumed 
in the world. The major polyphenolic group of compounds in tea leaves is catechins 
which induce apoptosis and cell cycle arrest in cancer cells and tumors. Other 
chemopreventive and chemotherapeutic properties of polyphenolics include their 
antioxidant activity  (436), inhibition of cyclooxygenase and lipooxygenase enzymes 
(437), inhibition of angiogenesis (438), and VEGF receptor phosphorylation (439), 
activation of tumor suppressor protein p53 (440) inhibition of telomerase enzyme (441)  
and also activation of NAG-1, a pro apoptotic  member of TGF-β superfamily (442). 
Curcumin (diferuloylmethane) is a polyphenolic natural product and the active 
component of tumeric (Curcuma species) which is used in cooking and in 
traditional medicines (443-445). Curcumin has been extensively investigated as an 
anticancer drug in various cancer cells and laboratory animal models. Curcumin has  
been evaluated in humans, for cancer chemotherapy; and one of the major problems 
associated with clinical applications of curcumin is its low bioavailability (446-449). 
The effects of curcumin in various tumor models are highly variable and dependent on 
both tumor type and cell context. In many studies, curcumin inhibits cancer cell 
proliferation, induces apoptosis, and inhibits angiogenesis (450-453). Mechanisms 
associated with these effects are variable and may involve direct effects on 
mitochondria, activation of endoplasmic reticulum (ER) stress, and modulation of kinase 
pathways including the inhibition of NFκB.  
Anticancer drugs have been derived not only from  plants but also from microbes 
(bleomycins,doxorubicin) (454) and marine sources (bryostatin I, eleutherobin) (455, 
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456). Nature has already provided scientists with highly complex mixtures of medicinal 
compounds which need to be isolated and identified and subsequently modified to make 
them more effective for treating different types of cancers. 
Triterpenoids 
A large number of structural classes of natural products and their derivatives 
have been developed as chemopreventive and chemotherapeutic agents, and these 
include triterpenoids.  Lanosterol, a C-30 triterpenol, is degraded in several steps to 
cholesterol which, in turn, serves as a precursor for the biosynthesis of androgens, 
estrogens, progestins, glucocorticoids and mineralocorticoids.  Lanosterol and other 
triterpenoids are derived from squalene which undergoes 2, 3-epoxidation and 
cyclization to give tetracyclic triterpenes such as lanosterol and many other tetra- and 
pentacyclic triterpenene compounds (Fig. 1.16).  In addition to the differences in the 
overall ring or skeletal structure of triterpenoids, there are multiple sites within each ring 
that can undergo site and stereoselective oxidation or dehydrogenation along with 
oxidation of the exocyclic methyl groups.  Not surprisingly, there are thousands of 
triterpenoid natural products, and these compounds along with their synthetic derivatives 
exhibit a wide spectrum of biological activities. 
Oleanolic and ursolic acids are oleane-derived triterpenes that contain a carboxyl 
group at C-28 (methyl oxidation), and they have been used as traditional medicines in 
Asian countries due to their anti-inflammatory  and potential anticancer activities (457-
460) (Fig. 1.16).  Honda, Sporn and coworkers have synthesized several hundred 
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Fig. 1.16. Chemical structures of Squalene and different triterpenoids.  
 
derivatives of oleanolic and ursolic acid, and evaluated their potential anti-inflammatory 
activities as inhibitors of inducible nitric oxide synthase (iNOS).  The IC50 values of 
these analogs ranged over at least 4 orders of magnitude (461-466) and they identified a 
lead compound, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), and an 
imidazole derivative (CDDO-Im) as a group of highly potent anti-inflammatory and 
anticancer drugs (Fig. 1.17) (234, 280, 302, 466-483).  Initial studies showed that CDDO 
was a peroxisome proliferator-activated receptor γ (PPARγ) agonist that bound and 
activated receptor-dependent responses; however, many of the activities of CDDO and 
related compounds are PPARγ-independent and highly dependent on cell context.  
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Fig. 1.17. Chemical structures of synthetic derivatives of oleanolinic acid, CDDO and 
CDDO-IM. 
 
 
 
These compounds typically inhibit cancer cell proliferation and induce apoptosis 
through a variety of mechanisms including induction of endoplasmic reticulum stress,  
cellular redox, and direct perturbations of mitochondrial pathways.  A recent report 
showed that CDDO-Im inhibited aflatoxin-induced hepatocarcinogenesis through 
induction of a battery NrF2-dependent cytoprotective genes that alter the metabolism of 
aflatoxin (484, 485).  Research in this laboratory showed that CDDO compounds induce 
PPARγ-dependent transactivation in colon cancer cells; and this is accompanied by 
receptor-dependent induction of the tumor suppressor gene caveolin-1.  In contrast, 
induction of apoptosis and the proapoptotic NSAID-activated gene-1 (NAG-1) by 
CDDO was receptor-independent (302).  Currently CDDO is undergoing clinical trials at 
the M. D. Anderson Cancer Center for treatment of patients with leukemia. 
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Glycyrrhetinic acid and its derivatives 
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Fig. 1.18.  Chemical Structures of GA and the synthetic CDODA-Me analogs.  
 
Licorice root extracts have been extensively used for their therapeutic properties 
which include the potentiation of cortisol action, inhibition of testosterone biosynthesis, 
reduction in body fat mass and other endocrine effects (486-489).  The activities of these 
extracts are linked to different classes of phytochemicals particularly the major water-
soluble constituent glycyrrhizin and its hydrolysis product glycyrrhetinic acid (GA) (Fig. 
1.18).   
Many of the properties of licorice root can be attributed to GA; for example, GA 
inhibits 11β-hydroxysteroid dehydrogenase activity increasing corticosterone levels, and 
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this has been linked to apoptosis in murine thymocytes, splenocytes and decreased body 
fat index in human studies (489-492).  GA directly acts on mitochondria to induce 
apoptosis through increased mitochondrial swelling, loss of mitochondrial membrane 
potential, and release of cytochrome c.  GA has also been used as a template to 
synthesize bioactive drugs such as the carbenoxolone, the 3-hemisuccinate derivative of 
GA, which is used in treatment of gastritis and ulcers (493).  Some of the activity of 
carbenoxolone may be due to hydrolysis to GA; however, carbenoxolone itself induced 
oxidative stress in liver mitochondria and decreased mitochondrial membrane potential.  
Other carboxyl and hydroxyl derivatives of glycyrrhizic acid inhibit HIV and exhibit 
anti-inflammatory and immunomodulatory activities (494).  In addition, GA derivatives 
containing a reduced carboxylic acid group at C-30 (CH2OH) and some additional 
functional changes exhibited strong antioxidant activity (495).   
Ongoing studies in this laboratory are developing GA derivatives for cancer 
chemotherapy and as ligands for some nuclear orphan receptors. Introduction of a cyano 
group at C-2 position of oleanolic and ursolic acid increased the cytotoxicity of the 
analogues (464). Methyl 2-cyano-3,11-dioxo-18βolean-1,12-dien-30-oate (βCDODA-
Me), a synthetic derivative of GA is isomeric with 2-cyano-3,12-dioxoolean-1,9-dien-
28-oic acid CDDO-Me (βCDDO-Me), a 2-cyano derivative of oleanolic acid but differs 
with respect to the position of carboxylic acid group in the E-ring, the stereochemistry at 
C-18 (β versus α) in the E/D ring junction, and the enone function in the C ring 
(Fig1.18).  
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To investigate the importance of the stereochemistry at the C-18 position methyl 
2-cyano-3, 11-dioxo-18αolean-1, 12-dien-30-oate (αCDODA-Me) was also synthesized 
in our laboratory. Introduction of the 2-cyano group into α-glycyrrhetinic acid or β-
glycyrrhetinic acid enhanced their cytotoxicity; both compounds induced 
PPARγ−dependent transactivation in colon cancer cells and act as selective receptor 
modulators based on their tissue selective induction of caveolin-1 and KLF-4. These 
genes are associated with growth inhibitory and pro-apoptotic responses and the role of 
these responses on the anticarcinogenic activity  of these compounds as new class of 
anticancer drugs will be investigated. 
Betulin and derived lupane triterpenoids 
  Lupeol and betulin are pentacylic triterpenoids that contain a five-membered E 
ring and an exocyclic propylidene group and triterpenoids with a lupane skeleton have 
been identified as highly promising anticancer drugs (Fig. 1.19) (496-503). Lupeol  is 
found in medicinal plants and various fruits and exhibits multiple biochemical activities 
including inhibition of protein kinases, serine proteases, and topoisomerase II (504-506).  
Lupeol induces differentiation and exhibits a broad spectrum of anti-inflammatory and 
anticarcinogenic activities (502, 503, 507).  A recent study showed that lupeol  inhibited 
proliferation and induced apoptosis in pancreatic cancer cells; this was due, in part, to 
inhibition of Ras signaling which is frequently mutated (and constitutively active) in 
pancreatic cancer (502).   
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Fig. 1.19. Chemical structures of lupane derivatives. 
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Betulin or lup-20(29)-ene-3β,28-diol is found in concentrations as high as 30% 
(dry weight) in birch bark (508), and extracts containing betulin have been used in 
traditional medicine for treating skin diseases (509).  Betulin can be chemically modified 
to give compounds with anti-inflammatory, antibacterial, antiviral and anticarcinogenic 
activities, and many studies within this class of lupane derivatives have focused on the 
anticancer activity of betulinic acid (BA) (Fig. 1.19) (499).  BA has been identified in 
bark extracts but can also be readily synthesized in 75% yield from commercially-
available betulin by oxidation to give betulonic acid which can then be reduced to BA;  
these reactions are routinely carried out in this laboratory.  Initial studies with BA 
showed that it was a highly selective inhibitor of human melanoma cell proliferation 
through induction of apoptosis, and at doses of 50 - 500 mg/kg every 4 days, BA 
inhibited tumor growth in nude mice bearing MEL-2 melanoma cells as xenografts 
(510).  In parallel xenograft studies using MEL-1 cells, doses of BA as low as 5 mg/kg 
inhibited tumor growth, whereas at doses as high as 500 mg/kg, minimal toxicity was 
observed. In a human neuroblastoma cell line (SHEP), BA decreased mitochondrial 
membrane potential resulting in the release of cytochrome c and activation of multiple 
caspases (511).  Treatment of human melanoma cells with BA also decreases 
mitochondrial membrane potential, and this is accompanied by modulation of other 
proapoptotic pathways including activation of p38 and JNK and induction of reactive 
oxygen species (512).  
Subsequent studies have reported that BA or its derivatives exhibit 
antitumorigenic activity, not only in melanoma cells (500, 510, 513-517) but in other 
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tumor-derived lung, colon, prostate, leukemia, ovarian, endothelial carcinoma, breast, 
cervical, medulloblastoma, neuroblastoma, glioblastoma, liver, osteosarcoma, oral 
epidermoid carcinoma, and rhabdomyosarcoma cell lines (500, 510, 517-540).  Other 
lupane derivatives similar in structure to BA exhibit comparable activities in cancer cells 
(536, 541).  In most of these cell lines, the mechanisms of action of BA are variable; 
however, induction of apoptosis is clearly a predominant pathway.  Studies in this 
laboratory have demonstrated that like BA, CDDO and related compounds induce 
apoptosis in several cancer cell lines; and we have observed similar responses using a 
series of new 2-cyano-substituted analogs of glycyrrhetinic acid (GA) that are isomeric 
with CDDO (302) .  However, results obtained with GA derivatives showed that the 
unsubstituted compounds exhibited minimal activity as inhibitors of cancer cell 
proliferation, whereas BA was active in several cell lines at 1 - 5 μM concentrations.  
The high cytotoxicity of 2-cyano substituted analogs of GA was due, in part, to their 
PPARγ activity which is not observed with BA and thus we hypothesized that 
introduction of 2-cyano group into the lupine skeleton of BA would generate a new class 
of PPARγ agonists. Studies to compare the effects of BA, CN-BA, and the 
corresponding methyl ester (CN-BA-Me) in pancreatic and colon cancer cells are carried 
out (Fig. 1.19). These data suggest that among the naturally-occurring triterpenoids 
which contain a carboxylic acid moiety in the E-ring derived from oleane (GA and 
oleanolic acid), ursane (ursolic acid), and lupane (BA), BA was clearly the most potent 
antitumorigenic compound.  Based on the reported low toxicity of BA (510) coupled 
with its high anticancer potency, we initiated both in vitro and in vivo studies to probe 
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the antiproliferative, antiangiogenic and proapoptotic mechanisms of action of BA and 
its cyano analogs in models for prostate, bladder and other cancers.  Our preliminary 
results now show a novel mechanism of action for BA which involves degradation of Sp 
proteins in tumors, whereas minimal effects on Sp protein expression were observed in 
non-tumor tissue.  These results are consistent with the low toxicity of BA in rodent 
models (510).  Moreover, we also show that BA-induced degradation of Sp proteins 
inhibits Sp-dependent antiapoptotic, angiogenic and proliferative pathways in prostate 
and colon cancer cells. 
SPECIFICITY PROTEINS AS NEW DRUG TARGETS 
 Specificity protein 1 (Sp1) was the first transcription factor identified in 1983 by 
its ability to selectively bind and activate transcription of the viral SV40 promoter (542) , 
and the Sp/Krüppel-like factor (KLF) family of zinc finger transcription factors exhibit a 
broad range of tissue-specific and overlapping functions (543-547). Subsequent studies 
revealed that multiple genes that contain GC-boxes are activated by Sp1 and related Sp 
proteins,  including genes such as thymidine kinase (548, 549) , insulin-like growth 
factor- receptor (550)(96), dihydrofolate reductase (DHFR) (551), growth hormone (GH) 
receptor (552)(98), and alcohol dehydrogenase 5 (ADH5) (553). Kadonaga et.al 
determined   various functional domains by cloning Sp1 cDNA from HeLa cell RNA 
using in vitro and whole cell assays (554). These proteins are characterized by their 
carboxy-terminal domains C and D, which contain three C2H2-type zinc fingers that 
recognize GC/GT boxes in promoters of target genes. The amino-terminal domains A 
and B of Sp/KLF proteins are highly variable in both structure and function (Fig. 1.20). 
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Fig. 1.20. Structural motifs in Sp family of proteins (554). 
 
Sp proteins interact with KLF proteins and also with other transcription factors on GC-
rich promoters to activate or repress different classes of genes that are important in the 
regulation of cellular homeostasis (555). Sp1 and Sp3 proteins are ubiquitously 
expressed and have been extensively investigated. For example, Sp1-/- embryos exhibit 
multiple abnormalities, retarded development and embryolethality on day 11 of gestation 
(556).  Sp3-/- mice also exhibit growth retardation, defects in late tooth development, and 
the animals die at birth (557, 558).   
Other members of the Sp/KLF family such as Sp5, Sp6, Sp7, Sp8, and the 
Krüppel-like factors differ from the first four members Sp1,Sp2,Sp3 and Sp4 because 
they are generally of lower molecular weight and do not contain the glutamine-rich N-
terminal activation domain  Sp1-dependent activation of gene expression requires 
interaction with a coactivator complex called CRSP (cofactors required for activation of 
Sp1). CRSP is a multisubunit complex consisting of six to eight polypeptides and is also 
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involved in Sp1-mediated activation of GC-rich genes with TATA boxes or initiator 
sequences and interacts with proteins of the RNA polymerase preinitiation complex 
(559, 560). Sp1 directly interacts with the TBP (561), TATA-binding protein associated 
factors (TAFs) such as TAF130 (562) and TAF110 (563, 564) and other members of the 
preinitiation complex through the glutamine-rich activation domains A and B and with 
TAF55 through the C-terminal domain (565).  Sp1 also interacts with proteins that are 
not involved directly with the transcription machinery and these interactions may 
activate or repress transcription. Most of the proteins that functionally interact with Sp1 
are other sequence-specific transcription factors and these include Oct-1 (566), NF-κB 
(567, 568), and E2F-1 (549, 569). Sp1 and E2F interact cooperatively on the 
dihydrofolate reductase (DHFR) and thymidine kinase promoters resulting in a 
synergistic activation of transcription. Sp1 also functionally and physically interacts with 
GATA-1, an erythroid transcription factor and this interaction activates the 
erythropoietin receptor (EpoR) and chicken α-globin promoters (570). 
Sp proteins and cancer 
The critical requirement for Sp proteins during embryonic and postnatal 
development is in contrast to decreased expression in mature tissue/organs, which are 
relatively quiescent.  In contrast, there is increasing evidence that Sp1 and other Sp 
proteins such as Sp3 and Sp4 are overexpressed in tumors compared to most other 
tissues/organs (571-576). In gastric cancer, expression of Sp1 was high in the tumor cells 
whereas the expression was weak in the stromal and normal glandular cells (576). Lou 
and coworkers (577) reported that transformation of fibroblasts resulted in an 8- to 18-
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fold increase in Sp1 expression; and these transformed cells formed highly malignant 
tumors in athymic nude mouse xenograft models, whereas untransformed fibroblasts 
expressing low levels of Sp1 did not form tumors.  In addition, ribozyme-dependent 
knockdown of Sp1 in the transformed cells decreased VEGF expression and increased 
apoptosis.  Sp1 knockdown by using small inhibitory RNA against Sp1  was shown to 
inhibit G0-G1 to S-phase progression in MCF-7 breast cancer cells (578). Knockdown of 
Sp3 and Sp4 along with Sp1 in pancreatic cancer cells show that these proteins regulate  
expression of VEGF, VEGF receptor 1(VEGFR1 or Flt), and VEGFR2 (KDR) (579-
581). In addition, Sp3 has been shown to act as a repressor of p27, a CDK inhibitor in 
pancreatic cancer cells showing that Sp1 and Sp3 play a role in cancer cell proliferation 
and angiogenesis. 
Since Sp proteins are overexpressed in tumors/cancer cells and regulate 
expression of growth, angiogenic and survival genes, then agents that target Sp protein 
degradation should be highly effective as anticancer drugs. Different strategies to 
degrade or repress Sp protein-dependent transactivation are illustrated in Figure 1.21. Sp 
proteins can be targeted by nucleic acid therapy by designing oligos that bind and 
sequester Sp proteins or develop chemical intercalators that inactivate or block Sp 
binding to GC rich motifs. In addition, small molecules that selectively inhibit Sp protein 
activation or expression would also block both Sp-dependent genes or pathways.  The 
COX-2 inhibitor celecoxib decreases  expression of Sp1 and VEGF by  downregulating 
the expression of  Sp1 in pancreatic cancer cells (582).  The Cox-2 inhibitor Celecoxib, 
the NSAID tolfenamic acid (and related anthranilic acids), and the phytochemical 
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Fig. 1.21. Strategies for targeting Sp proteins in cancer cells. 
 
betulinic acid also represses Sp protein expression in cancer cells and tumors but not in 
non-tumor tissue (331, 547, 578-581, 583-585). Moreover, these chemicals are potent 
inhibitors of tumor growth and metastasis and exhibit minimal toxic side-effects. 
Previous studies on these compounds demonstrated their cytotoxicity, proapoptotic and 
antiangiogenic activities but did not show the important contributions of Sp protein 
repression in mediating these responses. Many other anticancer drugs including 
phytochemicals are also cytotoxic and induce antiangiogenic and proapoptotic effects in 
cancer cells. We hypothesize that the underlying mechanism of action may be through 
repression of Sp proteins. 
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MICRORNA’S AS NEW DRUG TARGETS 
MicroRNA’s(miRNAs) are small noncoding single stranded RNA molecules 
about 18-24 nucleotides in length that  play a role in posttranscriptional gene regulation 
(586, 587). The first miRNA discovered was lin-4 from Caenorhabditis elegans (588). In 
mammalian cells, miRNAs are processed from primary transcripts known as pri-miRNA 
which are generated by type II RNA polymerase in the form of long, polycystronic 
messages (589, 590). These pri-miRNA’s are then processed into short hairpin 
precursors of about 60-110 basepair pre-miRNA’s by a microprocessor complex 
comprised of an RNase III endonuclease enzyme Drosha and a double stranded RNA 
binding protein DGCR8 in the nucleus. These pre-miRNA’s are again transported back 
to cytoplasm by exportin 5 where they are processed by Dicer into mature miRNA’s of 
about 18-24 base pair length with 5’ phosphates and a 2-nucleotide 3’ overhang (591-
593). Mature miRNA’s are partially complementary to multiple mRNA molecules and 
hybridization results in downregulation of their gene expression. The antisense strand of 
the miRNA is incorporated into the ribonucleoprotein complex called RNA-induced 
silencing complex (RISC) and this complex binds to the target mRNA at the 3’UTR 
through complementary base pairing as shown in the Figure 1.22 (594).  
Each miRNA interacts with multiple  mRNAs by perfect base pairing and this 
results in translational inhibition and silencing of multiple transcripts (595). MiRNAs 
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Fig. 1.22. Schematic representation of miRNA biogenesis (596). 
 
 
have a wide range of functions which include regulation of cell proliferation, 
differentiation, death, stress resistance, and fat metabolism (597). The number and tissue  
distribution of miRNAs is not yet been determined but some miRNAs are  present in all 
tissues and others are tissue specific (598). The function of miRNAs in normal and 
diseased tissues is being extensively studied and transgenic mice deficient in specific 
miRNAs have  clarified the physiologic roles of specific miRNAs (599-602). For 
example, miR-208 is a cardiac-specific miRNA and knockdown of this miR in mice 
resulted in modulation of both a and b myosin heavy chain expression of the muscle 
fibers and their response to both stress and hypothyroidism (602). 
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MicroRNA’s and cancer 
The role of microRNA’s in the development of cancer is being extensively 
studied and includes their use as biomarkers for cancer diagnosis and prognosis (603-
606). The technology of miRNA microarrays is an important element for  high 
throughput screening of miRNA fingerprints in normal and cancer cells (605). Other 
miRNA technologies have also been developed and these include macroarrays (607), 
bead-based flow cytometric miRNA expression (606) and quantitative reverse 
transcription-PCR (608) for determining microRNA expression profiles in different 
types of cancers. Cancer-specific miRNA’s have been identified in almost every tumor 
type using these technologies. The identification of miRNA’s that are altered in  
different types of solid tumors have lead to identification of the their role in pathways 
associated with the development of cancer (609). MicroRNA’s are located in  regions of 
DNA that are involved in cancer and these include minimal regions of  loss of 
heterozygosity (LOH), minimal amplicons or break point cluster regions leading to the 
widespread misexpression in cancers (588). MicroRNA’s are contributors to 
oncogenesis and are involved both in tumor-suppression (e.g. miR-15a and miR-16-1) 
and oncogenic (e.g. miR-155 or miR-17-92 cluster) activities. Repression of the tumor 
suppressor miR-15a/miR-16-1 leads to overexpression of the antiapoptotic protein, Bcl-
2, whereas overexpression of oncogenic miR-17-92 activates c-myc and leads to cell 
proliferation. Overexpressed oncogenic miRNAs are located in the amplified regions of 
DNA and dowregulated tumor suppressor miRNAs are located in the deleted regions in 
cancer. For example, miR-21 interacts with 3’UTR of tropomyosin (TPM1), a tumor 
  
 
91
suppressor in breast cancer cells and thus plays a role as an oncogenic miR by 
downregulating a tumor suppressor (610). 
MiRNA’s are located in all regions of the  human genome but several are  
concentrated in regions that are altered in many cancers (611) resulting in changes in 
miR expression. For example, miR-15 and –16 are downregulated in B-cell chronic 
lymphocytic leukemia (CLL) and miR-155 is upregulated in Burkitts lymphoma, 
nonsmall cell lung cancer and breast cancer (612-614) (615, 616); miR-143 and –145  
are downregulated in colon cancer whereas let-7, which targets RAS, is downregulated 
in nonsmall cell lung cancers (617) and is indicative of a poor prognosis. MiRNA 
alterations that are observed in somatic cells initiate tumorigenesis, and expression of 
specific miRNAs in germ line cells may predispose these individuals to cancer. 
MicroRNA’s and Sp proteins 
Scott and coworkers (618) reported that miR-27a suppressed ZBTB10/RINZF 
expression in SKBR3 breast cancer cells and  previous studies showed that ZBTB10 is a  
novel zinc finger protein that inhibits Sp-1 dependent activation of the gastrin gene 
promoter (619). This indicates that miR-27a supressess a Sp repressor ZBTB10 and 
could lead to overexpression of Sp proteins in cancer cells. The role of miR-27a in 
regulation of Sp proteins in MDA-MB-231 breast cancer cells was investigated by 
transfecting cells with antisense miR-27a (as-miR-27a) or ZBTB10 expression plasmid. 
As-miR-27a and ZBTB10 decreased levels of Sp proteins and as-miR27a increased 
ZBTB10 mRNA levels. In contrast, the effects of as-miR-27a and ZBTB10 
overexpression on the cell cycle were different.  ZBTB-10 overexpression blocked G0-
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G1 to S phase progression and this was consistent with previous studies in MCF-7 cells 
using RNA interference for Sp1. In contrast, transfection of as-miR-27a resulted in 
accumulation of MDA-MB-231 breast cancer cells in G2-M (585). The failure of cells to 
undergo mitosis is linked to decreased activity of cdc2/cyclin B and both Wee-1 and 
Myt-1 are two genes that are important in the downregulation of cdc2/cyclin B activity 
and are also potential targets of miR-27a since their 3’UTRs have miR-27a binding sites. 
In MDA-MB-231 cells, as-miR-27a induces Myt-1and but not Wee-1gene expression, 
and this results in phosphorylation of cdc-2 and cell cycle arrest at G2/M (585). 
EIF-4E AS A NEW ANTICANCER DRUG TARGET 
 The eukaryotic translation initiation factor eIF-4E is dysregulated in most  
human cancers including breast cancer and acute myeloid leukemia (620) where  it is 
used as a prognostic indicator for cancer survival (621). In experimental mouse models 
increased levels of eIF-4E results in increased tumor number and malignancy (622). 
Translation is a critical step in many important cellular processes and this requires 
regulation of the rate of translation. Translation has been described as a housekeeping 
mechanism but is now recognized as a critical step in different pathophysiological 
processes such as apoptosis and cell proliferation, and dysregulation of this step has  
been associated with malignant transformation and  development of multiple cancers 
(623, 624). Eukaryotic mRNA is monocistronic and has a 5’-7-methylguanosine cap and 
3’ poly (A) tail. Cap-dependent translation is the major translation mechanism in 
eukaryotes. Translation involves three different steps namely initiation, elongation and 
termination and translation initiation has always been the rate limiting step in the process 
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of protein synthesis. This rate limiting step is primarily controlled by two multiprotein 
complexes and their association with mRNA  and  includes the ternary and eIF-4F 
complexes (624). The convergence of these complexes on mRNA allows scanning of 
ribosomes and the initiation of translation. EIF-4F complex is comprised of the scaffold 
eIF4G, the ATP-dependent RNA-helicase eIF4A, and the cap binding protein eIF-4E. 
EIF-4E binds the 5’cap of mRNA and helps deliver mRNAs to the eIF-4F initiation 
complex. Elevated levels of eIF-4E result either from increased expression or release of 
eIF-4E from 4EBPs (eukaryotic binding proteins) after their phosphorylation by 
AKT/mTOR and ras signaling.  
The availability of eIF-4E is the rate limiting factor in the initiation process. The  
availability of eIF-4E  and the structure of mRNA 5’ untranslated region (5’UTR) dictate 
the efficiency of translation (625). Highly complex 5’UTR structured mRNA also called 
weak mRNAs requires eIF-4E in excess and the translation of these mRNAs is restricted 
whereas strong mRNAs those with simple 5’UTRs do not depend on the availability of 
eIF-4E and are translated. Weak mRNAs are those that are involved in cell proliferation 
(cyclin D1, c-Myc, and ornithine decarboxylase),  survival( Bcl-xl) and angiogenesis 
(VEGF, basic FGF, and HIF-1α) and malignancy (MMP9) (Fig. 1.23) (625). Increased  
levels of free eIF-4E  have been identified in multiple cancers including cancers of 
breast, colon, bladder, lung, prostate and head and neck, leukemias, and lymphomas and 
are associated with their progression to malignancy (625, 626). Overexpression and 
dysregulation of eIF-4E results in an increased number of tumors, invasion and 
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Fig. 1.23. Reducing translation initiation factor supresses malignancy (627). 
 
metastases in mouse models (628). Therefore eIF-4E is an attractive target for anticancer 
drugs since multiple genes can be affected (Fig. 1.23).  
At present there are no specific inhibitors of eIF-4E or its association with 
mRNA has not been identified. Ribavarin  is an antimetabolite drug, used in the 
treatment of viral diseases that inhibits the interaction of eIF-4E with the 5’cap of 
mRNA  resulting in  decreased expression of cyclin D1 and suppressesion of tumor 
growth (629). Inhibitors of eIF-4E-eIF4G interactions were developed  by Wagner and 
his colleagues; and these inhibitors  decreased the expression of c-myc and cyclinD1 in 
cell cultures (630).  
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Antisense oligonucleotide chemistry (ASO) has been developed to decrease eIF-
4E expression. Several modifications were made to increase the tissue stability and to 
avoid the immunostimulatory effects of a 20-mer ASO which suppresses the expression 
of eIF-4E (631). Graff and his colleagues  used second generation eIF4E ASOs to treat 
mice with subcutaneous xenograft tumors and the results showed that there was 
approximately 50% decrease in eIF4E levels within the tumors and  almost complete 
reduction in the tumor growth.  EIF4E ASO treatment also reduced VEGF levels and 
vessel number in the tumors with minimal or negligible effect on liver transaminase 
levels (631). Unlike cycloheximide which blocks translation elongation and reduces all 
new protein synthesis, ASO treatment decreases  protein synthesis by only 20% 
suggesting some specificity. Clinical trials are underway with eIF4E ASO to determine 
the efficacy of targeting eIF4E in human cancers.  
EIF-4E is phosphorylated by agents that aid in the activation of translation (632, 
633). In normal tissues eIF-4E is sequestered by hypophophorylated 4EBPs and thereby 
restrict the translation to housekeeping genes whereas in tumors, 4EBPs are 
phosphorylated and release eIF-4E resulting in increased translation of genes involved in 
cell proliferation, survival, and metastases (Fig. 1.24). EIF-4E in mammals is 
phosphorylated on serine209 by the Mnk1 and Mnk2 kinases which are bound to eIF4G. 
The role of eIF-4E  phosphorylation has not been determined; however, some studies 
indicate that phosphorylated eIF-4E aids in growth by increasing  affinity for cap 
analogs (634).  
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Fig. 1.24.  Availability and  phosphorylation of eIF-4E playing a role in differential 
translation in normal tissues and tumors (635). 
 
 
In contrast, some studies  have reported that there is decreased affinity of cap 
analogs for phospho- eIF-4E (636). A correlation between eIF-4E phosphorylation and 
enhanced protein synthesis has been reported; and two models have been proposed to 
describe the regulation of  eIF-4E activity by phosphorylation at Ser209 (637). Based on 
the crystallographic structure of the mouse eIF-4E complex with m7GDP, Marcotrigiano 
et al  (638) have  proposed a clamping model in which  there is formation of salt bridge 
between the phosphorylated Ser 209 and Lys 159 situated across the entry to the cap 
binding slot  and these are separated by 7 A0 . This clamp stabilizes the mRNA chain at 
the protein surface. Phosphorylation and clamping may occur only after mRNA binding. 
The second model was proposed by Scheper who observed 10-fold increase in the 
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dissociation rate of eIF-4E with cap analogs after phosphorylation and this is 
contradictory to the clamping model. With decreasing binding affinity for cap it is 
possible that the tethered eIF4F is released from the 5’end of mRNA to enhance 
ribosome scanning. Another explanation could be the reprogramming of the translational 
machinery by releasing initiation factors from the existing complexes to allow other 
mRNAs to be translated (639). A recent study by Topisirovic and his colleagues 
demonstrated that phosphorylation of eIF-4E though not necessary enhances its ability to 
transform cells and eIF-4E dependent nucleocytoplasmic transport of some mRNAs 
including cyclin D1 (640). Therefore inhibiting the activity of eIF-4E by decreasing the 
phsophorylation also stands as an exciting novel approach in the treatment of cancer. 
The potential for eliciting toxicity with a treatment that inhibits a general protein 
synthesis factor was of concern but surprisingly results from the ASO studies that target 
eIF4E show that there was minimal toxicity associated with this approach. Moreover, the 
ASO significantly decreased the tumor growth suggesting that this may be an effective 
strategy for treatment of human malignancies that should be further investigated.  
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CHAPTER II 
STRUCTURE-DEPENDENT ACTIVITY OF GLYCYRRHETINIC ACID 
DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTOR γ (PPARγ)  
AGONISTS IN COLON CANCER CELLS* 
INTRODUCTION 
 Licorice root extracts have been extensively used for their therapeutic properties 
which include the potentiation of cortisol action, inhibition of testosterone biosynthesis, 
reduction in body fat mass and other endocrine effects (487, 641-643). The activities of 
these extracts are linked to different classes of phytochemicals particularly the major 
water soluble constituent glycyrrhizin and its hydrolysis product 18β-glycyrrhetinic acid 
(GA) (Fig. 1.18). Glycyrrhizin is a pentacyclic triterpenoid glycoside which is 
hydrolyzed in the gut to GA and many of the properties of licorice root can be attributed 
to GA. For example, GA inhibits 11β-hydroxysteroid dehydrogenase activity increasing 
corticosterone levels and this has been linked to apoptosis in murine thymocytes, 
splenocytes and decreased body fat index in human studies (489, 644-647). GA also 
directly acts on mitochondria to induce apoptosis through increased mitochondrial 
swelling, loss of mitochondrial membrane potential and release of cytochrome C (648, 
649).  
____________ 
*Reprinted with permission from “Structure-dependent activity of glycyrrhetinic acid 
derivatives as peroxisome proliferator-activated receptor γ (pparγ) agonists in colon 
cancer cells” by Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S. Mol 
Cancer Ther 2007;64:1588-98. Copyright 2007 by American Association for Cancer 
Research. 
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GA has also been used as a template to synthesize bioactive drugs. For example 
carbenoxolone, the 3-hemisuccinate derivative of GA, has been used for the treatment of 
gastritis and ulcers (650). Some of the activity of carbenoxolone may be due to 
hydrolysis to GA however carbenoxolone itself induced oxidative stress in liver 
mitochondria and decreased mitochondrial membrane potential. Other carboxyl and 
hydroxyl derivatives of glycyrrhizic acid inhibit HIV and exhibit anti-inflammatory and 
immunomodulatory activities (651). In addition, GA derivatives containing a reduced 
carboxylic acid group at C-30 (CH2OH) and some additional functional changes 
exhibited strong antioxidant activity (652). 
 Structure-activity studies on the anti-inflammatory activities and cytotoxicity of 
several oleanolic and ursolic acid derivatives demonstrated that addition of a 2-cyano 
substituent greatly enhanced their activity (463, 464, 653-655). Moreover, one of the 2-
cyano analogs of oleanolic acid, namely 2-cyano-3,12-dioxo-17α-olean-1,9(11)-diene-
28-oic acid (CDDO) and its methyl ester (CDDO-Me) exhibited PPARγ agonist activity 
(234, 302, 656).  Although GA also has an oleanolane triterpenoid backbone, there are 
major structural differences between GA and oleanolic acid and between CDDO-Me and 
the synthetic GA analog methyl 2-cyano-3, 11-dioxo-18β-olean-1, 12-dien-30-oate (β-
CDODA-Me).  CDODA-Me (β-CDODA-Me) is isomeric with CDDO-Me (α-CDDO-
Me) but differs with respect to the carboxy substitution in the E ring, the stereochemistry 
at C-18 (β vs. α) in the E/D ring junction, and the enone function in the C ring (Fig. 
1.18).  In order to more fully investigate the importance of the stereochemistry at C-18 in 
modulating cytotoxicity and PPARγ agonist activity of triterpenoid acids, we also 
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synthesized methyl 2-cyano-3, 11-dioxo-18α-olean-1,12-dien-30-oate (α-CDODA-Me).  
Our results show that introduction of the 2-cyano group into α- or β-GA resulted in 
enhanced cytotoxicity, and both compounds induced PPARγ-dependent transactivation 
in colon cancer cells, including receptor and cell context-dependent activation of  
caveolin-1 and Krüppel-like factor-4 (KLF-4), two genes associated with growth 
inhibitory responses in colon cancer.  However, it was also apparent that the different 
stereochemistries at C18 and the altered confirmation of the E-ring resulted in different 
PPARγ-dependent effects in colon cancer cells, suggesting that the α-CDODA-Me and 
β-CDODA-Me isomers are selective receptor modulators (SRMs). 
MATERIALS AND METHODS 
Cell lines   
Human colon carcinoma cell lines SW480, HCT-15 and HT29 were provided by 
Dr. Stan Hamilton, M.D. Anderson Cancer Center (Houston, TX); SW-480 and HT-29 
cells were maintained in Dulbecco's modified Eagle's medium nutrient mixture with 
Ham's F-12 (DMEM/Ham's F-12; Sigma-Aldrich, St. Louis, MO) with phenol red 
supplemented with 0.22% sodium bicarbonate, 0.011% sodium pyruvate, and 5% fetal 
bovine serum and 10 ml/L 100x antibiotic antimycotic solution (Sigma-Aldrich).  HCT-
15 cells were maintained in RPMI 1640 (Sigma) supplemented with 0.22% sodium 
bicarbonate, 0.11% sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% fetal bovine 
serum, and 10 ml/L of 100X antibiotic antimycotic solution.  Cells were maintained at 37 
°C in the presence of 5% CO2. 
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Synthesis 
3, 11-Dioxo-18β-oleana-1,12-dien-30-oic acid (β-DODA) and α-DODA.  A 
mixture of 18β-glycyrrhetinic acid (157 mg, 0.3333 mmol) (Sigma-Aldrich) and 2-
iodoxybenzoic acid1 (IBX) (373.4 mg, 1.333 mmol, 4 equiv) in 7 ml DMSO was stirred 
with heating at 85 °C for 21 h.  After cooling, the solution was poured into water (100 
ml) giving a white precipitate which was filtered and washed with methanol/methylene 
chloride (1:9).  This material (381 mg) was triturated with ethyl acetate (5 ml), washed 
several times with this solvent, and the dissolved material recovered by evaporation and 
purified by preparative scale TLC using MeOH/CH2Cl2 (1:19) as eluant.  The main band 
gave β-DODA as a white solid (133 mg, 85.5%) which was crystallized from methanol 
(104 mg), mp 270-5 °C.  1H NMR δ 7.746 (1H, d, J = 10.4 Hz, C1-H), 5.816 (1H, d, J = 
10.4 Hz, C2-H), 5.817 (1H, s, C12-H), 2.691 (1H, s, C9-H), 1.422, 1.401, 1.245, 1.191, 
1.169, 1.118, 0.872 (all 3H, s, CMe).  A similar procedure was used for the synthesis of 
α-DODA from 18α-glycyrrhetinic acid (Sigma-Aldrich). 
 Methyl 3, 11-dioxo-18β-oleana-1,12-dien-30-oate (β-DODA-Me) and α-DODA-
Me.  Methyl 18β-glycyrrhetinate was prepared by diazomethylation of 18β-
glycyrrhetinic acid and a sample (161 mg, 0.3333 mmol) reacted with the IBX reagent 
(373 mg, 1.333 mmol, 4 equiv) as above for the parent acid.  After a similar work-up, 
the recovered product was purified by preparative TLC (MeOH/CH2Cl2; 1:19) to give a 
colorless solid (155.3 mg, 96.9%) which on crystallization, gave needles (140 mg), mp 
192-4 °C.  1H NMR δ 7.745 (1H, d, J = 10.0 Hz, C1-H), 5.812 (1H, d, J = 10.0 Hz, C2-
H), 5.770 (1H, s, C12-H), 3.078 (3H, s, OMe), 2.681 (1H, s, C9-H), 1.419, 1.390, 1.184, 
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1.166, 1.159, 1.118, 0.833 (all 3H, s, CMe).  A similar procedure was used for the 
synthesis of α-DODA-Me from α-DODA.  
 2-Cyano-3,11-dioxo-18β-oleana-1,12-dien-30-oic acid (β-CDODA) and α-
CDODA.  The two cyano derivative of 18β-glycyrrhetinic acid was synthesized as 
previously described (657), and a sample (422 mg, 0.8961 mmol) of this compound and 
DDQ3 (247 mg, 1.088 mmol) in dry benzene (55 ml) was heated to reflux, with stirring, 
for 6 h.  The reaction mixture was filtered, washed with benzene, and the filtrate plus 
washings were combined, evaporated and purified by preparative TLC (ethyl 
acetate/hexane, 1:1) to give β-CDODA (149 mg, 33.7%).  This material was crystallized 
twice from ethyl acetate/hexane to give a yellow solid (55.5 mg), mp 195-7 °C.  1H 
NMR δ 8.550 (1H, s, C1-H), 5.846 s, C12-H), 2.2.715 (1H, s, C9-H), 1.455, 1.404, 
1.255, 1.225, 1.200, 1.162, 0.876 (all 3H, s, CMe).  A similar procedure was used for the 
synthesis of α-CDODA from 18α-glycyrrhetinic acid. 
 Methyl 2-cyano-3, 11-dioxo-8β-oleana-1,12-dien-30-oate (β-CDODA-Me) and 
α-CDODA-Me.  The nitrile was also prepared from methyl 18β-glycyrrhetinate, and the 
resulting ester (246 mg, 0.4863 mmol) and DDQ (134 mg, 0.5905 mmol) in dry benzene 
(20 mL) was refluxed for 5 h to give β-CDODA-Me.  The compound was purified by 
TLC (ethyl acetate/hexane; 1:3) to give β-CDODA-Me and crystallized from ethyl 
acetate/hexane (138 mg), mp 243-5 °C.  1H NMR δ 8.553 (1H, s, C1-H), 5.805 s, C12-
H), 3.716(3H, s, OMe), 2.706 (1H, s, C9-H), 1.454, 1.393, 1.223, 1.194, 1.168, 1.161, 
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0.834 (all 3H, s, CMe).  A similar procedure was used for the synthesis of α-CDODA-
Me from α-DODA.  
Antibodies and reagents 
Caveolin 1 antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA).  Monoclonal β-actin antibody and 18α- and 18β-glycyrretinic acid (GA) 
were purchased from Sigma-Aldrich.  Reporter lysis buffer and luciferase reagent for 
luciferase studies were supplied by Promega (Madison, WI).  β-Galactosidase (β-Gal) 
reagent was obtained from Tropix (Bedford, MA), and LipofectAMINE reagent was 
purchased from Invitrogen (Carlsbad, CA).  Western Lightning chemiluminescence 
reagent was obtained from PerkinElmer Life and Analytical Sciences (Boston, MA).  
The PPARγ antagonists 2-chloro-5-nitro-N-phenylbenzamide (GW9662) and N-(4'-
aminopyridyl)-2-chloro-5-nitrobenzamide (T007) were synthesized in this laboratory, 
and their identities and purity (>98%) were confirmed by gas chromatography-mass 
spectrometry.  Melting points were determined with a Kofler hot-stage apparatus.  1H 
NMR spectra were run in CDCl3 on a Bruker Avance-400 spectrometer using Me4Si as 
an internal standard.  For analytical and preparative use, TLC plates were spread with 
Silica Gel 60 GF (Merck).  Elemental microanalyses were carried out by Guelph 
Chemical Laboratories Ltd.   
Plasmids  
The Gal4 reporter containing 5x Gal4 response elements (pGal4) was kindly 
provided by Dr. Marty Mayo (University of North Carolina, Chapel Hill, NC).  
Gal4DBD-PPARγ construct (gPPARγ) was a gift of Dr. Jennifer L. Oberfield 
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(GlaxoSmithKline Research and Development, Research Triangle Park, NC).  PPRE3-luc 
construct contains three tandem PPREs with a minimal TATA sequence in pGL2.  The 
GAL4 coactivator (PM coactivator) and VP-PPARγ chimeras were provided by Dr. S. 
Kato, University of Tokyo (Tokyo, Japan)  (658).  
Transfection and luciferase assay   
Colon cancer cell lines SW480 and HT29 (1 x 105 cells/well) were plated in 12-
well plates in DMEM/Ham's F-12 media supplemented with 2.5% charcoal-stripped 
FBS.  After 16 h, various amounts of DNA [i.e., Gal4Luc (0.4 μg), β-Gal (0.04 μg), 
Gal4PPARγ and PPRE-Luc (0.04 μg)] were transfected using Lipofectamine reagent 
(Invitrogen) following the manufacturer's protocol.  Five h after transfection, the 
transfection mix was replaced with complete media containing either vehicle (DMSO) or 
the indicated ligand for 20 to 22 h.  Cells were then lysed with 100 μL of 1x reporter 
lysis buffer, and 30 μL of cell extract was used for luciferase and β-Gal assays.  A 
LumiCount luminometer (PerkinElmer Life and Analytical Sciences) was used to 
quantitate luciferase and β-Gal activities, and the luciferase activities were normalized to 
β-Gal activity.  Results are expressed as means ± S.E. for at least three replicate 
determinations for each treatment group. 
Mammalian two-hybrid assay  
 SW480 cells were plated in 12-well plates at 1 x 105 cells/well in DMEM/F-12 
media supplemented with 2.5% charcoal-stripped fetal bovine serum.  After growth for 
16 h, various amounts of DNA, i.e. Gal4Luc (0.4 μg), β-gal (0.04 μg), VP-PPARγ (0.04 
μg), pMSRC1 (0.04 μg), pMSRC2 (0.04 μg), pMSRC3 (0.04 μg), pMPGC-1 (0.04 μg), 
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pMDRIP205 (0.04 μg), and pMCARM-1 (0.04 μg) were transfected by Lipofectamine 
(Invitrogen) according to the manufacturer's protocol.  After 5 h, the transfection mix 
was replaced with complete media containing either vehicle (DMSO) or the indicated 
ligand for 20 - 22 h.  Cells were then lysed with 100 ml of 1x reporter lysis buffer, and 
30 μL of cell extract was used for luciferase and β-galactosidase assays.  Lumicount was 
used to quantitate luciferase and β-galactosidase activities, and the luciferase activities 
were normalized to β-galactosidase activity. 
Cell proliferation assay   
SW480, HCT-15 and HT 29 cells (2 x 104) were plated in 12-well plates, and 
media was replaced the next day with DMEM/Ham's F-12 media containing 2.5% 
charcoal-stripped FBS and either vehicle (DMSO) or the indicated ligand and dissolved 
in DMSO.  Fresh media and compounds were added every 48 h.  Cells were counted at 
the indicated times using a Coulter Z1 cell counter.  Each experiment was done in 
triplicate, and results are expressed as means ± S.E. for each determination. 
Western blot analysis   
SW-480, HCT-15 and HT-29 (3 x 105) cells were seeded in six-well plates in 
DMEM/Ham's F-12 media containing 2.5% charcoal-stripped FBS for 24 h and then 
treated with either the vehicle (DMSO) or the indicated compounds.  Whole-cell lysates 
were obtained using high-salt buffer [50 mM HEPES, 500 mM NaCl, 1.5 mM MgCl2, 1 
mM EGTA, 10% glycerol, and 1% Triton X-100, pH 7.5, and 5 μL/ml Protease Inhibitor 
Cocktail (Sigma-Aldrich)].  Protein samples were incubated at 100 °C for 2 min, 
separated on 10% SDS-PAGE at 120 V for 3 to 4 h in 1x running buffer (25 mM Tris-
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base, 192 mM glycine, and 0.1% SDS, pH 8.3), and transferred to polyvinylidene 
difluoride membrane (PVDF; Bio-Rad, Hercules, CA) at 0.1 V for 16 h at 4 °C in 1x 
transfer buffer (48 mM Tris-HCl, 39 mM glycine, and 0.025% SDS).  The PVDF 
membrane was blocked in 5% TBST-Blotto (10 mM Tris-HCl, 150 mM NaCl, pH 8.0, 
0.05% Triton X-100, and 5% nonfat dry milk) with gentle shaking for 30 min and was 
incubated in fresh 5% TBST-Blotto with 1:1000 (for caveolin-1), and 1:5000 (for β-
actin) primary antibody overnight with gentle shaking at 4 °C.  After washing with 
TBST for 10 min, the PVDF membrane was incubated with secondary antibody (1:5000) 
in 5% TBST-Blotto for 90 min.  The membrane was washed with TBST for 10 min, 
incubated with 10 ml of chemiluminescence substrate (PerkinElmer) for 1.0 min, and 
exposed to Kodak X-OMAT AR autoradiography film (Eastman Kodak, Rochester,-
NY).  
Semi quantitative reverse transcription-PCR analysis  
 SW480, HT-29 and HCT-15 cells were treated with either DMSO (control) or 
with the indicated concentration of the compound for 12 h.  Total RNA was extracted 
using RNeasy Mini Kit (Qiagen Inc., Valencia, CA), and one microgram of RNA was 
used to synthesize cDNA using Reverse Transcription System (Promega).  The PCR 
conditions were as follows:  initial denaturation at 94 °C (1 min) followed by 28 cycles 
of denaturation for 30 sec at 94 °C, annealing for 60 sec at 55 °C and extension at 72 °C 
for 60 sec, and a final extension step at 72 °C for 5 min.  The mRNA levels were 
normalized using GAPDH as an internal housekeeping gene.  Primers were obtained 
from IDT (Coralville, IA) and used for amplification were:  KLF4 (sense 5'-CTA TGG 
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CAG GGA GTC CGC TCC-3') (antisense 5'-ATG ACC GAC GGG CTG CCG TAC -
3'); GAPDH (sense 5'-ACG GAT TTG GTC GTA TTG GGC G-3') (antisense 5'-CTC 
CTG GAA GAT GGT GAT GG-3').  PCR products were electrophoresed on 1% agarose 
gels containing ethidium bromide and visualized under UV transillumination. 
Statistical analysis 
 Statistical differences between different groups were determined by ANOVA 
and Scheffe's test for significance.  The data are presented as mean ± standard deviation 
for at least three separate determinations for each treatment. 
RESULTS 
Growth inhibitory effects of isomeric GA derivatives 
 This study compares the cytotoxicity of 18β-GA and 18α-GA derivatives and 
results in Figure 2.1 summarize the cytotoxicity of β-DODA-Me, β-CDODA-Me, and 
the corresponding 18α-isomers.  Initial studies showed that GA and its methyl esters 
exhibit minimal cytotoxicity and the methyl esters were more potent than the 
corresponding free triterpenoid acids (data not shown).  The α-DODA and β-DODA 
methyl esters exhibited growth inhibitory IC50 values of 10-20 and 10-15 μM, 
respectively, whereas introduction of the 2-cyano substituents into the α- and β-isomers 
greatly enhanced cytotoxicity.  The IC50 values for α-CDODA-Me and β-CDODA-Me 
were 0.5 and 0.2-0.5 μM, respectively, demonstrating the greatly enhanced cytotoxicity 
of the GA derivatives containing the 2-cyano substituents.  Similar results were observed 
in HT-29 and HCT-15 colon cancer cells (data not shown). 
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α-CDODA-Me and β-CDODA-Me activate PPARγ 
 Previous studies have demonstrated that introduction of 2-cyano substituents into 
oleanolic acid and ursolic acid derivatives enhances cytotoxicity of these triterpenoid 
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Fig. 2.1. Growth inhibition studies.  SW480 colon cancer cells were treated with different concentrations 
of α-DODA-Me , α-CDODA-Me (A), β-DODA-Me  and β-CDODA-Me (B) for 6 days, and cell numbers 
were determined using a Coulter Counter as described in the Materials and Methods.  Results are 
expressed as means ± SE for 3 separate determinations at each time point.  Significant (p<0.05) inhibition 
of cell growth was observed for β-DODA-Me (≤ 5 μM), β-CDODA-Me (≤ 0.2 μM), α-DODA-Me (≤ 10 
μM), and α-CDODA-Me (≤ 0.5 μM). 
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acids  (463, 464, 655) as observed in this study for the α- and β-GA derivatives (Fig. 
2.1).  2-Cyano derivatives of oleanolic acid also exhibit PPARγ agonist activity (234)  
and in this study, we have investigated the PPARγ agonist activity of α- and β-CDODA-
Me isomers which exhibit major structural differences in the E-ring of GA.  Results in 
Figure 2.2 A compare activation of PPARγ by α-CDODA-Me and α-DODA-Me in 
SW480 cells transfected with PPARγ-GAL4/pGAL4; 5 μM α-CDODA-Me induces a 
>10-fold increase in activity, whereas α-DODA-Me was inactive at concentrations as 
high as 20 μM.  In a separate experiment, similar results were obtained for β-CDODA-
Me and β-DODA-Me.  The former compound (5 μM) induced a >18-fold increase in 
luciferase activity, whereas the latter compound (30 μM) was inactive (Fig. 2.2 B).  A 
direct comparison of both α-CDODA-Me and β-CDODA-Me is illustrated in Figure 2.2 
C where 5 μM of both compounds induced an (12- to 16- fold) increase in luciferase 
activity in SW480 cells transfected with PPARγ-GAL4/pGAL4.  Cotreatment with 10 
μM of the PPARγ antagonist T007 significantly decreased α-CDODA-Me/β-CDODA-
Me-induced transactivation.  Both α-CDODA-Me and β-CDODA-Me also induced 
transactivation (Figs. 2.2 D and 2.2 E) in SW480 cells transfected with PPRE3-luc, a 
construct which contains three tandem PPARγ response elements linked to luciferase 
and which relies on activation of the endogenous PPARγ-RXR complex expressed in 
this cell line (302).  In addition, both PPARγ antagonists T007 and GW9662 inhibited α-
CDODA-Me/β-CDODA-Me-induced transactivation.  These results demonstrate for the 
first time that introduction of a 2-cyano group into the GA triterpenoid acid structure is  
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Fig. 2.2. Ligand-induced activation of PPARγ, and effects of PPARγ antagonists.  Activation of PPARγ-
GAL4/pGAL4 in SW480 cells treated with α-DODA-Me/α-CDODA-Me (A), β-DODA-Me/β-CDODA-Me (B), and 
both isomers plus T007 (C).  Cells were transfected with PPARγ-GAL4/pGAL4, treated with different concentrations 
of the triterpenoids alone or in combination with T007, and luciferase activity was determined as described in the 
Materials and Methods.  Results of all transactivation studies in this Figure are presented as means ± SE for at least 3 
separate determinations for each treatment group and significant (p < 0.05) induction compared to solvent (DMSO) 
control (*) and inhibition by cotreatment with T007 (**) is indicated.  Activation of PPRE-luc in SW480 cells treated 
with α-CDODA-Me (D) or β-CDODA-Me (E) alone or in combination with PPARγ antagonists.   SW480 cells were 
transfected with PPRE-Luc, treated with different concentrations of CDODA-Me isomers alone or in combination 
with 10 μM GW9662 and/or T007, and luciferase activities were determined as described in Figure 3A.  Significant (p 
< 0.05) induction of luciferase activity (*) and inhibition of induced transactivation by GW9662 or T007 (**) is 
indicated.   
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sufficient for conferring PPARγ agonist activity on the resulting compound.  Moreover, 
both the α-and β-CDODA-Me isomers exhibit similar potencies as PPARγ agonists (β-
CDODA-Me ≥ α-CDODA-Me), suggesting that the conformational differences in the E-
ring which are observed for the 18α- and 18β-isomers do not affect their PPARγ agonist 
activities in the PPARγ-GAL4/pGAL4 and PPRE-luc transactivation assays. 
α-CDODA-Me and β-CDODA-Me as Selective Receptor Modulators (SRMs) 
 PPARγ agonists are structurally diverse (658-661) and there is evidence that 
many of these compounds are selective PPARγ modulators that exhibit tissue-specific 
differences in their activation of receptor-dependent genes/protein.  The selectivity of 
various structural classes of PPARγ ligands is due, in part, to differential interactions 
within the ligand binding domain of PPARγ which can lead to different conformations of 
the receptor.  This can result in differential interactions of the ligand-bound PPARγ with 
nuclear receptor coactivators (658), and results in Figure 2.3 A summarize β-CDODA-
Me-induced transactivation in SW480 cells transfected with GAL4-coactivator and VP-
PPARγ (ligand binding domain) chimeras and a pGAL4 reporter gene.  In this 
mammalian two-hybrid assay, β-CDODA-Me induced PPARγ interactions only with 
PGC-1 and SRC-1 but not with AIB1 (SRC-3), TIFII (SRC-2), CARM1, TRAP220 and  
the corepressor SMRT.  α-CDODA-Me also induced PPARγ-PGC-1 interactions (Fig. 
 2.3). These results suggest that the two α- and β-CDODA-Me isomers, which differ 
only in the conformations of their E-rings, are selective receptor modulators (SRMs) and             
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Fig. 2.3. Ligand-induced PPARγ-coactivator interactions.  SW480 cells were transfected with VP-PPARγ, 
coactivator-GAL4/pGAL4, treated with different concentrations of α-CDODA-Me (A) or both α- and β-
CDODA-Me (B), and luciferase activity was determined as described in the Materials and Methods.  
Results are expressed as means ± SE for 3 replicate determinations for each treatment group, and 
significant (p < 0.05) induction is indicated by an asterisk. 
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induce different patterns of coactivator-receptor interactions in a mammalian two-hybrid 
assay.  These results also suggest that the α- and β-CDODA-Me isomers should exhibit 
some tissue/cell or response-specific differences in their activation of receptor-dependent 
genes. 
 PPARγ agonists induce caveolin-1 in colon cancer cells through a receptor-
dependent mechanism (257, 300).  The effects of α-CDODA-Me on caveolin-1 
expression in HT-29, HCT-15 and SW480 cells is summarized in Figure 2.4 A, and 
induction was observed in all three cell lines.  In contrast, β-CDODA-Me induced 
caveolin-1 in HT-29 and HCT-15 but not SW480 colon cancer cells (Fig. 2.4 B), and the 
failure to observe induction of caveolin-1 in SW480 cells was noted in several replicate 
experiments.  Figures 2.4 C and 2.4 D show that induction of caveolin-1 by α- and β-
CDODA-Me isomers was inhibited in HT-29 and HCT-15 cells cotreated with the 
PPARγ antagonist T007, and similar results were observed for α-CDODA-Me in SW480 
cells (data not shown).  These results demonstrate the tissue-selective induction of 
caveolin-1 expression by β-CDODA-Me and this is consistent with the activity of α- and 
β-CDODA-Me isomers as SRMs.   
 Based on results of preliminary studies on growth inhibitory/proapoptotic genes 
induced by CDODA-Me isomers, we investigated the induction of the tumor suppressor 
gene KLF-4 in colon cancer cells.  Results in Figure 2.5 A show that 1-5 μM  
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Fig. 2.4. Induction of caveolin-1 in colon cancer cells.  SW480, HT-29 or HCT-15 colon cancer cells were treated with α-CDODA-Me (A) or β-
CDODA-Me (B) for 72 hr as previously described (302), and whole cell lysates were analyzed by Western immunoblot analysis as described in the 
Materials and Methods.  Inhibition of caveolin-1 induction by α- or β-CDODA-Me by T007 in HT-29 (C) or HCT-15 (D) cells.  Cells were treated with 
5 μM T007, 0.5 - 1.0 μM α- or β-CDODA-Me or combinations (as indicated) for 72 hr, and whole cell lysates were analyzed by Western immunoblot 
analysis as described in the Materials and Methods.  Similar results were observed for α-CDODA-Me in SW480 cells (data not shown).  Caveolin-1 
protein expression (relative to β-actin) in the DMSO-treated cells (A and B) was set at 1.0, and significant (p < 0.05) induction is indicated (*).  Results 
are means ± SE for three replicate determinations for each treatment group. 
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concentrations of both α- and β-CDODA-Me isomers induced KLF-4 mRNA levels in 
SW480 cells.  The PPARγ antagonist T007 (10 μM) alone did not induce KLF-4.  In 
SW480 cells cotreated with T007 and the CDODA-Me isomers, there was a significant 
inhibition of the induced response.  A similar experiment was carried out in HT-29 cells 
(Fig. 2.5 B), and both CDODA-Me isomers induced KLF-4 mRNA levels which were 
inhibited after cotreatment with T007.  In contrast, α- and β-CDODA-Me isomers did 
not consistently alter expression of KLF-4 mRNA levels in HCT-15 cells (< 2-fold and 
variable) (Fig. 2.5 C).  These results demonstrate that CDODA-Me isomers exhibited 
similar activities as PPARγ agonists in HT-29 and SW480 colon cancer cells; however, 
induction of KLF-4 mRNA was cell context-dependent and, over several experiments, 
we did not observe significant induction of KLF-4 in HCT-15 cells.  These results on the 
receptor-dependent induction of KLF-4 gene expression by CDODA-Me isomers 
contrasts to the reported receptor-independent induction of KLF-4 gene expression by 
the PPARγ agonist 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) in HT-29 cells (662).  
DISCUSSION 
 PPARγ and other members of the nuclear receptor superfamily are characterized 
by their modular structure which contains several regions and domains that are required 
for critical receptor-protein and receptor-DNA interactions (659-661).  Nuclear receptors 
typically contain N- and C- terminal activation functions (AF1 and AF2, respectively), a 
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Fig. 2.5. Induction of KLF-4 gene expression by α- and β-CDODA-Me.  Induction of 
KLF-4 in SW480 (A), HT-29 (B) and HCT-15 (C) cells.  Cells were treated with 
different concentrations of CDODA isomers or T007 alone or in combination and KLF-4 
mRNA levels were determined by real time PCR as described in the Materials and 
Methods.  Quantitated results(A, B) are means ± SE from three replicate experiments, 
and significant (p < 0.05) induction or inhibition of KLF-4 mRNA levels (*) and 
inhibition of these responses after cotreatment with T007 (**) are indicated.  Induction 
of KLF-4 in HCT-15 cells was highly variable (< 2-fold) and was not further quantitated 
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DNA binding domain and a flexible hinge region.  The addition of receptor ligand 
usually results in formation of a transcriptionally active nuclear receptor complex which 
binds cognate response elements in promoter regions of target genes and activates 
transcription.  However, receptor-mediated transactivation is dependent on several 
factors including cell context-specific expression of coregulatory proteins (e.g. 
coactivators), gene promoter accessibility and ligand structure (663).  The complex 
pharmacology of receptor ligands is due, in part, to the ligand structure-dependent 
conformational changes in the bound receptor complex which may differentially interact 
with coregulatory factors and exhibit tissue-specific agonist and/or antagonist activity 
(663, 664).  This has led to development of selective receptor modulators (SRMs) for 
several nuclear receptors which selectively activate or block specific receptor-mediated 
responses in different tissues/cells.   
 There is evidence that different structural classes of PPARγ agonists are also 
SRMs and induce tissue-specific receptor-dependent and independent responses.  For 
example, induction of NAG-1 in HCT116 colon cancer cells by PGJ2 was PPARγ-
dependent, whereas both troglitazone and PPARγ-active 1,1-bis(3'-indolyl)-1-(p-
substitutedphenyl) methanes (C-DIMs) also enhanced NAG-1 expression through 
receptor-independent pathways in the same cell line (278, 299, 665).  Evidence that 
different structural classes of PPARγ agonists are SRMs has been reported in 
mammalian two-hybrid assays in which cells have been transfected with VP-PPARγ and 
GAL4-coactivator constructs.  For example, PGJ2 and rosiglitazone differentially 
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induced coactivator-PPARγ interactions in COS-1 cells (658), and differences in ligand-
dependent coactivator-receptor interactions were also observed for rosiglitazone and 
PPARγ-active C-DIMs in colon cancer cells (300).   
 Previous studies demonstrated that introduction of a cyano group at C-2 of 
oleanolic acid or ursolic acid enhanced the cytotoxicity of the resulting synthetic analogs 
(464).  Moreover, the oleanolic acid derivatives CDDO and CDDO-Me exhibited 
PPARγ agonist activities (234, 302, 666).  Results of this study also demonstrated that 2-
cyano analogs of the α- and β-GA methyl esters also exhibited increased cytotoxicity 
(Fig. 2.1) and PPARγ agonist activity.  Similar results were observed for the 
corresponding acid derivatives which were less active than α-CDODA-Me or β-
CDODA-Me (data not shown).  Thus, introduction of the 2-cyano group into the 
oleanolic acid and GA backbone is necessary for their PPARγ agonist activities and 
differences in their substitution in the C-ring and the position of carboxymethyl groups 
at C-30 (in GA) or C-28 (in oleanolic acid) did not affect PPARγ agonist activity.  GA 
and oleanolic acid are 18β- and 18α-isomers, respectively (e.g. Fig. 1.18), and their 
different sterochemistries at C-18 results in conformational differences in the E-ring of 
these triterpenoids.  Therefore, in order to directly compare the effects of different E-ring 
conformations on cytotoxicity and PPARγ agonist activity, we investigated the 
comparative effects of α- and β-CDODA-Me.  Both isomers exhibited similar 
cytoxtoxicities and PPARγ agonist activities, suggesting that the sterochemical 
differences at C-18 do not affect PPARγ-dependent transactivation in reporter gene 
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assays (Fig. 2.2), indicating that the PPARγ agonist activity in this assay was primarily 
governed by the 2-cyano substituents. 
 However, results of the mammalian two-hybrid assay (Fig. 2.3) show that α-
CDODA-Me induces interactions between PGC-1 and TIFII (SRC-2), whereas β-
CDODA-Me induces interactions between PGC-1 and SRC-1.  These differences must 
be due to the unique conformations of the E-ring of these isomeric triterpenoids which is 
dependent on the different sterochemistries (α and β) at C-18 located at the E/D ring 
junction (Fig. 1.18).  The mammalian two-hybrid assay uses the GAL4-coactivator 
chimeras as probes for investigating differences in ligand-dependent conformational 
changes in PPARγ.  These results do not necessarily identify which coactivators are 
important for activation of PPARγ since this will also depend on tissue-specific 
expression of coactivators and other important coregulatory proteins.  However, data 
from the two-hybrid assay suggest that, like other structural classes of PPARγ agonists, 
α-CDODA-Me and β-CDODA-Me are selective receptor modulators and this selectivity 
was further investigated using induction of caveolin-1 and KLF-4 as end-points.  Both 
caveolin-1 and KLF-4 were selected as potential PPARγ-dependent responses based on 
results of previous studies showing that both genes are induced by one or more structural 
classes of PPARγ agonists (302, 667-669).  Caveolin-1 expression in colon cancer and 
some other cancer cell lines is associated with reduced rates of cancer cell proliferation 
and anchorage-independent growth (670-673).  KLF-4 is a member of the Sp/KLF 
family of zinc finger transcription factors (674, 675), and KLF-4 expression is also 
correlated with tumor/cancer cell growth inhibition in gastric and colon cancer 
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suggesting that KLF-4 acts as a tumor suppressor gene (676-679).  Previous studies have 
shown that caveolin-1 is induced by thiazolidinediones, CDDO/CDDO-Me, and 1,1-
bis(3'-indolyl)-1-(p-substitutedphenyl)methanes (C-DIMs) in HT-29 and other colon 
cancer cell lines.  However, PPARγ-active C-DIMs, but not rosiglitazone, induced 
caveolin-1 in HCT-15 cells (300, 302) and this was related, in part, to a mutation in 
PPARγ expressed in the HCT-15 cell line.  The differences in caveolin-1 induction 
between the two structurally unrelated PPARγ agonists in HCT-15 cells is an example of 
the SRM activity of different structural classes of PPARγ agonists.  We also observed 
cell-specificity differences between α-CDODA-Me and β-CDODA-Me with respect to 
their induction of caveolin-1 in colon cancer cells (Fig. 2.4).  Although α- and β-
CDODA-Me induced caveolin-1 in HT-29 and HCT-15 cells, only the former isomer 
induced this response in SW480 cells and this was observed in replicate experiments.  
Since α-CDODA-Me and CDDO-Me contain the 18α configuration and both 
compounds also induce caveolin-1 (Fig. 2.4 ) (302), this suggests that differences in 
caveolin-1 induction by α- and β-CDODA-Me are due to their different E-ring 
conformations (Fig. 1.18) which also affects ligand-induced PPARγ-coactivator 
interactions (Fig. 2.3).   
 A previous report (680) showed that KLF-4 induction by PGJ2 was PPARγ-
independent and this response was used as a model to investigate mechanistic 
differences in KLF-4 induction by α and β-CDODA-Me and PGJ2.  α- and β-CDODA-
Me induce KLF-4 mRNA levels in HT-29 and SW480 cells (Fig. 2.5A and 2.5B), and 
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cotreatment of these cells with the PPARγ antagonist T007 inhibits induction of KLF-4.  
Similar results were observed for induction of KLF-4 protein (data not shown) 
demonstrating receptor-dependent (α- and β-CDODA-Me) and receptor-independent 
(PGJ2) induction of KLF-4 in HT-29 cells and that the two different structural classes of 
PPARγ agonists exhibit SRM-like activity.   
 Results of this study demonstrate for the first time that introduction of 2-cyano 
substituents into the A ring of α- and β-GA significantly enhances their cytotoxicity and 
is necessary for their activity as PPARγ agonists.  This represents an important extension 
of the potential therapeutic applications of synthetic analogs of GA, a major component 
of licorice extracts.  In addition, we also demonstrate that both α- and β-CDODA-Me 
are SRMs based on their tissue-selective induction of caveolin-1 and KLF-4 in colon 
cancer cells.  These differences in activity are consistent with their structure-dependent 
induction of PPARγ interactions with different coactivators in SW480 cells.  Thus, 
synthetic analogs of GA exhibit potent anticancer activity in colon cancer cells and 
mechanisms of their induction of KLF-4 and other receptor-dependent and -independent 
responses and in vivo applications of these compounds as a new class of anticancer drugs 
is currently being investigated. 
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CHAPTER  III 
METHYL 2-CYANO-3,11-DIOXO-18 β-OLEAN-1,12-DIEN-30-OATE IS A 
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ AGONIST 
THAT INDUCES RECEPTOR-INDEPENDENT APOPTOSIS IN LNCaP 
PROSTATE CANCER CELLS* 
INTRODUCTION 
Peroxisome proliferator-activated receptors (PPARs) are a sub-family of the nuclear 
receptor superfamily of ligand-activated receptors (681, 682).  The three members of this 
family, PPARα, PPARγ and PPARβ/σ are lipid sensors and play a key role in regulating 
tissue-specific lipid homeostasis and metabolism (683).  PPARs also play an important 
role in many diseases particularly those related to obesity, metabolic disorders, cancer 
and atherogenesis (659, 684, 685).  Endogenous ligands for PPARs include fatty acid 
derived compounds and 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) which exhibits high 
affinity for PPARγ; however, PGJ2 may not be the endogenous ligand for this receptor 
due to the low cellular expression of this metabolite.  Synthetic PPARγ agonists, such as 
the thiazolidinediones (TZDs) rosiglitazone and pioglitazone, are insulin-sensitizing 
drugs that are widely used for clinical treatment of type II diabetes. Several different 
structural classes of PPARγ agonists have been characterized and these include flavones,  
____________  
*Reprinted with permission from “Methyl 2-cyano-3,11-dioxo-18 β-olean-1,12-dien-30-
oate is a peroxisome proliferator-activated receptor γ agonist that induces receptor-
independent apoptosis in Lncap prostate cancer cells” by Papineni S, Chintharlapalli S, 
Safe S. Mol Pharmacol 2008;73:553-65. Copyright 2008 by American Society for 
Pharmacology and Experimental Therapeutics. 
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 various indole derivatives, chromane carboxylic acids, phosphonophosphates, and 
triterpenoids such as 2-cyano-3,12-dioxo-17α-olean-1,9-dien-28-oic acid (CDDO) and 
related compounds (281, 463, 482, 686-691).  PPARγ is overexpressed in many tumor 
types and cancer cell lines (283) and PPARγ agonists show promise for the clinical 
treatment of various types of tumors (242, 253, 692-694).  Ligands for this receptor 
typically inhibit G0/G1 to S phase progression and this is accompanied by 
downregulation of cyclin D1 expression and induction of the cyclin-dependent kinase 
inhibitors p27 or p21.  Research from our laboratory has identified a series of 1,1-bis(3'-
indolyl)-1-(p-substituted phenyl)methanes [methylene-substituted diindolyl-methanes 
(C-DIMs)] which inhibit cancer cell and tumor growth (281, 296, 297, 299, 300, 313, 
695) (301)through both receptor-dependent and independent pathways and similar 
observations have been reported for other PPARγ agonists (262, 696-699). 
 A new class of synthetic PPARγ agonists has been derived from glycyrrhetinic 
acid (GA), a major triterpenoid acid found in licorice extracts.  Methyl 2-cyano-3,11-
dioxo-18β-olean-1,12-dien-30-oate (β-CDODA-Me) is a 2-cyano derivative of GA and 
has the same oleanolic acid pentacyclic triterpene backbone structure as CDDO which is 
also a 2-cyano derivative of oleanolic acid (482).  However, there are major structural 
differences between CDODA and CDDO with respect to the position of the carboxylic 
acid group in the E ring, the position of the double bonds and keto group in the C-ring.  
We recently reported that the 18α and 18β isomers of CDODA-Me activate PPARγ in 
colon cancer cells and induced both caveolin-1 and Krüppel-like Factor-4 (KLF4) 
through receptor-dependent pathways (312).  In this study, we have investigated the 
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effects of β-CDODA-Me on the proliferation of LNCaP prostate cancer cells and the 
IC50 value for growth inhibition was approximately 1 μM.  In contrast to studies in colon 
cancer cells, β-CDODA-Me had minimal effects on caveolin-1 or KLF4 expression in 
LNCaP cells.  The proapototic and growth inhibitory effects of β-CDODA-Me in 
LNCaP cells were associated with induction of p21 and p27 expression, downregulation 
of cyclin D1, and induction of NAG-1.  β-CDODA-Me also decreased androgen 
receptor (AR) and prostate specific antigen (PSA) protein and RNA expression and all of 
these responses were PPARγ-independent.  Thus, β-CDODA-Me, a PPARγ agonist, 
inhibited growth and induced apoptosis in LNCaP cells through activation of multiple 
receptor-independent pathways including ablation of AR gene expression. 
MATERIALS AND METHODS  
Cell lines  
 LNCaP human prostate carcinoma cells were obtained from American Type 
Culture Collection (Manassas, VA).  Fetal bovine serum was obtained from JRH 
Biosciences, Lenexa, KS. LNCaP cells were maintained in RPMI 1640 (Sigma 
Chemical, St. Louis, MO) supplemented with 0.22% sodium bicarbonate, 0.011% 
sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% FBS, and 10 mL/L of 100X 
antibiotic/antimycotic solution (Sigma).  Cells were maintained at 37°C in the presence 
of 5% CO2. 
Antibodies and reagents 
 Antibodies for poly(ADP-ribose) polymerase, cyclin D1, p27, FKBP51, AR, 
ATF3, Akt and caveolin-1 were purchased from Santa Cruz Biotechnology, Inc. (Santa 
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Cruz, CA).  PSA was obtained from Dako Denmark A/S (Glostrup, Denmark); NAG-1 
was purchased from Upstate Biotechnology (Charlottesville, VA); and EGR-1, pAKT, 
pERK, ERK, pJNK, JNK were obtained from Cell Signaling Technology Inc. (Danvers, 
MA).  Monoclonal β-actin antibody and dihydrotesterone were purchased from Sigma-
Aldrich.  Reporter lysis buffer and luciferase reagent for luciferase studies were 
purchased from Promega (Madison, WI).  β-Galactosidase (β-Gal) reagent was obtained 
from Tropix (Bedford, MA), and lipofectamine reagents were supplied by Invitrogen 
(Carlsbad, CA).  Western blotting chemiluminescence reagents were from Perkin-Elmer 
Life Sciences (Boston, MA).  The PPARγ antagonist N-(4'-aminopyridyl)-2-chloro-5-
nitrobenzamide (T007) was prepared in this laboratory and the synthesis of the GA 
derivatives has been previously described (312). 
Cell proliferation and DNA fragmentation assays 
LNCaP prostate cancer cells (2 x 104 per well) were added to 12-well plates and 
allowed to attach for 24 hr.  The medium was then changed to DMEM/Ham's F-12 
media containing 2.5% charcoal-stripped FBS, and either vehicle (DMSO) or the 
indicated C-DIMs were added.  Fresh medium and indicated compounds were added 
every 48 hr, and cells were then trypsinized and counted after 2, 4, and 6 days using a 
Coulter Z1 cell counter (Beckman Coulter, Fullerton, CA).  Each experiment was done 
in triplicate, and results are expressed as means ± S.E. for each set of three experiments.  
The DNA fragmentation assay was performed using a BioVision Apoptotic DNA ladder 
extraction kit (BioVision, Mountain View, CA) according to the manufacturer's protocol. 
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Transfections 
The Gal4 reporter construct containing 5X Gal4 response elements (pGal4) was 
kindly provided by Dr. Marty Mayo (University of North Carolina, Chapel Hill, NC).  
The Gal4DBD-PPARγ construct was a gift of Dr. Jennifer L. Oberfield (Glaxo 
Wellcome Research and Development, Research Triangle Park, NC).  The PPRE-luc 
construct contains three tandem PPREs with a minimal TATA sequence linked to the 
luciferase gene in pGL2.  The AR-luc construct containing the -5400 to +580 region of 
the androgen receptor promoter was provided by Dr. Donald J. Tindall (Mayo Clinic, 
Rochester, MN), and the PSA-luc construct containing the 5.8-kilobase region of the 
PSA promoter was provided by Dr. Hong-Wu Cheng (University of California, Davis, 
CA).  LNCaP cells (1 x 105) were seeded in 12-well plates in DMEM/Ham's F-12 media 
supplemented with 2.5% charcoal-stripped FBS and grown overnight.  Transient 
transfections were performed using Lipofectamine reagent (Invitrogen) according to the 
protocol provided by the manufacturer.  Transfection studies were performed using 0.4 
μg of Gal4Luc, 0.04 μg of β-galactosidase, 0.04 μg of Gal4DBD-PPARγ, 0.4 μg of AR-
luc, and 0.3 μg of PSA-luc.  Six hr after transfection, the transfection mix was replaced 
with complete media containing either vehicle (DMSO) or the indicated ligand for 20 to 
22 hr.  Cells were then lysed with 100 μl of 1 x reporter lysis buffer, and 30  μl of cell 
extract was used for luciferase and β-galactosidase assays.  A Lumicount luminometer 
(PerkinElmer Life and Analytical Sciences) was used to quantify luciferase and β-
galactosidase activities, and the luciferase activities were normalized to β-galactosidase 
activity. 
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Real-time PCR 
Total RNA was isolated using the RNeasy Protect Mini kit (QIAGEN, Valencia, 
CA) according to the manufacturer's protocol.  RNA was eluted with 30 μl of RNasefree 
water and stored at -80°C.  RNA was reverse transcribed using Superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer's protocol.  cDNA was prepared 
from the LNCaP cell line using a combination of oligodeoxythymidylic acid and dNTP 
mix (Applied Biosystems, Foster City, CA) and Superscript II (Invitrogen).  Each PCR 
was carried out in triplicate in a 25-μl volume using SYBR Green Master mix (Applied 
Biosystems) for 15 min at 95°C for initial denaturing, followed by 40 cycles of 95°C for 
30 s and 60°C for 1 min in the ABI Prism 7700 sequence detection system (Applied 
Biosystems).  The ABI Dissociation Curves software was used after a brief thermal 
protocol (95°C 15 s and 60°C 20 s, followed by a slow ramp to 95°C) to control for 
multiple species in each PCR amplification.  The comparative CT method was used for 
relative quantitation of samples.  Values for each gene were normalized to expression 
levels of TATA-binding protein.  Primers were purchased from Integrated DNA 
Technologies (Coralville, IA).  The sequences of the primers used for reverse 
transcription-PCR were as follows:  AR forward, 5'-GTA CCC TGG CGG CAT GGT-3' 
and AR reverse, 5'-CCC ATT TCG CTT TTG ACA CA-3'; PSA forward, 5'-GCA TTG 
AAC CAG AGG AGT TCT TG-3' and PSA reverse, 5'-TTG CGC ACA CAC GTC 
ATT G-3'; and TATA-binding protein forward, 5'-TGC ACA GGA GCC AAG AGT 
GAA-3' and reverse, 5'-CAC ATC ACA GCT CCC CAC CA-3'. 
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Western blot analysis 
 Cells were seeded in DMEM:Ham’s F-12 media containing 2.5% charcoal-
stripped FBS for 24 hr and then treated with either the vehicle (DMSO) or the indicated 
compounds.  Cells were collected by scraping in 150 μl high salt lysis buffer (50 mM 
HEPES, 0.5 M NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% (v/v) glycerol, 1% (v/v) 
Triton-X-100 and 5 μL/ml of Protease Inhibitor Cocktail (Sigma).  The lysates were 
incubated on ice for 1 hr with intermittent vortexing followed by centrifugation at 
20,000 g for 10 min at 4°C.  Before electrophoresis, samples were boiled for 3 min at 
100°C; the amount of protein was determined and 60 μg protein applied per lane.  
Samples were subjected to SDS-PAGE on 10% gel at 120 V for 3 to 4 hr.  Proteins were 
transferred on to polyvinylidene difluoride membrane (PVDF; Bio-Rad, Hercules, CA) 
at 0.9 amp for 90 min at 4°C in 1x transfer buffer (48 mM Tris-HCl, 39 mM glycine, and 
0.025% SDS).  The membranes were blocked for 30 min with 5% TBST-Blotto (10 mM 
Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Triton X-100 and 5% non-fat dry milk) and 
incubated in fresh 5% TBST-Blotto with primary antibody overnight with gentle shaking 
at 4°C.  After washing with TBST for 10 min, the PVDF membrane was incubated with 
secondary antibody (1:5000) in 5% TBST-Blotto for 2-3 hr.  The membrane was washed 
with TBST for 10 min and incubated with 10 ml of chemiluminiscence substrate 
(PerkinElmer Life Sciences) for 1.0 min and exposed to ImageTeK-H medical imaging 
film (Eastman American X-ray Supply, Inc.). 
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Statistical analysis 
Statistical differences between different groups were determined by ANOVA and 
Scheffe's test for significance.  The data are presented as mean ± S.E. for at least three 
separate determinations for each treatment group. 
RESULTS 
 Cell proliferation and activation of PPARγ   
β-DODA or 1, 2-dehydro-GA exhibited minimal inhibition of LNCaP cell 
growth with a IC50 value > 15 µM whereas the IC50 for the corresponding methyl ester 
derivative was between 10-15 μM (Fig. 3.1).  Introduction of a 2-cyano group to give β-
CDODA-Me increased the cytotoxicity by at least an order of magnitude and the IC50 
was approximately 1 μM in LNCaP cells (Fig. 3.1A).  These results were similar to 
those observed in colon cancer cells (312) and demonstrate the importance of 2-cyano 
substituents in mediating the cytotoxicity of GA derivatives.  The induction of PPARγ-
dependent transactivation by β-CDODA-Me was also investigated in LNCaP cells 
transfected with PPARγ-GAL4/GAL4-Luc or PPRE3-Luc constructs and treated with 1-
5 μM concentrations.  β-CDODA-Me significantly induced luciferase activity (Fig. 
3.1B) and in cells cotreated with β-CDODA-Me plus 10 μM T007 (a PPARγ 
antagonist), there was significant inhibition of induced transactivation.  In contrast, β-
DODA-Me did not activate PPARγ (data not shown) demonstrating the requirement for 
the 2-cyano substituent to confer PPARγ agonist activity on the GA derivative.  PPARγ  
agonists typically modulate expression of one or more of the cell cycle proteins p27, p21 
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Fig. 3.1. Effects of β-CDODA-Me and related compounds on LNCaP cell survival and activation of PPAR. Cell survival of LNCaP 
(A and B), PC3, and DU145 (C) cells. Prostate cancer cells were treated with different concentrations of β-DODA, β-DODA-Me, or 
β-CDODA-Me alone or in combination with 5 µM T007 (C) for 96 h, and the percentage of cell survival relative to DMSO (solvent 
control set at 100%) was determined as described under Materials and Methods. Results are expressed as means ± S.E. for three 
separate determinations for each treatment group, and significantly (p < 0.05) decreased survival is indicated (*). D, β-CDODA-Me 
activates PPAR. LNCaP cells were treated with β-CDODA, T007, or their combination, transfected with PPAR-GAL4/pGAL4 or 
PPRE-luc, and luciferase activity determined as described under Materials and Methods. Results are expressed as means ± S.E. for 
three replicate determinations for each treatment group, and significant (p < 0.05) induction by β-CDODA-Me (*) and inhibition after 
cotreatment with T007 (**) are indicated. 
 
  
 
131
and cyclin D1, and Figure 3.1C illustrates the effects of 1-5 μM β-CDODA-Me on  
expression of these proteins in LNCaP cells.  There was a concentration-dependent 
induction of p27 and p21 and a decrease in cyclin D1 proteins and Rb phosphorylation in  
cells treated with β-CDODA-Me alone, and similar results were observed in cells 
cotreated with the PPARγ antagonist T007 and β-CDODA-Me (Fig. 3.1 D) suggesting 
that these responses were PPARγ-independent. 
Induction of proapoptotic responses by β-CDODA-Me   
NAG-1 and ATF-3 are proapoptotic proteins induced by PPARγ agonists and 
results in Figure 3.2 A show that 1-5 μM β-CDODA-Me induced NAG-1 and ATF-3 
which are often co-induced and this was accompanied by caspase-dependent PARP 
cleavage, DNA fragmentation, and decreased bcl2 expression in LNCaP cells.  In 
LNCaP cells cotreated with β-CDODA-Me plus T007 (Fig. 3.2 B), the induced 
responses were not inhibited by the PPARγ antagonist indicating that induction of these 
proapototic responses was receptor-independent.  Previous studies show that different 
structural classes of PPARγ agonists downregulate AR expression in LNCaP cells and  
this response can also result in activation of apoptosis (695, 699).  Figure 2C 
summarizes the effects of β-CDODA-Me on AR expression in the presence or absence 
of 10 nM DHT and also on the expression of FKBP51 and PSA, two androgen-
responsive genes in LNCaP cells.  DHT increases expression of AR due to stabilization 
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Fig. 3.2. β-CDODA-Me modulates the cell cycle and cell cycle genes and induces apoptosis in prostate cancer cells. 
Modulation of cell cycle genes by β-CDODA-Me alone (A) and in combination with T007 (B). Cells were treated as 
indicated for 24 h, and whole-cell lysates were analyzed by Western blot analysis as described under Materials and 
Methods. C, cell cycle progression. LNCaP cells were treated with DMSO and different concentrations of β-CDODA-
Me for 24 h and analyzed for the percentage of distribution of cells in different phases of the cell cycle by FACS 
analysis as described under Materials and Methods. Results are expressed at means ± S.E. for three replicate 
determinations, and significant (p < 0.05) changes (compared with DMSO group) are indicated by an asterisk. D, 
induction of PARP cleavage. PC3 and DU145 cells were treated for 24 h with different concentrations of β-CDODA-
Me, and whole-cell lysates were analyzed by Western blots as described under Materials and Methods 
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of the receptor and also induces both androgen-responsive FKBP51 and PSA genes and, 
in cells treated with 1-5 μM β-CDODA-Me, there was a concentration-dependent 
decrease in AR, PSA and FKBP51 expression in the presence or absence of DHT.  In 
addition, downregulation of AR, PSA and FKBP51 proteins in LNCaP cells treated with 
β-CDODA-Me was not affected by cotreatment with the PPARγ antagonist T007 (Fig. 
3.2D) or the proteasome inhibitor MG132 (Fig. 3.2D).  In contrast, β-CDODA-Me-
dependent degradation of cyclin D1 was inhibited after cotreatment with MG132 and 
these observations are similar to those reported for other PPARγ agonists that induce 
proteasome-dependent degradation of cyclin D1 (300-302).  These results clearly show 
that β-CDODA-Me decreases expression of androgen-responsive genes and AR through 
PPARγ-independent pathways.  The downregulation of AR in cells treated with β-
CDODA-Me is consistent with the induction of apoptosis by this compound since 
decreased AR expression by small inhibitory RNAs in LNCaP cells also induces 
apoptosis (700).  
β-CDODA-Me induces kinase-dependent activation of proapoptotic/growth 
inhibitory pathways 
  Previous studies show that NAG-1 is induced by some PPARγ agonists and  
other cytotoxic compounds in colon cancer cells (278, 299, 313, 442, 665) through 
PI3K-dependent activation of EGR-1 which acts as a trans-acting factor to induce NAG-
1 expression.  Figure 3.3A summarizes the time-dependent induction of EGR-1, ATF-3 
and NAG-1 by 2.5 μM β-CDODA-Me  and the induction responses followed a similar 
time course, whereas EGR-1 dependent induction of NAG-1 in colon cancer cells is 
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associated with the increased expression of EGR-1 prior to induction of NAG-1 (299, 
442).  Previous studies show that NAG-1 induction is kinase-dependent (299, 442), and 
results in Figure 3.3B show that 2.5 μM β-CDODA-Me induces activation of the JNK 
(p-JNK), PI3K (p-Akt) and MAPK (p-Erk) pathways.  Maximal activation of JNK and 
PI3K was observed after 8 and 8-12 hr, respectively, whereas p-Erk activation remained 
elevated for 24 hr.  The effects of inhibitors of MAPK (PD98059), PI3K (LY294002), 
protein kinase C (GF109203X) and JNK (SP600125) on induction of NAG-1 and ATF3 
and decreased expression of AR, PSA and FKBP51 was also investigated in LNCaP 
cells treated with 2.5 μM β-CDODA-Me (Fig. 3.3C).  Both PD98059 and LY294002 
inhibited induction of NAG-1 by β-CDODA-Me.  However, the JNK inhibitor 
SP600125 was the most potent inhibitor of ATF-3 induction (Figs. 3.3C and 3.3D).  In 
contrast, decreased expression of AR, PSA and FKBP51 in LNCaP cells treated with β-
CDODA-Me was unaffected by kinase inhibitors. These results suggest that the 
underlying pathways associated with the growth inhibitory/proapoptotic pathways 
induced by β-CDODA-Me in LNCaP cells are due in part to activation of kinases. 
Therefore, the effects of kinase inhibitors on modulation of cell cycle proteins 
 by β-CDODA-Me were also investigated and the downregulation of cyclin D1 and 
induction of p21 were partially blocked in cells cotreated with the MAPK inhibitor 
PD98059 (Fig. 3.4A), and MAPK-dependent activation of p21 has previously been 
observed in embryonal rhabdomyosarcoma cell lines treated with TPA (701).  Results in 
Figure 4B show that the 1-5 μM β-CDODA-Me also induces luciferase activity in 
LNCaP cells transfected with constructs containing -2325 to +8 [p21-Luc (Fl)], -124 to 
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Fig. 3.3. β-CDODA induces apoptotic pathways and decreases androgen-responsiveness in LNCaP cells. β-CDODA-Me alone (A) 
and in combination with T007 (B and C) induces proapoptotic pathways. LNCaP cells were treated as indicated for 24 h, and whole-
cell lysates were analyzed by Western blot analysis as described under Materials and Methods. β-CDODA-Me-induced DNA 
fragmentation (A and B) was also determined as described. Effects of β-CDODA-Me alone and in combination with DHT or T007 
(D) or MG132 (E) on AR and androgen-responsive proteins. LNCaP cells were treated with DMSO or the various compounds for 24 
h, and whole-cell lysates were analyzed by Western blot analysis as described under Materials and Methods. 
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+8 [p21-Luc (-124)], -101 to +8 [p21-Luc (-101)], and -60 to +8 [p21-Luc (-60)] p21 
promoter inserts.  The latter 3 constructs contain the 6 proximal GC rich site (VI - I) and 
the results of the transfection studies suggest that these GC-rich sites are necessary for β-
CDODA-Me-induced transactivation.  Deletion analysis of the p21 promoter indicates 
that loss of inducibility [i.e. p21-luc(60)] is associated with loss of GC-rich sites IV and 
III which are essential for MAPK-dependent activation of p21 by  
β-CDODA-Me.  The role of MAPK in activation of the p21 promoter was 
confirmed in LNCaP cells transfected with p21-luc (101); β-CDODA-Me induced 
luciferase activity and cotreatment with the MAPK inhibitor PD98059 inhibited this 
response (Fig. 3.4C).  These results show that the induction of p21 and the proapototic 
NAG-1 protein by β-CDODA-Me were related to the activation of MAPK and PI3K but 
were independent of PPARγ (Figs. 3.1 D and 3.2 B). 
 β-CDODA-Me differentially decreases AR and PSA gene expression in LNCaP 
cells 
  β-CDODA-Me decreases expression of AR, PSA and FKBP51 protein levels 
through proteasome and PPARγ-independent pathways (Fig 3.2 C-3.2 E) and these 
responses are also not modulated by kinase inhibitors (Fig. 3.3 B).  The results in Figure 
3.5 A show that β-CDODA-Me also decreases AR mRNA levels after treatment for 12 
and 18 hr, and cotreatment with the PPARγ antagonist T007 did not affect mRNA levels 
confirming the β-CDODA-Me-induced downregulation of AR mRNA levels was also 
PPARγ-independent.  Similar results were obtained in LNCaP cells treated with β- 
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Fig. 3.4. β-CDODA-Me induces proapoptotic proteins and kinases. Induction of NAG-1, ATF3, and Egr-1 
(A) and kinases (B) by β-CDODA-Me. LNCaP cells were treated with 2.5 µM β-CDODA-Me, and whole-
cell lysates isolated at different times after treatment were analyzed by Western blot analysis as described 
under Materials and Methods. Effects of kinase inhibitors on proapoptotic responses (C) and quantitation 
of NAG-1 and ATF3 expression (D). LNCaP cells were treated with 2.5 µM β-CDODA alone or in 
combination with various kinase inhibitors, and after 24 h, whole-cell lysates were analyzed by Western 
blot analysis. Levels of NAG-1 and ATF3 proteins (normalized to β-actin) (D) are means ± S.E. for three 
separate determinations for each treatment group, and significantly (p < 0.05) decreased levels after 
cotreatment with a kinase inhibitor are indicated (**). 
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Fig. 3.5. β-CDODA-Me induction of p21 is MAPK-dependent. A, effects of kinase inhibitors on induction of p21. 
LNCaP cells were treated with DMSO, 2.5 µM β-CDODA-Me alone or in combination with kinase inhibitors for 24 h, 
and whole-cell lysates were analyzed by Western blot analysis as described under Materials and Methods. B, β-
CDODA-Me activates p21 promoter constructs. LNCaP cells were transfected with p21 promoter constructs, treated 
with DMSO or different concentrations of β-CDODA-Me, and luciferase activity was determined as described under 
Materials and Methods. Results are means ± S.E. for three separate determinations for each treatment group, and 
significant (p < 0.05) induction of activity is indicated (*). C, inhibition by PD98059. Cells were transfected with p21-
luc(101), treated with DMSO or β-CDODA-Me alone or in combination with 10 µM PD98059. Results are expressed 
as means ± S.E. for three separate determinations for each treatment group, and significant (p < 0.05) induction by β-
CDODA-Me (*) and inhibition after cotreatment with PD98059 (**) are indicated. 
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 Fig 3.5 Continued 
 
CDODA-Me alone or in the presence of the protein synthesis inhibitor cycloheximide 
(10 μg/ml) (Fig. 3.5 B); cycloheximide did not modulate the effects of β-CDODA-Me,  
suggesting that an induced inhibitory protein(s) does not mediate the effects of β-
CDODA-Me on AR mRNA expression.  β-CDODA-Me also decreased luciferase 
activity in LNCaP cells transfected with the AR-Luc construct that contains the -5400 to 
+580 region of the AR promoter linked to the luciferase genes (Fig. 3.5 C).  The results 
indicate that β-CDODA-Me inhibits AR transcription without the parallel induction of  
inhibitory trans-acting factors.  Recent studies suggest that AR downregulation of a 
PPARγ-inactive thiazolidinedione analog was due to downregulation of Sp protein 
(702).  Results in Figure 3.5 D show that β-CDODA-Me induces a time-dependent 
induction of PARP cleavage and a decrease of both AR and Sp1, suggesting that 
decreased expression of AR may be Sp1-dependent as previously reported (702) . 
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 PSA protein expression is also decreased in LNCaP cells treated with β-
CDODA-Me (Fig. 3. 2 C) and similar effects were observed for PSA mRNA levels after 
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Fig. 3.6. β-CDODA-Me decreases AR gene expression. Effects of T007 (A) and 
cycloheximide (B) on β-CDODA-Me-dependent effects on AR gene expression. LNCaP 
cells were treated with β-CDODA-Me alone or in combination with T007 or 
cycloheximide for 18 h, and AR mRNA levels were determined by real-time PCR as 
described under Materials and Methods. Similar results were observed after treatment 
for 12 h (data not shown). C, β-CDODA-Me decreases AR promoter activity. LNCaP 
cells were transfected with AR-luc, treated with DMSO or β-CDODA-Me, and 
luciferase activity was determined as described under Materials and Methods. Results 
are means ± S.E. for three separate experiments for each treatment group, and a 
significant (p < 0.05) decrease in activity is indicated (*). D, time-dependent effects of β-
CDODA-Me on AR, Sp1, and PARP (cleaved). LNCaP cells were treated with DMSO 
or β-CDODA-Me for up to 24 h, and whole-cell lysates were analyzed by Western blot 
analysis as described under Materials and Methods. 
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treatment for 12 or 18 hr, and these responses were not inhibited after cotreatment with 
the PPARγ antagonist T007 (Fig.3.6A).  However, β-CDODA-Me-induced 
downregulation of PSA mRNA levels after treatment for 12 or 18 hr was significantly  
 inhibited after cotreatment with cycloheximide (Fig. 3.6 B).  In addition, β-CDODA-Me 
inhibited transactivation in LNCaP cells transfected with the PSA-Luc construct 
(contains 5.85 kb of the PSA promoter insert) (Fig. 3.6 C) and similar results were 
obtained for DHT-induced luciferase activity (Fig. 3.6 D).  Thus, in contrast to results 
obtained for AR, β-CDODA-Me inhibits PSA expression through induction of inhibitory 
trans-acting factors and the mechanisms associated with the decreased PSA expression 
and the cis-elements important for this response are currently being investigated. 
DISCUSSION 
 PPARγ agonists have been extensively investigated in both in vitro and in vivo 
cancer models for their potential applications in cancer chemotherapy (281, 463, 482, 
659, 685-691).  PPARγ agonists inhibit prostate cancer cell and tumor growth (249, 695, 
703, 704) and the fact that approximately 40% of prostate cancer patients carry 
hemizygous deletions of PPARγ (705) suggests that this receptor may serve as a tumor 
suppressor gene for prostate cancer.  However, in animal studies using the transgenic 
adenocarcinoma mouse prostate (TRAMP) model with hemizygous deletion in PPARγ, 
it was shown that the loss of receptor expression did not enhance or inhibit prostate 
tumor development in these animals (706).  Thus, at least in the TRAMP mouse model, 
PPARγ does not appear to act as a tumor suppressor gene. 
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 One of the perplexing problems with PPARγ agonists is that although these 
compounds inhibit cancer cell and tumor growth, their mechanisms of action are both 
receptor-dependent and -independent in different cancer cell lines.  For example, PGJ2, 
troglitazone and PPARγ-active C-DIMS induce NAG-1 in HCT-116 colon cancer cells; 
however, only induction by PGJ2 is inhibited by a PPARγ antagonist (278, 299, 665).  
Caveolin-1 is induced by C-DIM compounds and CDDO in colon cancer cell lines, and 
this response is inhibited after cotreatment with PPARγ antagonists (300, 302).  In 
contrast, C-DIMs decreased caveolin-1 expression in LNCaP cells and this response was 
PPARγ-independent (695). 
 β-CDODA-Me is a triterpenoid acid that contains an oleanolic acid backbone 
structure similar to that of CDDO and CDDO-Me (methyl ester) (463, 482), but there are 
important structural differences in the C, D and E rings that differentiate between these 
compounds; however, for both compounds the 2-cyano group was necessary for 
activation of PPARγ.  
 In this study, we investigated the growth inhibitory and proapoptotic effects of β-
CDODA-Me in LNCaP cells and the role of PPARγ in mediating these responses.  β-
CDODA-Me was a more potent inhibitor of LNCaP cell growth than analogs (β-DODA 
and β-DODA-Me) that did not contain a 2-cyano substituent (Fig. 3.1A).  Moreover, β-
CDODA-Me also activated PPARγ-dependent transactivation in transient transfection 
studies in LNCaP cells (Fig. 3.1B), and compounds without the CN-group were inactive 
(data not shown) as previously reported for these analogs in colon cancer cells (312).  β-
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CDODA-Me induced p27 expression and downregulated levels of cyclin D1 protein 
(Figs. 3.1C and 3.1D).  Similar effects were previously reported for C-DIMs (695) and 
the effects of both compounds were receptor-independent; however, β-CDODA-Me-
induced responses were observed at lower concentrations (1 - 2.5 μM) than the C-DIM 
compounds (7.5 - 10 μM).  C-DIMs did not induce p21 in LNCaP cells (695), whereas 
β-CDODA-Me induced p21 protein and this response was not inhibited after cotreatment 
with PPARγ antagonist T007 (Fig. 3.1D).  Differences between PPARγ-active C-DIMs 
and β-CDODA-Me in their induction of p21 in LNCaP cells was due to activation of 
MAPK signaling by the latter compound (Fig. 3.3 C) which was required for induction 
of p21 protein (Fig. 3.4A) and activation of the p21 promoter (Fig. 3.4 C).  This is a 
novel pathway for induction of p21 in LNCaP cells; however, previous studies in other 
cell lines also demonstrated MAPK-dependent induction of p21 expression (701, 707, 
708).   
 NAG-1 and ATF3 are growth inhibitory and proapoptotic proteins (709, 710), 
and previous studies with PPARγ agonists report both receptor-dependent and -
independent induction of NAG-1 (278, 299, 302, 665).  Induction of NAG-1 and ATF3 
by β-CDODA-Me in LNCaP cells was also PPARγ-independent.  Both PI3K and MAPK 
inhibitors blocked induction of NAG-1; however, the JNK inhibitor SP600125 was the 
most potent inhibitor of ATF-3 (but not NAG-1) induction.  The inhibitory effects of 
SP600125 are consistent with previous studies showing that homocysteine also induces 
ATF3 in vascular cells through activation of JNK which activates c-jun and ATF-3 
through an AP-1 site in the ATF-3 promoter (711).  The kinase-dependent induction of 
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NAG-1 has previously been reported and these effects are both structure and cell 
context-dependent.  For example, troglitazone and PPARγ-active C-DIMs induce NAG-
1 in HCT116 colon cancer cells through rapid activation of Egr-1 which subsequently 
activates NAG-1 through direct interaction with the proximal region of the NAG-1 
promoter (278, 299).  However, this induction response is MAPK-dependent for 
troglitazone and PI3-K-dependent for the C-DIM compound.  In this study, the time-
dependent induction of both EGR-1 and NAG-1 are similar in LNCaP cells (Fig. 3.3 A), 
and inhibition of NAG-1 expression is observed with both PI3K and MAPK inhibitors 
(Fig. 3.3 B).  This may involve cooperative interactions of both kinase pathways for 
induction of NAG-1 by β-CDODA-Me in LNCaP cells, and mechanisms for these 
responses are currently being investigated.  Interestingly, induction of NAG-1 by 
PPARγ-active C-DIMs in LNCaP cells was inhibited only by the MAPK inhibitor 
PD98059 (695), suggesting differences between β-CDODA-Me and C-DIMs in the same 
cell line.  Thus, induction of both NAG-1 and ATF3 in LNCaP cells is differentially 
induced by two PPARγ agonists, C-DIMs and β-CDODA-Me through receptor-
independent activation of different kinase pathways. 
 Two recent reports show that in LNCaP cells AR knockdown by RNA 
interference results in apoptosis (700) and stable knockdown using short hairpin RNAs 
for AR results in decreased AR and PSA expression and inhibition of tumor growth in 
vivo (712).  Like β-CDODA-Me, AR and PSA expressions are also decreased by C-
DIMs and troglitazone in LNCaP cells, and 3,3'-diindolylmethane (DIM) also decreases 
expression of both genes and proteins (713, 714).  Troglitazone differentially decreases 
  
 
145
PSA and AR expression at relatively low (IC50 ≤ 10 μM) and high (IC50 ~ 40 μM) 
concentrations, respectively (699) .  In contrast, C-DIMs decreased AR and PSA mRNA, 
protein and reporter gene activity in cells transfected with PSA-Luc and AR-Luc 
constructs over a narrow range of concentrations (7.5 - 10 μM) (695) and similar results 
were observed for β-CDODA-Me (1 - 2.5 μM) in this study (Figs 3.5 and 3.6).  
Moreover, cycloheximide reversed the β-CDODA-Me- and C-DIM-dependent 
downregulation of PSA but not AR mRNA levels, suggesting a similar mechanism of 
action for both compounds.  One study reported that DIM inhibited nuclear uptake of 
AR in LNCaP cells (715), and like β-CDODA-Me, DIM also decreased AR and PSA 
expression in LNCaP and androgen-insensitive C4-2B cells (713, 714).  However, there 
are several differences between the pathways associated with downregulation of these 
genes by β-CDODA-Me and DIM and this includes the pivotal role for DIM as an 
inhibitor of phospho-Akt (713, 714), whereas β-CDODA-Me induces phospho-Akt (Fig. 
3.3B) and the PI3K inhibitor LY294002 does not affect β-CDODA-dependent 
downregulation of AR, PSA or FKBP51 (Fig. 3.3C) or induction of p21 or p27 (Fig. 3.4 
A).   
 A recent report indicated that decreased AR expression in LNCaP cells treated 
with a PPARγ-inactive thiazolidinedione derivative was due to proteasome-dependent 
degradation of Sp1 (702) and our results also show a parallel decrease in AR and Sp1 in 
LNCaP cells treated with β-CDODA-Me (Fig. 3.5 D).  However, in contrast to the 
previous report, this effect on AR was not reversed by a proteasome inhibitor (Fig. 3.2 
D).   Loss of AR by RNA interference results in the induction of apoptosis in LNCaP 
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cells (700).  In contrast, 2.5 μM β-CDODA-Me rapidly induces PARP cleavage and 
apoptosis in LNCaP cells prior to decreased AR expression (Fig. 3.5D) demonstrating 
that apoptotic pathways activated by β-CDODA-Me in LNCaP cells are not associated 
with loss of AR, and the proapoptotic mechanisms are currently being investigated.   
 Results of this study demonstrate that β-CDODA-Me is a potent inhibitor of 
LNCaP cell growth and induces proapoptotic responses through activation of kinases 
which differentially activate ATF3, NAG-1 and p21.  In contrast, decreased expression 
of AR and PSA are kinase independent and occur through different pathways (Fig. 3.7).   
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Fig. 3.7. β-CDODA-Me decreases PSA expression.  Effects of T007 (A) and cycloheximide (B) on β-
CDODA-Me-dependent effects on PSA gene expression.  LNCaP cells were treated with β-CDODA-Me 
alone or in combination with T007 or cycloheximide for 12 or 18 hr, and PSA mRNA levels were 
determined by real time PCR as described in the Materials and Methods.  β-CDODA-Me decreases PSA 
promoter (C) and DHT-induced (D) PSA promoter activity.  LNCaP cells were transfected with PSA-luc, 
treated with DMSO, β-CDODA-Me, DHT and β-CDODA-Me plus DHT (combined), and luciferase 
activity determined as described in the Materials and Methods.  Results are means ± SE for three replicate 
determinations for each treatment group, and significantly (p < 0.05) decreased basal or DHT-induced 
luciferase activity by β-CDODA-Me is indicated (*). 
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β-CDODA-Me, C-DIMs, DIM and troglitazone exhibited both differences and 
similarities in their modes of action in LNCaP cells, although all of these compounds 
decreased expression of AR and PSA.  The growth inhibitory and proapoptotic effects of 
β-CDODA-Me were primarily receptor-independent in LNCaP cells, and similar results 
have been observed for other PPARγ agonists such as the C-DIMs and troglitazone.  
Thus, each agent activates multiple pathways, and the successful use of β-CDODA-Me 
and other such compounds for single or combined prostate cancer chemotherapies 
requires detailed insights on their mechanisms of action and prostate cancer cell context-
dependent differences in activating critical pathways such as those illustrated in Figure 
3.8. 
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Fig. 3.8. β-CDODA-Me-dependent activation of kinases and kinase-dependent genes 
and repression of AR and PSA. 
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CHAPTER IV 
 
 
BETULINIC ACID INHIBITS PROSTATE CANCER GROWTH THROUGH 
INHIBITION OF SPECIFICITY PROTEIN TRANSCRIPTION FACTORS* 
INTRODUCTION 
 Natural products derived from plant sources have been used extensively in 
traditional medicine for treatment of a myriad of diseases including various types of 
cancers (410, 716, 717).  Several individual phytochemicals or their synthetic analogs 
are among the most widely used drugs for cancer chemotherapy and these include taxane 
microtubule inhibitors such as paclitaxel and synthetic analogs that are now widely used 
in cancer chemotherapy (718, 719).  Phytochemical and microbial extracts from various 
sources are routinely screened for biological activities, and it is estimated that 20-25% of 
new drugs are derived from natural products or their synthetic analogs (720-722).  The 
triterpenoids oleanolic acid, ursolic acid and their derivatives, exhibit anti-inflammatory 
and anticarcinogenic activities (459, 723, 724).  Structure-activity studies among several 
oleanolic and ursolic acid derivatives (462, 463, 465) have identified 2-cyano-3,12-
dioxoolean-1,9-dien-28-oic acid (CDDO) and related compounds as highly potent anti- 
inflammatory compounds that inhibit growth and induce apoptosis in several 
____________ 
*Reprinted with permission from “Betulinic acid inhibits prostate cancer growth through 
inhibition of specificity protein transcription factors” by Chintharlapalli S, Papineni S, 
Ramaiah SK, Safe S. Cancer Res.2007;67:2816-23.Copyright 2007 by American 
Association for Cancer Research. 
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cancer cells and tumor types (302, 482, 483, 725-727).  CDDO-like compounds act 
through multiple pathways and are currently undergoing clinical trials for treatment of 
leukemia.   
 Betulin is a lupane-derived triterpene which is present in high concentrations in 
birch bark and betulinic acid (BA), an oxidation product of betulin has also been 
detected in bark extracts (499).  BA was initially characterized as a highly selective 
inhibitor of human melanoma cell and tumor growth through induction of apoptosis 
(510).  Subsequent research has shown that BA and other derivatives are effective 
inhibitors of cell proliferation and induce apoptosis in many different cancer cells.  
However, the underlying mechanisms for these responses are not well understood.   
 In this study, we show that BA decreased proliferation of several cancer cell lines 
including SK-MEL2 melanoma cells and, using LNCaP prostate cancer cells as a model, 
we determined a unique mechanism of action of this compound.  BA modulates 
expression of several growth-related proteins and decreases expression of the 
proangiogenic and proapoptotic proteins vascular endothelial growth factor (VEGF) and 
survivin, respectively.  Previous reports show that in some cancer cell lines, VEGF and 
survivin expression is dependent, in part, on Sp proteins (331, 547, 580, 583, 728-732), 
and Sp1 is overexpressed in cancer cells and tumors (576, 733-736).  Results of this 
study now show that BA induces proteasome-dependent degradation of Sp1, Sp3 and 
Sp4 in LNCaP cells.  The proteasome inhibitor MG132 not only blocked BA-induced 
degradation of Sp proteins but also inhibited the decreased expression of VEGF and 
survivin in cells treated with BA.  In vivo studies showed that BA inhibited tumor 
  
 
151
growth in athymic nude mice bearing LNCaP cell xenografts, and this was accompanied 
by decreased expression of Sp1, Sp3 and Sp4 proteins and VEGF and increased 
apoptosis in tumors from BA-treated mice.  The results indicate that the antitumorigenic 
effects of BA are associated with targeted degradation of Sp transcription factors which 
are overexpressed in many tumors and this results in activation of proapoptotic and 
antiangiogenic responses in tumor but not in non-target tissues (e.g. liver) which exhibit 
low Sp protein expression. 
MATERIALS AND METHODS 
Chemicals, antibodies, plasmids and reagents  
 BA and β-actin antibody were purchased from Sigma Aldrich (St. Louis, MO) 
and proteasome inhibitor MG132 was  purchased from Calbiochem (San Diego, CA).  
Antibodies against Sp1, Sp4, Sp3, VEGF, CD1, AR, KLF6, survivin and PARP were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and CD31 antibody from 
DakoCytomation (Glostrup, Denmark).  The pVEGF-2018 and pVEGF-133 constructs 
contain VEGF promoter inserts (positions -2018 to +50 and positions -131 to +54, 
respectively) linked to luciferase reporter gene (580).  The pSurvivin-269 and pSurvivin-
150 were kindly provided by Dr. M. Zhou (Emory University, Atlanta, GA).  Reporter 
lysis buffer and luciferase reagent for luciferase studies were purchased from Promega 
(Madison, WI).  β-Galactosidase (β-gal) reagent was obtained from Tropix (Bedford, 
MA).  Lipofectamine reagent was supplied by Invitrogen (Carlsbad, CA).  Western 
Lightning chemiluminescence reagent was from Perkin-Elmer Life Sciences (Boston, 
MA).   
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Cell lines  
 Human carcinoma cell lines LNCaP (prostate) and SK-MEL2 (melanoma) were 
obtained from American Type Culture Collection (Manassas, VA).  Cell lines were 
maintained in RPMI 1640 (Sigma) supplemented with 0.22% sodium bicarbonate, 
0.011% sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% FBS, and 10 mL/L of 
100x Antibiotic Antimycotic solution (Sigma).  Cells were maintained at 37°C in the 
presence of 5% CO2. 
Cell proliferation assay 
Prostate and melanoma cancer cells (2 x 104 per well) were plated in 12-well 
plates and allowed to attach for 24 hr.  The medium was then changed to DMEM:Ham's 
F-12 medium containing 2.5% charcoal-stripped FBS, and either vehicle (DMSO) or 
different concentrations of the compound were added.  Fresh medium and compounds 
were added every 48 hr and cells were then trypsinized and counted after 48 and 96 hr 
using a Coulter Z1 cell counter.  Each experiment was done in triplicate and results are 
expressed as means ± SE for each set of experiments 
Transfection and luciferase assay  
Prostate cancer cells were plated in 12-well plates at 1 x 105 cells/well in 
DMEM:Ham’s F-12 media supplemented with 2.5% charcoal-stripped FBS.  After 
growth for 16 - 20 hr, various amounts of reporter gene constructs, i.e., pVEGF-2018 
(0.4 μg), pVEGF-133 (0.04 µg), pSurvivin-269 (0.04 μg), pSurvivin-150 (0.04 μg) and 
β-gal (0.04 μg), were transfected by Lipofectamine (Invitrogen) according to the 
manufacturer’s protocol.  After 5 hr of transfection, the transfection mix was replaced 
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with complete media containing either vehicle (DMSO) or the indicated compound for 
20 to 22 hr.  Cells were then lysed with 100 μL of 1x reporter lysis buffer, and 30 μL of 
cell extract were used for luciferase and β-gal assays.  Lumicount was used to quantitate 
luciferase and β-gal activities, and the luciferase activities were normalized to β-gal 
activity. 
Western blotting  
An equal amount of cell lysate (60 μg/well) was separated by 7.5% to 12% SDS-
PAGE, which was followed by immunoblotting onto polyvinylidene difluoride (Bio-
Rad, Hercules, CA).  After blocking in TBST-Blotto (10 mmol/L Tris-HCl, 150 mmol/L 
NaCl (pH 8.0), 0.05% Triton X-100, 5% nonfat dry milk) for 30 min, the membranes 
were incubated with primary antibodies overnight at 4°C, and then with horseradish 
peroxidase-conjugated secondary antibody for 2 hr at room temperature.  Proteins were 
visualized using the chemiluminescence substrate (Perkin-Elmer Life Sciences) for 1 
min and exposed to Kodak X-OMAT AR autoradiography film (Eastman Kodak, 
Rochester, NY).   
Xenograft study  
Male athymic BALB/c nude mice (age 4 - 6 weeks) were purchased from Harlan 
(Indianapolis, IN).  LNCaP cells (1 x 106) were implanted with matrigel (BD 
Biosciences, San Jose, CA) subcutaneously into the flank of each mouse.  Ten days after 
cell inoculation, animals were divided into three equal groups of 10 mice each.  The first 
group received 100 μL vehicle (1% DMSO in corn oil) by oral gavage and the second 
and third groups of animals received 10 and 20 mg/kg/d doses of BA in vehicle every 
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second day for 14 days (7 doses).  The mice were weighed, and tumor areas were 
measured throughout the study.  After 22 days, the animals were sacrificed, final body 
and tumor weights were determined, and selected tissues were further examined by 
routine hematoxylin and eosin staining and immunohistochemical analysis. 
Immunohistochemistry   
Tissue sections (4 - 5 μM thick) mounted on poly-L-lysine-coated slide were 
deparaffinized by standard methods.  Endogenous peroxidase was blocked by the use of 
3% hydrogen peroxide in PBS for 10 min.  Antigen retrieval for VEGF and CD31 
staining was done for 10 min in 10 mmol/L sodium citrate buffer (pH 6) heated at 95°C 
in a steamer followed by cooling for 15 min.  The slides were washed with PBS and 
incubated for 30 min at room temperature with a protein blocking solution 
(VECTASTAIN Elite ABC kit, Vector Laboratories, Burlingame, CA).  Excess blocking 
solution was drained, and the samples were incubated overnight at 4°C with one of the 
following: a 1:100 dilution of VEGF antibody or a 1:40 dilution of CD31 antibody.  
Sections were then incubated with biotinylated secondary antibody followed by 
streptavidin (VECTASTAIN Elite ABC kit).  The color was developed by exposing the 
peroxidase to diaminobenzidine reagent (Vector Laboratories), which forms a brown 
reaction product.  The sections were then counterstained with Gill's hematoxylin.  VEGF 
and CD31 expression was identified by the brown cytoplasmic staining.  hematoxylin 
and eosin staining was determined as previously described (583).   
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RESULTS 
Antiproliferative, proapoptotic and antiangiogenic effects of BA 
 The antiproliferative effects of BA were initially investigated in SK-MEL2 
melanoma and LNCaP prostate cancer cells, and 6-day IC50 values for growth inhibition 
were 5 - 10 μM and 1 - 5 μM, respectively.  Similar results were observed for pancreatic 
(Panc28, L3.6pl), bladder (KU7), and colon (SW480) cancer cells (data not shown).  
Cell survival curves for LNCaP and SK-MEL2 cells after treatment for 48 or 96 hr are 
illustrated in Figures 4.1A and 4.1B.  At higher concentrations of BA (≥ 10 μM), there 
was an overall decrease in the number of cells remaining compared to the number of 
initially seeded cells which was consistent with the cytotoxicity of BA.   
 We further investigated the effects of BA on growth inhibitory and proapoptotic 
proteins using LNCaP cells as a model.  Results illustrated in Figure 4.1C show that 
relatively short term exposure (24 hr) to BA (≥ 10 μM) induced downregulation of 
cyclin D1, whereas the cyclin-dependent kinase inhibitors p21 and p27 were expressed 
at low levels in these cells and were not affected by the treatment (data not shown).  AR 
expression in LNCaP cells was decreased after treatment with 5 μM BA, and this protein 
was almost completely absent in cells treated with 10 μM concentrations.  Recent studies 
have demonstrated that AR knockdown by RNA interference in LNCaP cells resulted in 
induction of apoptosis (700), suggesting that the proapoptotic effects of BA in LNCaP 
cells may be due, in part, to the effects on AR expression.  However, this mechanism 
would not be applicable to melanoma and other cancer cell lines which are AR-
independent.  The tumor suppressor gene KLF6 was also induced by BA at  
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Fig. 4.1. BA inhibits growth and induces apoptosis in cancer cells.  Decreased cell 
survival in LNCaP (A) and SK-MEL2 (B) cancer cells.  Cells were seeded, treated with 
solvent (DMSO) or different concentrations of BA (1 - 20 μM) for 6 days as described in 
the Materials and Methods.  Cell survival is expressed as the percentage of BA-treated 
cells remaining compared to DMSO (set at 100%), and significantly (p < 0.05) decreased 
survival is indicated by an asterisk.  (C) and (D)  Western blot analysis for modulation of 
protein expression by BA.  LNCaP cells were treated with DMSO or BA (5 - 20 μM) for 
24 hr and whole cell lysates were analyzed by Western blot analysis as described in the 
Materials and Methods.   
 
concentrations between 10 - 15 μM.  BA also induced caspase-dependent PARP 
cleavage in LNCaP cells, and this was accompanied by decreased expression of the 
antiapoptotic protein survivin (Fig. 4.1D) and induction of DNA laddering (data not 
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shown) typically observed in cells undergoing  apoptosis.  In addition, BA also 
decreased expression of the angiogenic protein VEGF.   
BA induces proteasome-dependent degradation of Sp1, Sp3 and Sp4 proteins 
 Previous studies in this laboratory have shown that both basal and hormone-
induced expression of VEGF in cancer cell lines is dependent on Sp protein expression 
(331, 547, 580, 583), and regulation of survivin in some cells is also dependent on these 
transcription factors (737-740).  Moreover, since Sp proteins are upregulated in many 
tumors/cancer cells (576, 741-743) and are associated with proliferative, angiogenic and 
antiapoptotic pathways, we hypothesized that the anticarcinogenic activity of BA may be 
due, in part, to downregulation of Sp proteins.  Results in Figure 4.2A show that 
treatment of LNCaP cells with 5 - 10 μM BA for 24 hr induced downregulation of Sp1, 
Sp3 and Sp4 proteins, and this was also accompanied by decreased expression of VEGF 
and survivin (Fig. 4.1D).  The time-dependent decrease of Sp proteins in LNCaP cells 
treated with 15 μM BA for 4, 8, 12, 16, 20 and 24 hr showed that lower expression of 
these proteins is first observed after treatment for 12 hr (Fig. 4.2B).  Prolonged treatment 
of LNCaP cells with BA for 48 or 72 hr showed that Sp protein degradation and PARP 
cleavage can be observed as doses as low as 1 to 2.5 μM (Fig. 4.2C).  Figure 4.2D 
illustrates that BA also decreased expression of Sp1, Sp3 and Sp4 proteins in SK-MEL2 
melanoma cancer cells, and similar results were obtained in other cancer lines (data not 
shown).   
 Since BA induces degradation of Sp proteins within 12 hr after treatment (Fig. 
4.2 B), we investigated the possible role of induced protein(s) in mediating this response  
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Fig. 4.2. BA induces degradation of Sp and other proteins in LNCaP.  Decreased 
expression of Sp1, Sp3, Sp4 and VEGF in LNCaP (A - C) and SK-MEL2 (D) cells.  
LNCaP or SK-MEL2 cells were treated with DMSO or BA (1 - 20 μM) for 24 (A and 
D), 4 - 24 (B), 48 or 72 (C) hr, and whole cell lysates were analyzed by Western blot 
analysis as described in the Materials and Methods.   
 
by treating LNCaP cells with BA alone (10 - 20 μM) or in the presence of 10 μg/ml 
cycloheximide (Fig. 4.3A).  The protein synthesis inhibitor did not modulate the effects 
of BA on Sp protein levels.  Previous studies showed that COX-2 inhibitors, the NSAID 
tolfenamic acid, and related compounds induced proteasome-dependent degradation of 
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Fig. 4.3. BA induces proteasome-dependent degradation of Sp proteins in LNCaP cells.  
(A)  Effects of cycloheximide.  Cells were cotreated with 10 - 20 μM BA or 10 μg/ml 
cycloheximide alone or in combination, and expression of Sp proteins in whole cell 
lysates was determined by immunoblot analysis as described in the Materials and 
Methods.  Effects of the proteasome inhibitor MG132 on BA-induced decrease of Sp 
proteins/VEGF (B), PARP cleavage, cyclin D1 and AR (C), and PARP cleavage and 
survivin (D).  LNCaP cells were treated with DMSO or BA alone or in combination with 
5 or 10 μM MG132 (pretreated for 30 min) for 24 hr, and protein expression in whole 
cell lysates was analyzed by Western blot analysis as described in the Materials and 
Methods. 
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Sp proteins (331, 583) and therefore we investigated the effects of the proteasome  
inhibitor MG132 on BA-induced downregulation of Sp1, Sp3, Sp4 and VEGF in LNCaP 
cells.  MG132 reversed the effects of BA on expression of these transcription factors 
(Fig. 4.3 B).  BA selectively induced proteasome-dependent degradation of Sp proteins 
and cyclin D1 in LNCaP cells (Fig. 4.3C); however, MG132 did not modulate 
expression of β-actin or reverse BA-dependent downregulation of AR which is due to 
decreased AR RNA expression (data not shown).  MG132 (10 μM) and other 
proteasome inhibitors induced caspase-dependent cleavage of PARP in LNCaP cells; 
however, MG132 also partially inhibited BA-induced apoptosis.  Moreover, using a 
lower concentration of MG132 (5 μM), the effects of the compound alone on PARP 
cleavage were decreased but in combination with BA, there was inhibition of BA-
induced PARP cleavage (Fig. 4.3D).    MG132 also blocked BA-induced downregulation 
of survivin protein (Fig. 4.3 D), suggesting that Sp protein degradation plays a role in the 
apoptosis-inducing effects of BA. 
BA inhibits VEGF and survivin promoter expression through proteasome-
dependent degradation of Sp proteins 
 Expression of both VEGF and survivin in some cancer cell lines is regulated by 
Sp protein interactions with GC-rich promoter sites (744, 745), and therefore the effects 
of BA on decreased expression of VEGF and survivin through Sp protein degradation 
was further investigated in transfection studies.  The effects of BA on transactivation 
was investigated in LNCaP cells transfected with the pVEGF1 and pVEGF2 constructs 
containing the -2068 to +50 and -133 to +50 VEGF gene promoter inserts.  Results in 
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Figures 4.4A and 4.4B show that BA decreased luciferase activity in LNCaP cells 
transfected with pVEGF1 and pVEGF2, and these effects were reversed by the 
proteasome inhibitor MG132, and similar results were observed using the proteasome 
inhibitor lactacystin (data not shown).  These observations further confirm that BA-
induced degradation of Sp proteins results in decreased VEGF expression in LNCaP 
cells, and this is consistent with previous RNA interference studies demonstrating that 
Sp1, Sp3 and Sp4 regulate VEGF expression in cancer cell lines (580). 
 Since the proteasome inhibitor MG132 partially blocks BA-induced PARP 
cleavage (Figs. 4.3C and 4.3D), we further investigated the role of Sp protein 
degradation on induction of apoptosis by examining the effects of BA on transactivation 
in LNCaP cells  transfected with the GC-rich pSurvivin-269 and pSurvivin-150 
constructs contain the -269 to +49 and -150 to +49 survivin promoter inserts.  BA causes 
a concentration-dependent decrease in luciferase activity which was significantly 
reversed by 10 μM MG132 (Figs. 4.4C and 4.4D).  In parallel studies, electrophoretic 
mobility shift assays also show that lysates from BA-treated LNCaP cells exhibited 
decreased binding to GC-rich survivin sequences (data not shown).  These results 
complement a recent study showing that the DNA binding drug hedamycin also 
decreases survivin expression through inhibition of Sp protein interactions with the GC-
rich survivin promoter (746). 
BA inhibits tumor growth an athymic nude mice bearing LNCaP cells as xenografts 
 Pisha and coworkers previously reported that BA inhibits growth of tumors in 
athymic nude mice bearing MEL-1 melanoma cells as xenografts (510).  Results in 
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Fig. 4.4. BA decreases transactivation in LNCaP cells transfected with VEGF and 
survivin constructs.  Transfection with pVEGF-2068 (A), pVEGF-133 (B), pSurvivin-
269 (C), and pSurvivin-150 (D).  LNCaP cells were transfected with the various 
constructs, treated with DMSO or BA (2.5 - 20 μM) alone or in combination with 10 μM 
MG132, and luciferase activity (relative to β-gal) was determined as described in the 
Materials and Methods.  Luciferase activity significantly (p < 0.05) decreased by BA (*) 
and inhibition of this response by cotreatment with MG132 (**) is indicated. 
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Figure 4.5A show that 10 and 20 mg/kg/d betulinic acid inhibited tumor growth in mice 
bearing LNCaP cell xenografts and this was accompanied by significantly decreased 
tumor weights in both treatment groups (Fig. 4.5B).  Examination of the mice showed 
that there were no treatment-related changes in organ or body weights or in the 
histopathology of liver and other tissues (data not shown), and this was consistent with 
the reported low toxicity of this compounds (510).  Representative hematoxylin- and 
eosin-stained histopathology sections of prostate tumors from the control and treated 
mice were examined.  Tumors from untreated mice consisted of minimally encapsulated  
[Fig. 4.5C (a)], dense expansile nests of epithelial cells with marked atypical features 
such as anisocytosis, anisokaryosis, multiple variably sized nucleoli, nuclear molding, 
bi- and multinucleation.  Bizarre mitotic figures were frequently noted within the 
neoplastic cells [Fig. 4.5C (b), arrow heads].  Abundant vascular channels were 
frequently present within neoplastic cells [Fig. 4.5C (b), arrows].  Tumors from the 
treated mice consisted of neoplastic cells similar to that noted from the untreated mice.  
However, the mitotic activity (1-2 microfigures/hpf compared to 6-8 microfigures/hpf in 
the corn oil group) and the epithelial atypia appeared to be decreased [Fig. 4.5C (c)].  In 
addition, the tumor tissue was remarkably less vascular with evidence for necrosis [Fig. 
4.5C (d), area within box], and this is consistent with the antiangiogenic effect of BA 
through decreased expression of Sp proteins and VEGF.   
BA decreases Sp protein and VEGF expression in tumors but not liver 
 We also compared expression of Sp proteins, AR and VEGF as well as PARP 
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Fig. 4.5. Antitumorigenic activity by BA in  vivo.  (A) Decreased tumor area.  Athymic nude mice (10 per 
group) bearing LNCaP cells as xenografts were treated with corn oil (control) or BA in corn oil (10 or 20 
ml/kg) every second day, and tumor areas were determined as described in Materials and Methods.  (B) 
Tumor weights.  After the final treatment, animal were sacrificed and tumor weights were determined as 
described in the Materials and Methods.  Significantly (p < 0.05) decreased tumor areas or volumes are 
indicated by an asterisk.  (C) Histopathological evaluation of tumors.  Tumors from corn oil (a and b) and 
BA (c and d) mice were fixed, stained with hematoxylin and eosin, and examined histopathologically as 
described in the Materials and Methods. 
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cleavage in tumor lysates from control and BA-treated mice (5 animals per group) by 
Western blot analysis using β-actin as a loading control.  Relatively high levels of Sp1, 
Sp3, Sp4 and VEGF proteins were observed in the control tumors, and we did not detect 
PARP cleavage in protein lysates from these tumors (Fig. 4.6A).  In contrast, expression 
of Sp1, Sp3, Sp4, AR and VEGF proteins was decreased in tumors from BA-treated 
mice and PARP cleavage was observed.  Sp protein levels in liver from untreated or BA-
treated mice could be visualized only after prolonged exposures, and the pattern of Sp1, 
Sp3 or Sp4 protein expression was similar in both groups (Fig. 4.6B).  A direct 
comparison of Sp protein expression in tumors and liver from untreated animals (Fig. 4.6 
C) indicates high levels in tumors, whereas in liver only Sp3 could be detected and 
levels of Sp1 and Sp4 were very low.  We also examined Sp proteins in other 
tissues/organs from mice treated with corn oil or BA and observed uniformly very low to 
non-detectable Sp1, Sp3 and Sp4 in both treatment groups (data not shown).  Tumors 
from untreated and treated mice were also stained for VEGF and CD31 (microvessel 
density), and the staining for both factors was decreased in tumors from BA-treated mice 
(Fig. 4.6D).  This study demonstrates that BA is a potent inhibitor of prostate cancer cell 
and tumor growth, and this parallels results showing that BA exhibited anticancer 
activity in in vitro and in vivo models of melanoma (510).  The underlying mechanisms 
of proapoptotic, antiproliferative and antiangiogenic activities of BA are associated with 
induction of proteasome-dependent degradation of Sp proteins in prostate tumor cells.  
Moreover, Sp protein expression was decreased in SK-MEL2 (Fig. 4.2D) and other 
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cancer cell lines (data not shown), suggesting that BA-dependent downregulation of Sp 
proteins which is accompanied by both proapoptotic and antiangiogenic responses is an 
integral part of the anticarcinogenic activity of this compound. 
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Fig.4.6. Sp and VEGF protein expression in tumors and liver.  Whole cell lysates from 
corn oil (untreated) and BA-treated tumors (A) and liver (B) were obtained from tissue 
from at least 5 rats per group and analyzed by Western blot analysis as described in the 
Materials and Methods.  (C)  Comparative Sp protein expression in tumors and liver from 
corn oil (solvent)-treated animals.  Tumor and liver lysates containing the same amount 
of protein were analyzed by electrophoresis and visualized as described in the Materials 
and Methods.  (D)  Immunostaining for CD31 and VEGF.  Fixed tumor tissue from corn 
oil and BA-treated mice were stained with CD31 and VEGF antibodies as described in 
the Materials and Methods. 
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Fig. 4.6 Continued 
 
DISCUSSION 
 BA is a natural product identified in various bark extracts and is readily 
synthesized from betulin, a major component in bark from birch trees (499).  Pisha and 
coworkers (510) initially reported that this triterpenoid inhibited growth of several 
melanoma cell lines, and ED50 values for cytotoxicity varied from 4.8 - 1.1 μg/ml, 
whereas the corresponding values for a series of colon, prostate, breast, lung, squamous 
and glioma cancer cells were > 20 μg/ml.  However, other reports also show that BA 
inhibits growth and induces apoptosis in several different cancer cell lines (499), and this 
corresponds to results of this study in which IC50 values (growth inhibition) for 
melanoma and prostate cancer cells were 5 - 10 μM and 1 - 5 μM, respectively, and 
similar results were obtained in other cancer cell lines.  It has also been reported that BA 
derivatives and related lupane analogs are more cytotoxic than BA to cancer cells (499); 
however, a major advantage in using the latter compound for cancer chemotherapy is the 
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low toxicity.  Doses as high as 500 mg/kg every fourth day (X6) exhibited no detectable 
toxic side effects (510). 
 It has been reported that BA induces apoptosis in several different cancer cell 
lines through multiple pathways which include direct effects on the mitochondria 
accompanied by decreased mitochondrial membrane potential, upregulation of death 
receptors, and interactions with other agents (511, 517, 528, 532, 537, 539, 540, 747-
750).  In addition, BA exhibits antiangiogenic activity in an in vitro assay for tube-like 
structures in ECV304 (751); however, the underlying mechanisms of action for these 
responses are unknown.  In this study, BA also induces proapoptotic and antiangiogenic 
responses in LNCaP cells as evidenced by decreased expression of VEGF and survivin 
and activation of caspase-dependent PARP cleavage (Fig. 4.1D) and DNA laddering 
(data not shown).  BA decreases AR expression in LNCaP cells (Fig. 4.1C) and this 
response is in itself proapoptotic in this cell line since it has been reported that decreased 
AR expression via RNA interference results in increased apoptosis in LNCaP cells 
(700).  Previous studies show that in several cancer cell lines VEGF expression is 
dependent, in part, on Sp1 and other Sp proteins (331, 752), and there is also evidence 
that survivin expression is Sp-dependent (753-755).  Therefore, we examined the effects 
of BA on expression of Sp1, Sp3 and Sp4 proteins in LNCaP cells and the results 
demonstrate for the first time that BA decreases expression of Sp1, Sp3 and Sp4, and 
similar results are observed in SK-MEL2 and other cancer cell lines (Figs. 4. 2A – 
4.2D).   
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 The role of BA-induced downregulation of Sp proteins in mediating the 
proapoptotic and antiangiogenic activities of this compound was further investigated in 
LNCaP cells.  Proteasome inhibitors such as MG132 block Sp protein degradation 
induced by COX-2 inhibitors and tolfenamic acid in colon and pancreatic cancer cells 
(331, 511).  The results in Figure 2D show that MG132 inhibited BA-induced 
degradation of Sp proteins.  Moreover, MG132 blocked degradation of VEGF and 
survivin proteins in LNCaP cells treated with BA, and similar results were observed for 
cyclin D1 but not AR (Figs. 4.3B – 4.3D) which is decreased through proteasome-
independent pathways.  Moreover, in LNCaP cells transfected with constructs containing 
critical GC-rich sequences from the VEGF and survivin gene promoters, BA decreased 
transactivation which was inhibited after cotreatment with MG132 (Fig. 4.4).  These 
results confirm the linkage between the decreased expression of survivin and VEGF in 
LNCaP cells treated with BA with degradation of Sp1, Sp3 and Sp4 in this cell line. 
 Sp proteins are overexpressed in many human tumors and cell lines (576, 756-
759), and therefore these transcription factors are potential targets for development of 
drugs for cancer chemotherapy.  Lou and coworkers (760) reported that transformation 
of fibroblasts resulted in an 8- to 18-fold increase in Sp1 expression and these 
transformed cells formed highly malignant tumors in athymic nude mouse xenograft 
models, whereas fibroblasts expressing low levels of Sp1 did not form tumors.  In 
addition, ribozyme-dependent knockdown of Sp1 in the transformed cells decreased 
VEGF expression and increased apoptosis.  Results in Figure 4.5 clearly showed that BA 
(10 and 20 mg/kg/d) inhibited tumor growth and final tumor weights in athymic nude 
  
 
170
mice bearing LNCaP cells as xenografts.  Moreover, examination of individual tumors 
clearly showed that Sp1, Sp3 and Sp4 proteins were highly expressed in tumors from 
control animals, whereas there was a marked decreased in expression of these proteins in 
tumors from mice treated with BA (Fig. 4.6A).  Decreased VEGF expression also 
paralleled decreased Sp protein levels in tumors from BA-treated animals, although the 
magnitude of decreased VEGF was lower than that observed for Sp proteins in the latter 
treatment group.  The antiangiogenic activity of BA was confirmed by decreased VEGF 
and CD31 staining in tumors from BA- vs. corn oil-treated mice (Fig. 4.6D), and this 
was consistent with the antiangiogenic activity previously reported for BA (761).  
Hematoxylin and eosin staining also showed that the vascularity of tumors in mice 
treated with BA was significantly lower than in tumors from corn oil treated mice (Fig. 
4.5C).   
 We also examined Sp1, Sp3 and Sp4 protein expression in non-tumor tissue from 
control and BA-treated mice, and levels were barely detectable to non-detectable in both 
treatment groups; however, when gels were overexposed, it was evident that levels of Sp 
protein expression were similar in liver lysates from control and BA-treated mice (Figs. 
4.6B and 4.6C).  These results suggest that activation of proteasome-dependent 
degradation of Sp proteins by BA may be specific for cancer cells and tumors which 
overexpress these transcription factors in order to gain a growth and metastatic 
advantage over normal tissue.  The critical role for Sp proteins in regulating expression 
of antiapoptotic and proangiogenic genes/proteins in tumors is supported by results of 
this study which also highlights the efficacy of anticancer drugs that target specific 
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transcription factors such as Sp proteins that are overexpressed in tumors.  The effects of 
BA in this study were also observed for the closely related derivative betulonic acid 
(data not shown), and we conclude that BA and similar derivatives represent a novel 
class of transcription factor-targeting anticancer drugs.  Moreover, since BA induces 
many other cytotoxic and proapoptotic effects in cancer cell lines (511, 517, 528, 532, 
537-540, 762-765), it is likely that downrequlation of Sp proteins differentially 
contributes to the overall effect of this compound.  Current studies with BA are 
investigating tumor-type similarities and differences in its mechanism of action and the 
development of more potent analogs for clinical applications in the treatment of cancer. 
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CHAPTER V 
 
MICRORNA-27A IS A TARGET FOR ANTICANCER AGENT METHYL 
2-CYANO-3,11-DIOXO-18β-OLEAN-1,12-DIEN-30-OATE IN COLON CANCER 
CELLS 
INTRODUCTION 
 
MicroRNAs (miRNAs) are 20 to 25 bp oligonucleotides that interact with 
complementary binding sites in 3'-untranslated regions of target mRNAs to inhibit their 
expression by blocking translation or by decreasing mRNA stability (766, 767).  MiRNA 
interactions with mRNA requires the overlap of 6 to 8 base pairs and, due to this 
relatively low stringency, computational studies show that miRNAs can potentially 
interact with several hundred mRNAs. 
 Despite this lack of specificity, miRNAs have a profound effect on gene 
expression and cellular homeostasis and, in cancer cells, expression of several critical 
oncogenes and tumor suppressor genes are regulated by miRNA expression (610, 768-
770).  miR-221 and miR-222 target the cyclin-dependent kinase inhibitor p27 (770) and 
miR-21 decreases expression of several mRNAs including the tumor suppressor gene 
tropomyosin 1 (610).   
 Recent studies in this laboratory showed that miR-27a targets ZBTB10 mRNA, a 
putative zinc finger protein that suppresses specificity protein (Sp) transcription factors 
and Sp-dependent gene expression (585).  The Sp transcription factors Sp1, Sp3 and Sp4  
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are highly expressed in cancer cell lines, and results of RNA interference studies show 
that Sp proteins regulate expression of angiogenic genes such as vascular endothelial 
growth factor (VEGF), VEGF receptor 1 (VEGFR1, Flt-1), VEGFR2 (KDR), and the 
antiapoptotic gene survivin (331, 547, 579-581, 583, 584).   
 Betulinic acid and the non-steroidal anti-inflammatory drug tolfenamic acid 
inhibit prostate and pancreatic cell and tumor growth through activation of proteasome-
dependent degradation of Sp1, Sp3 and Sp4 proteins (583, 584).  In this study, we show 
that methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (β-CDODA-Me) is highly 
cytotoxic to colon cancer cells and also decreases Sp and Sp-dependent genes and 
proteins.  However, these effects are proteasome-independent.  We now show for the 
first time that β-CDODA-Me acts through downregulation of miR-27a and this is 
accompanied by enhanced expression of ZBTB10 and Myt-1 which arrests colon cancer 
cells at G2/M phase.  The cell culture studies are complemented by inhibition of tumor 
growth and decreased miR-27a expression in athymic nude mice bearing RKO cells as 
xenografts and treated with β-CDODA-Me 915 mg/kg/d). 
MATERIALS AND METHODS 
Plasmids, antibodies and reagents 
 Sp1 and Sp3 promoter constructs were kindly provided by Drs. Carlos Cuidad 
and Veronique Noe (University of Barcelona, Barcelona, Spain).  The pVEGF-133 
construct contain VEGF promoter insert (positions -131 to +54) linked to luciferase 
reporter gene.  The pSurvivin-269 was kindly provided by Dr. M. Zhou (Emory 
University, Atlanta, GA).  The pCMV6-XL4-ZBTB10 expression vector and empty 
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vector (pCMV6-XL4) were from Origene (Rockville, MD).  Antibodies for Sp1, Sp3, 
Sp4, VEGF and VEGFR1 were purchased from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA).  c-PARP and survivin antibodies were from Cell Signaling Technology Inc. 
(Danvers, MA).  Monoclonal β-actin antibody was purchased from Sigma-Aldrich.  
Reporter lysis buffer, and luciferase reagent for luciferase studies were supplied by 
Promega (Madison, WI).  β-Galactosidase (β-Gal) reagent was obtained from Tropix 
(Bedford, MA), and LipofectAMINE 2000 reagent was purchased from Invitrogen 
(Carlsbad, CA).  Western Lightning chemiluminescence reagent was obtained from 
PerkinElmer Life and Analytical Sciences (Boston, MA).  The PPARγ antagonist N-(4'-
aminopyridyl)-2-chloro-5-nitrobenzamide (T007) were synthesized in this laboratory, 
and their identities and purity (>98%) were confirmed by gas chromatography-mass 
spectrometry. 
Cell proliferation and transfection assay and western blot analysis  
 RKO and SW480 colon cancer cells (2 x 104 per well) were plated in 12-well 
plates and allowed to attach for 24 hr.  The medium was then changed to DMEM/Ham’s 
F-12 medium containing 2.5% charcoal-stripped FBS, and either vehicle (DMSO) or 
different concentrations of the compound were added.  Fresh medium and compounds 
were added every 48 hr, and cells were then trypsinized and counted after 48 and 96 hr 
using a Coulter Z1 cell counter.  Transfection experiments in RKO and SW480 cells 
used 0.4 μg of reporter gene constructs and 0.04 μg of β-Gal and LipofectAMINE 2000 
reagent (Invitrogen).  Results of cell proliferation and transfection studies are expressed 
as means ± S.E. for at least three replicate determinations for each treatment group.  
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Western blots were determined with whole cell lysates essentially as described (331, 
579-581, 583). 
Northern blot analysis  
 For miRNA analysis, 20 μg total RNA per lane was electrophoresed on 15% 
TBE urea polyacrylaminde gel (Invitrogen), electrophoretically transferred in 0.5X TBE 
at 300 mA for 45 minutes to GeneScreen Plus membrane (PerkinElmer, Boston, MA), 
UV cross-linked, and hybridized in ULTRAhyb-Oligo hybridization buffer (Ambion, 
Austin, TX) at 42 °C with 32P end-labeled DNA oligonucleotides complementary to the 
miRNA under examination.  Blots were washed at 42 °C in 2x SSC and 0.5% SDS for 
30 min with gentle agitation.   
Semiquantitative RT-PCR  
 RKO and SW480 colon cancer cells were transfected with either as-miRNA-27a 
or with pCMV6-XL4 control and pCMV6-XL4-ZBTB10 expression plasmid using 
Lipofectamine 2000 following manufacturer’s protocol.  Total RNA was extracted using 
RNeasy Mini Kit (Qiagen, Inc.), and 2 μgm of RNA was used to synthesize cDNA using 
Reverse Transcription System (Promega).  Primers were obtained from IDT and used for 
amplification were as follows:  Sp1 (sense 5'- ATG GGG GCA ATG GTA ATG GTG G 
-3'; antisense 5'- TCA GAA CTT GCT GGT TCT GTA AG -3'), Sp3 (sense 5'- ATG 
ACT GCA GGC ATT AAT GCC G -3'; antisense 5'- TGT CTC TTC AGA AAC AGG 
CGA C -3'), Sp4 (sense 5'- ATG GCT ACA GAA GGA GGG AAA AC -3'; antisense 5'- 
TTG ACC AGG GGT GGA AGA ATT AC -3'), ZBTB10 (sense 5'- GCT GGA TAG 
TAG TTA TGT TGC -3'; antisense 5'- CTG AGT GGT TTG ATG GAC AGA G -3'), 
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VEGF (sense 5'- CCA TGA ACT TTC TGC TGT CT T -3'; antisense 5'- ATC GCA 
TCA GGG GCA CAC AG -3'), VEGFR1 (sense 5'- ATG GAG CGT AAG AAA GAA 
AAA ATG -3'; antisense 5'- TCA AGT ACC TCC TTT TCT CAC AT -3'), Survivin 
(sense 5'- ATG GCC GAG GCT GGC TTC ATC -3'; antisense 5'- ACG GCG CAC TTT 
CTT CGC AGT T -3') and GAPDH (sense 5'- ACG GAT TTG GTC GTA TTG GGC G 
-3'; antisense 5'- CTC CTG GAA GAT GGT GAT GG -3').  PCR products were 
electrophoresed on 1% agarose gels containing ethidium bromide and visualized under 
UV transillumination.   
Quantitative real-time PCR of mRNA and miRNA  
 cDNA was prepared from the RKO and SW480, cell lines using Reverse 
Transcription System (Promega).  Each PCR was carried out in triplicate in a 20-μl 
volume using SYBR Green Mastermix (Applied Biosystems, Foster City, CA) for 15 
min at 95 °C for initial denaturing, followed by 40 cycles of 95 °C  for 30 s and 60 °C 
for 1 min in the Applied Biosystems 7900HT Fast Real-time PCR System.  The ABI 
Dissociation Curves software was used following a brief thermal protocol (95 °C  for 15 
s and 60 °C  for 15 s, followed by a slow ramp to 95 °C) to control for multiple species 
in each PCR amplification.  Values for each gene were normalized to expression levels 
of TATA-binding protein.  The primers used for real-time PCR were Myt-1 (sense 5'- 
CCT TCC AAG AGT AGC TCC AAT TC -3'; antisense 5'- GCC GGT AGC TCC CAT 
ATG G -3') and TATA-binding protein (sense 5'- TGC ACA GGA GCC AAG AGT 
GAA -3'; antisense 5'- CAC ATC ACA GCT CCC CAC CA -3').  miRNA was extracted 
using the mirVana miRNA extraction kit (Applied Biosystems).  Quantification of 
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miRNA (RNU6B and  miRNA-27a) was done using the Taqman miRNA kit (Applied 
Biosystems) according to the manufacturer’s protocol with real-time PCR.  U6 small 
nuclear RNA was used as a control to determine relative miRNA expression.   
Fluorescence-activated cell sorting analysis  
 RKO and SW480 cells were treated with either the vehicle (DMSO) or the 
compound for 24 hr or with as-miR27a.  Cells were trypsinized, centrifuged, and 
resuspended in staining solution containing 50 μg/mL propidium iodide, 4 mmol/L 
sodium citrate and 30 units/mL RNase.  After incubation at room temperature for 1 hr, 
cells were analysed on a FACS Vantage SE DiVa made by Becton Dickinson (BD), 
using BD FACSDiva Software V4.1.1.  Propidium iodide (PI) fluorescence was 
collected through a 610SP bandpass filter, and list mode data were acquired on a 
minimum of 50,000 single cells defined by a dot plot of PI width vs. PI area.  Data 
analysis was performed in BD FACSDiva Software V4.1.1 using PI width vs. PI area to 
exclude cell aggregates. 
Xenograft studies in athymic mice  
 Mice were used in accordance with institutional guidelines when they were 8 - 
12 wk old.  To produce tumors, RKO cells were harvested from subconfluent cultures by 
a brief exposure to 0.25% trypsin and 0.02% EDTA and only suspensions consisting of 
single cells with >90% viability were used for the injections.  A xenograft was 
established by s.c. injection of the cells (5 x 106) into the flanks of individual mice and, 
after 6 days, mice were randomized into two groups of 5 mice per group and dosed by 
oral gavage in corn oil or 15 mg/kg/d B-CDODA-Me 5 days a week for 22 days.  The 
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mice were weighed, and tumor size was measured every third day with calipers to permit 
calculation of tumor volumes:  V = LW2/2, where L and W were length and width, 
respectively.  Final tumors weights were determined at the end of the dosing regimen.  
Tumor tissues and selected body organs (liver and kidney) were either stored in 
RNAlater solution (per manufacture's recommendations) for later microRNA analysis, 
snap frozen and stored at -80°C, or fixed in 10% formalin and embedded in paraffin.   
RESULTS 
 β-CDODA-Me is a PPARγ agonist in colon cancer cell lines (312).  Although β-
CDODA-Me decreased proliferation (Fig. 5.1A) and induced apoptosis (Fig. 5.1B) in 
RKO and SW480 cells, these responses were not affected after cotreatment with the 
PPARγ agonist T007, and receptor-independent effects have been observed for other 
PPAR agonists in colon cancer cells (302).  Recent studies with tolfenamic acid and the 
structurally-related triterpenoid betulinic acid show that many of the growth inhibitory 
and proapoptotic responses in pancreatic and prostate cancer cells are due to decreased 
expression of Sp proteins (581, 583, 584).  Results summarized in Figure 5.1C show that 
β-CDODA-Me induced a concentration- and time-dependent decrease in Sp1, Sp3 and 
Sp4 proteins in RKO and SW480 cells and, in RKO cells, decreases were observed with 
concentrations lower than 1.0 μM after treatment for 48 hr.  The role of PPARγ and 
activation of proteasomes in mediating the effects of β-CDODA-Me on Sp protein 
expression was also investigated in RKO cells (Fig. 5.1D).  β-CDODA-Me-induced 
downregulation of Sp1, Sp3 and Sp4 in RKO cells was not affected after cotreatment 
with the PPARγ antagonist T007 or the proteasome inhibitor lactacystin, and similar 
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results were observed in SW480 cells (data not shown).  The proteasome inhibitor 
MG132 also did not block Sp protein downregulation in RKO and SW480 cells treated 
with β-CDODA-Me (data not shown), suggesting that β-CDODA-Me-dependent Sp 
protein degradation is proteasome-independent. 
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Fig. 5.1. β-CDODA-Me inhibits growth, induces apoptosis, and degradation of Sp proteins.  (A) 
Decreased cell survival in RKO and SW480 cells.  Cells were seeded and treated with solvent 
(DMSO) or different concentrations of β-CDODA-Me (0.5-5 μM) alone or in combination with 
T007 for 4 days.  Cell survival is expressed as the percentage of β-CDODA-Me-treated cells 
remaining compared to DMSO (set at 100%).  Results are expressed as means ± SE for three 
replicate determinations for each treatment group and significantly (p < 0.05) decreased survival 
is indicated by an asterisk.  Induction of apoptosis (B) and decreased expression of Sp1, Sp3 and 
Sp4 (C, D).  RKO and SW480 cells were treated with DMSO, β-CDODA-Me (1-5 μM), T007 
(10 μM), Lactacystin (2 μM), or combinations as indicated  for 24 hr or 48 hr and whole cell 
lysates were analyzed by Western blot analysis as described in the Materials and Methods. 
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Fig. 5.1 Continued 
 
Using RKO cells as a model, we showed that β-CDODA-Me induced caspase-
dependent PARP cleavage and decreased expression of at least three Sp-dependent 
proteins including survivin, VEGFR1 (Flt-1), and VEGF (Fig. 5.2A).  Figure 5.2B 
shows that β-CDODA-Me also decreased expression of Sp1, Sp3 and Sp4 mRNA levels 
after treatment for 24 hr, and similar effects were observed for mRNA levels of the Sp-
dependent genes VEGFR1, VEGF and survivin (Fig. 5.2B).  Both the Sp1 and Sp3 
promoters contain GC-rich sites, and Figure 5.2C shows that β-CDODA-Me decreased 
luciferase activity in RKO cells transfected with pSp1For4, pSp1For2 and pSp1For1 
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constructs which contain the -751 to -20, -281 to -20, and -146 to -20 regions 
(respectively) of the Sp1 gene promoter.  Similarly, β-CDODA-Me also decreased 
luciferase activity in RKO cells transfected with pSp3For5 and pSp3For2 constructs 
which contain the -417 to -38 and -213 to -38 regions (respectively) of the Sp3 gene 
promoter.  These results demonstrate that β-CDODA-Me decreases Sp1, Sp3 and Sp4 
transcription. 
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Fig. 5.2. Effects of β-CDODA-Me on Sp and Sp-dependent expression.  β-CDODA-Me 
decreases expression of Sp1, Sp3 and Sp4 proteins (A) and expression of 
angiogenic/survival genes (A) and proteins (B).  RKO cells were treated with different 
concentrations of β-CDODA-Me and after 24 hr, mRNA and protein were extracted and 
analyzed by semi-quantitative RT-PCR and Western blots, respectively, as described in 
the Materials and Methods. β-CDODA-Me decreases Sp1 (C) and Sp3 (D) promoter 
activity.  RKO cells were transfected with various constructs, treated with different 
concentrations of β-CDODA-Me, and luciferase activity determined as described in the 
Materials and Methods.  Results are expressed as means ± SE for three replicate 
determinations for each treatment group and significantly (p < 0.05) decreased activity is 
indicated by an asterisk. 
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It was recently reported that microRNA-27a (miR-27a) suppresses ZBTB10 mRNA 
levels in breast cancer cells and treatment with antisense miR-27a (as-miR-27a) 
increases expression of ZBTB10 and decreases expression of Sp mRNA and proteins  
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Fig. 5.3. Effects of β-CDODA-Me and as-miR27a.  β-CDODA-Me decreases miR-27a 
(A) and increases ZBTB10 (B) expression.  RKO and SW480 colon cancer cells were 
treated with DMSO or different concentrations of β-CDODA-Me and after 18 hr, total 
RNA was extracted and analyzed for miR27a by Northern blot analysis and real time 
PCR and ZBTB10 by semi-quantitative RT-PCR as described in the Materials and 
Methods.  (C) as-miR27a decreases Sp1, Sp4 and Sp3 proteins. RKO cells were 
transfected with 50 and 100 ng as-miR27a and after 24 hr, whole cell lysates were 
analyzed by Western blot analysis for Sp1, Sp4 and Sp3 proteins as described in the 
Materials and Methods. 
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(585).  Results illustrated in Figure 5.3A show that β-CDODA-Me decreased miR-27a in 
RKO and SW480 cells as determined by Northern blot analysis (top) and this was  
confirmed by quantitative real time PCR (bottom).  In addition, treatment of RKO or 
SW480 cells with β-CDODA-Me also induced ZBTB10 levels (Fig. 5.3B).  Thus, the 
effects of β-CDODA-Me on miR-27a and ZBTB10 expression in colon cancer cells are 
identical to those observed in breast cancer cells transfected with as-miR-27a which also 
increases ZBTB10 and decreases Sp protein expression (585).  Results in Figure 5.3C 
confirm that as-miR-27 also decreased expression of Sp1, Sp3 and Sp4 protein levels in 
RKO and SW480 colon cancer cells.   
 The direct effects of ZBTB10 as a "putative" Sp repressor were further 
investigated in colon cancer cells transfected with ZBTB10 expression plasmid.  
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Transfection of SW480 and RKO cells with 2 or 4 μg ZBTB10 expression plasmid 
decreased Sp1, Sp3 and Sp4 mRNA levels and decreased the Sp-dependent VEGF and 
survivin mRNA levels (Fig. 5.4A).  These responses were more pronounced in RKO 
cells and this may be due, in part, to higher basal expression of ZBTB10 in SW480 than 
in RKO cells.  These differences between the two cell lines were less apparent for the 
effects of ZBTB10 on Sp and Sp-dependent proteins (Fig. 5.4B).  ZBTB10 
overexpression decreased levels of Sp1, Sp3 and Sp4 proteins, survivin and VEGF and  
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Fig. 5.4. ZBTB10 decreases expression of Sp proteins and Sp-dependent angiogenic and 
survival genes.  ZBTB10 expression decreases expression of Sp and angiogenic/survival 
proteins (A) and mRNA (B).  RKO and SW480 cells were transfected with ZBTB10 
expression plasmid and after 24 hr, protein and mRNA were extracted and analyzed by 
Western blots and semi-quantitative RT-PCR, respectively, as described in the Materials 
and Methods.  ZBTB10 expression decreases Sp1 and Sp3 (C) and VEGF and survivin 
(D) promoter activity.  RKO cells were transfected with various constructs and ZBTB10 
expression plasmid, and luciferase activity was determined as described in the Materials 
and Methods.  Results are expressed as means ± SE for three replicate determinations for 
each treatment group and significantly (p < 0.05) decreased activity is indicated by an 
asterisk. 
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induced PARP cleavage in these cells.  The effects of ZBTB10 on luciferase activity in 
RKO cells transfected with constructs containing GC-rich Sp1 and Sp3 gene promoter 
inserts (Fig. 4C) and VEGF and survivin promoter inserts (Fig. 5.4D) complemented the 
effects of ZBTB10 on their respective mRNAs and proteins (Figs. 5.4A and 5.4B).  
Luciferase activity was decreased in RKO cells transfected with all constructs and 
similar results were observed in SW480 cells.  
Figure 5.5A summarizes the effects of β-CDODA-Me on distribution of RKO and 
SW480 cells in G0/G1, S and G2/M phases of the cell cycle.  Compared to treatment with 
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Fig. 5.5. Modulation of cell cycle progression.  (A) Effects of β-CDODA-Me.  RKO and 
SW480 cells were treated for 24 hr with DMSO (0), 2.5 and 5.0 μM β-CDODA-Me, and 
analyzed by FACS analysis as described in the Materials and Methods.  iSp modulates 
Sp protein expression and the cell cycle in SW480 (B) and RKO (C) cells.  Cells were 
transfected with iSp, a combination of small inhibitory RNAs for Sp1, Sp3 and Sp4 or a 
non-specific oligonucleotide (iLamin), and analyzed for Sp proteins by Western blots (to 
confirm Sp knockdown) and FACS analysis as described in the Materials and Methods.  
(D) as-miR-27a modulates the cell cycle.  SW480 and RKO cells were transfected with 
different amounts of as-miR-27a and, after 48 hr, analyzed by FACS as described in the 
Materials and Methods.  All experiments in this Figure [(A) - (D)] were repeated three 
times, and results are expressed as means ± SE.  Significant (p < 0.05) changes 
compared to untreated (0) or iLamin-treated cells are indicated by asterisks. 
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DMSO, β-CDODA-Me induced a concentration-dependent decrease in the  
 percentage of cells in G0/G1 and an increase of cells in G2/M.  The percentage of cells in 
S phase increased and then decreased after treatment with 2.5 and 5.0 μM β-CDODA-
Me, respectively; however, the dominant effects of β-CDODA-Me were associated with 
a block in progression through G2/M.  The potential role of Sp protein degradation on 
mediating the effects of β-CDODA-Me on distribution of cells in different phases of the 
cell cycle was determined by RNA interference using a combination of small inhibitory 
RNAs for Sp1 (iSp1), Sp3 (iSp3) and Sp4 (iSp4) as previously described for knockdown 
of these proteins in other cancer cell lines (331, 547, 579-581, 583, 771).  Transfection 
of SW480 (Fig. 5.5B) and RKO (Fig. 5.5C) with iSp1/iSp3/iSp4 (combined; iSp) 
significantly decreased expression of all three proteins (least efficiency observed for 
Sp4) and, compared to the results for iLamin (non-specific RNA), Sp knockdown caused 
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a significant G0/G1 to S phase arrest (Figs. 55B and 5.5C).  Thes.e results are comparable 
to previous studies in MCF-7 breast cancer cells transfected with iSp1 (578); however, 
the data were in contrast to the effects of β-CDODA-Me which induced a G2/M arrest in 
both RKO and SW480 cells (Fig. 5.5A).  Since β-CDODA-Me and as-miR-27a induced 
similar responses in colon cancer cells (Figs. 5.1 – 5.4), we also investigated the effects 
of as-miR-27a on distribution of RKO and SW480 cells in G0/G1, S and G2/M phases.  
The results (Fig. 5.5D) demonstrate that like β-CDODA-Me, as-miR-27a induced a 
G2/M arrest in colon cancer cells.  Transfection of as-miR-27a (100 nM RKO; 200 nM 
SW480) increased accumulation of cells in G2/M and this was accompanied by a 
decrease in percentage of cells in S (SW480) and G0/G1 (RKO) phases.  However, the 
magnitude of the G2/M arrest observed in colon cancer cells transfected with as-miR-27a 
was lower than observed for β-CDODA-Me, suggesting that the compound-induced 
response may also be due to other factors. 
 As-miR-27a also arrests MDA-MB-231 breast cancer cells in G2/M phase and 
this is due to upregulation of Myt-1 (585) which is a target for miR-27a and catalyzes 
phosphorylation of cdc2 to inhibit progression through the G2/M checkpoint enzyme 
(772).  Results in Figure 5.6A show that β-CDODA-Me induced Myt-1 mRNA 
expression in RKO and SW480 cells, and this was accompanied by the time-dependent 
induction of cdc2 phosphorylation as previously described in breast cancer cells  
transfected with as-miR-27a (585).  Myt-1 catalyzed inactivation of cdc2 by 
phosphorylation of tyrosine-15 and this resulted in G2/M arrest.  Wee-1 is a potential 
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Fig. 5.6. In vitro and in vivo effects on G2/M and tumor growth.  Effects of β-CDODA-Me
(A) and as-miR-27a (B) on Myt-1 and cdc2 phosphorylation.  Colon cancer cells were
treated with different amounts of β-CDODA-Me or as-miR-27a for the indicated times, and 
Myt-1 expression and cdc2 phosphorylation were determined by real time PCR or Western blots, 
respectively, as described in the Materials and Methods.  β-CDODA-Me inhibits tumor growth 
(volume) (C) and weight/miR-27a expression (D) in a mouse xenograft model.  Nude mice 
bearing RKO cells as xenografts were treated with corn oil (solvent control) or β-CDODA-Me 
(15 mg/kg/d), and tumor volumes, tumor weights, and miR-27a expression were determined as 
described in the Materials and Methods.  Results are expressed as means ± SE for replicate (at 
least three or more) determinations for each treatment group, and significantly (p < 0.05) 
decreased tumor volume or weight is indicated by an asterisk. 
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miR-27a target that also inactivates cdc2; however, β-CDODA-Me and as-miR-27a did  
not affect Wee-1 expression in SW480 or RKO cells (data not shown).  We also 
investigated the in vivo activity of β-CDODA-Me as an inhibitor of tumor growth in  
 athymic nude mice bearing RKO cells as xenografts.  β-CDODA-Me (15 mg/kg/d) 
inhibited tumor growth (Fig. 5.6C) and tumor weight/miR-27a expression (Fig. 5.6D), 
and this was not accompanied by any body or organ weight loss associated with toxic 
side effects (data not shown).  Thus, like other compounds such as tolfenamic and 
betulinic acids that decrease Sp protein expression (583, 771), β-CDODA-Me inhibits 
both colon cancer cell and tumor growth and represents a novel class of anticancer 
agents that act through targeting miR-27a downregulation in colon cancer cells and 
tumors. 
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DISCUSSION 
 Sp transcription factors are critical for early embryonic development and for 
regulating expression of multiple genes including those important for cell proliferation 
and differentiation (773).  The age-dependent expression of Sp proteins has not been 
extensively investigated; however, a recent study reported that levels of these proteins 
decrease during cellular senescence and aging (774).  Sp1 protein is overexpressed in 
several tumor types compared to non-tumor tissue, and Sp1 was a negative prognostic 
factor for cancer survival (775-780).  For example, Sp1 is overexpressed in human 
gastric tumors compared to non-tumor tissue and overexpression of this protein in 
tumors is a predictor for a poor prognosis.  Sp1 is also overexpressed in malignant 
human fibroblast cell lines and results of Sp1 overexpression or knockdown in 
fibroblasts and fibrosarcoma cells has established a causal linkage between Sp1 
overexpression and malignant transformation (781).   
 Research in this laboratory has shown Sp1, Sp3 and Sp4 are highly expressed in 
cancer cell lines, and RNA interference studies clearly demonstrate that these 
transcription factors cooperatively regulate prosurvival, growth promoting, and 
angiogenic genes, suggesting that targeting Sp protein degradation may be a viable 
strategy for cancer chemotherapy (331, 547, 579-581, 583, 771, 782). 
 Both betulinic acid and tolfenamic acid inhibit growth of prostate and pancreatic 
tumors and cells, and these effects are linked to induction of proteasome-dependent 
degradation of Sp1, Sp3 and Sp4 proteins which is accompanied by decreased 
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expression of Sp-dependent genes such as survivin, VEGF and VEGFR1 (580, 581, 583, 
584).  However, ongoing studies with betulinic and tolfenamic acids in other cancer cell 
lines indicate that their effects on decreased Sp protein and mRNA levels are primarily 
proteasome-independent.  Results in Figure 5.1 show that β-CDODA-Me induced 
apoptosis and inhibited SW480 and RKO colon cancer cell growth and the responses 
were not inhibited by the PPARγ antagonist T007 (Figs. 5.1A and 5.1B) or other PPARγ 
antagonists (data not shown).  β-CDODA-Me also decreased Sp1, Sp3 and Sp4 protein 
expression in SW480 and RKO cells, and these responses were not inhibited by T007 or 
proteasome inhibitors (Figs. 5.1C and 5.1D) but were related to decreased Sp1, Sp3 and 
Sp4 transcription factors (Fig. 5.2). β-CDODA-Me decreased Sp proteins and mRNA 
levels and also decreased protein and mRNA levels of the Sp-dependent genes VEGF, 
VEGFR1 and survivin (Figs. 5.3A and 5.3B).  Interestingly, β-CDODA-Me decreased 
transactivation in colon cancer cells transfected with pSp1For1-luc and pSp3-For2-luc 
(Figs. 5.3C and 5.3D) which do not contain GC-rich sequences, suggesting modulation 
of other trans-acting factors and these are currently being investigated.  
 The effects of β-CDODA-Me on Sp proteins and Sp-dependent genes in colon 
cancer cells were reminiscent of the effects of antisense miR-27a (as-miR-27a) in ER-
negative MDA-MB-231 breast cancer cells (782).  In MDA-MB-231 cells transfected 
with as-miR-27a, there was a parallel increase in a zinc finger transcription factor, 
ZBTB10, which also binds GC-rich promoter sequences (619) and inhibits expression of 
Sp1, Sp3 and Sp4 and Sp-dependent genes (585)f.  Figures 5.3A and 5.3B show that β-
CDODA-Me decreased miR-27a and increased ZBTB10 expression in RKO and SW480 
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colon cancer cells.  Moreover, as previously reported in MDA-MB-231 cells, as-miR-
27a or ZBTB10 overexpression decreased Sp proteins and mRNA levels and Sp-
dependent genes (e.g. survivin and VEGF) in colon cancer cells (Figs. 5.3A and 5.3B).  
The effects of β-CDODA-Me on distribution of RKO and SW480 cells in the G0/G1, S 
and G2/M phases of the cell cycle (Fig. 5.5A) showed that the dominant effect was 
accumulation of cells in G2/M.  Decreased Sp1 expression in MCF-7 cells by RNA 
interference arrests cells in G0/G1 (331) and, in colon cancer cells transfected with small 
inhibitory RNAs for Sp1, Sp3 and Sp4 (combined), we observed a significant block in 
G0/G1 to S phase progression but no effects on G2/M (Figs. 5.5B and 5.5C).  Similar 
results were observed in MDA-MB-231 breast cancer cells transfected with ZBTB10 
(782).  However, transfection of MDA-MB-231 or colon cancer cells with as-miR-27a 
resulted in G2/M arrest (Fig. 5.5D), and this mimicked the effects of β-CDODA-Me 
(Fig. 5.5A).  Growth arrest in colon cancer cells treated with β-CDODA-Me was greater 
than observed for as-miR-27a, suggesting that the compound may activate other 
pathways and these are currently being investigated. 
 Since miR-27a potentially targets both Myt-1 and Wee-1, two kinases that inhibit 
cdc2 and progression of cells through the G2/M checkpoint, we investigated the effects 
of β-CDODA-Me on cdc2 and phospho-cdc2 expression.  β-CDODA-Me induced Myt-1 
but not Wee-1 expression in both RKO and SW480 cells (Fig. 5.6A), and this was 
accompanied by phosphorylation of cdc2 in RKO and SW480 cells.  As-miR-27a also 
induced Myt-1 and cdc2 phosphorylation in these cell lines (Fig. 5.6B) as previously 
observed in MDA-MB-231 breast cancer cells (782).  Thus, like as-miR-27a, β-
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CDODA-Me acts through decreased expression of miR-27a, resulting in enhanced 
expression of ZBTB10 and Myt-1 which subsequently induce downstream growth 
inhibitory, proapoptotic and antiangiogenic genes and pathways in colon cancer cells.  
These in vitro responses induced by β-CDODA-Me were complemented by the 
inhibition of tumor growth and tumor weight in athymic nude mice bearing RKO cells as 
xenografts (Figs. 5.6C and 5.6D), and miR-27a expression was also decreased in tumors 
from β-CDODA-Me-treated animals compared to tumors from corn oil-treated mice. 
 In summary, results of this study show that β-CDODA-Me decreases expression 
of Sp proteins and Sp-dependent genes and induces G2/M arrest in colon cancer cells, 
and these responses are due to repression of miR-27a and increased expression of 
ZBTB10 and Myt-1.  β-CDODA-Me also decreased tumor growth and this was also 
accompanied by decreased miR-27a expression in the tumor and this represents one of 
the first in vivo examples of drug-miR interaction.  Other compounds such as betulinic 
and tolfenamic acids also decrease Sp proteins in prostate and pancreatic cancer cells 
(581, 771), and there is evidence that a hydroxamic acid histone deacetylase inhibitor 
decreases expression of miR-27a and other miRs in SKBR3 cells(618).  The similarities 
of these drugs to β-CDODA-Me and the effects of cancer cell context on their activities 
and their mechanisms of miR-27a downregulation are currently being investigated in this 
laboratory.   
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CHAPTER VI 
2-CYANO-LUP-1-EN-3-OXO-20-OIC ACID, A CYANO DERIVATIVE OF 
BETULINIC ACID, ACTIVATES PEROXISOME PROLIFERATOR-
ACTIVATED RECEPTOR γ IN COLON AND PANCREATIC CANCER CELLS* 
INTRODUCTION 
 Lup-20(29)-ene-3β,28-diol (betulin) is a triterpene natural product found in 
extracts of many bushes and trees, and betulin can constitute up to 30% of the dry weight 
of bark from birch trees (783, 784).  Betulin has been used in folk medicine for treating 
skin diseases; however, betulinic acid (BA), which is both a natural product and 
chemical oxidation product of betulin, induces a broad range of pharmacological 
activities.  BA and several derivatives exhibit anticancer activity, inhibit HIV and other 
viruses through multiple pathways, are effective antibacterial and antimalarial drugs, and 
exhibit anti-inflammatory activity (783, 784).  The antitumorigenic activities of BA has 
been extensively investigated.  Studies show that this compound inhibits tumor growth 
through multiple pathways and these responses are also cancer cell/tumor-dependent 
(510, 511, 517, 528, 532, 533, 537-540, 783-788). Pisha and coworkers reported that BA 
selectively inhibited melanoma cancer cell and tumor growth and in in vivo studies, this 
was accompanied by minimal toxic side-effects at  repeated doses of 
____________ 
*Reprinted with permission from “2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano 
derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma 
in colon and pancreatic cancer cells” by Chintharlapalli S, Papineni S, Liu S, Jutooru I, 
Chadalapaka G, Cho SD, Murthy RS, You Y, Safe S. Carcinogenesis. 2007;28(11); 
2337-46..Copyright 2007 by Oxford Journals Inc. 
  
 
197
up to 500 mg/kg (510).  Subsequent studies showed that BA was cytotoxic to many other 
cancer cell lines and this was associated with different activities (511, 517, 528, 532, 
533, 537-540, 789-792).  For example, BA induces apoptosis through decreased 
mitochondrial membrane potential, activation of mitogen-activated protein kinase, and 
modulation of nuclear factor κB (NFκB) (511, 793, 794). 
 Structural modifications of BA and other lupane-derived triterpenoids 
differentially affect their pharmacologic activities (534-536, 795-798).  For example, 
modification of the C-20 exocyclic position of BA did not affect the cytotoxicity of these 
derivatives to a panel of prostate and colon cancer and melanoma cell lines (799).  In 
contrast, A-ring modifications of betulinic acid containing a 1-ene-3-oxo moiety 
substituted at C-2 with electron withdrawing groups were highly cytotoxic (534).  These 
result were similar to ursane and oleanane triterpenoid acids where analogs containing 
electron-withdrawing substituents at C-2 within a 1-ene-3-one functionality were also 
highly cytotoxic to cancer cells compared to the parent acids (234, 312, 463, 464, 655).  
Typical among these synthetic derivatives were 2-cyano-3,12-dioxo-18β-oleana-1,19-
diene-28-oic acid (CDDO; synthesized from oleanolic acid) and 2-cyano-3,12-dioxo-
18β-olean-1,12-diene-30-oic acid (β-CDODA; synthesized from glycyrrhetinic acid, a 
major constituent of licorice extracts).  The high cytotoxicity of both β-CDODA, CDDO 
and related compounds was due, in part, to their peroxisome proliferator-activated 
receptor γ (PPARγ) agonists activity since ligands for this receptor are being developed 
as new anticancer drugs (659, 660). 
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 Although there are multiple structural differences between BA and oleanolic acid 
(the synthetic precursor of CDDO and CDODA) , we hypothesized that introduction of a 
2-cyano group into the lupane skeleton of BA would generate a new class of PPARγ 
agonists.  Previous studies showed that 2-cyano-lup-1-en-3-oxo-20-oic acid (CN-BA), 
the 2-cyano derivative of 20(29)-dihydro betulinic acid, was highly cytotoxic to cancer 
cells, and in this study, we compared the effects of BA, CN-BA and the corresponding 
methyl ester (CN-BA-Me) (Fig. 1.19) in Panc-28 pancreatic and in colon cancer cell 
lines.  Results of growth inhibition studies showed that both CN-BA and CN-BA-Me 
were more cytotoxic than BA in pancreatic and colon cancer cells.  CN-BA and CN-BA-
Me but not BA induced PPARγ-dependent transactivation; however, the receptor-
dependent induction of p21, caveolin1 and Krüppel-like factor-4 expression was cell 
context and gene-dependent.  These results demonstrate for the first time that CN-BA 
and CN-BA-Me are PPARγ agonists and their enhanced cytotoxicity compared to BA is 
due, at least in part, to activation of PPARγ.  Moreover, the structure- and cell context-
dependent activities of CN-BA and CN-BA-Me as PPARγ agonists suggest that these 
compounds are selective PPARγ modulators. 
MATERIALS AND METHODS 
Cell Lines and reagents   
SW480, HT-29 and HCT-15 human colon cancer cells were kindly provided by 
Dr. Stan Hamilton (M. D. Anderson Cancer Center (Houston, TX).  Panc-28 human 
pancreatic cancer cells and 3T3-L1 pre-adipocytes were obtained from American Type 
Culture Collection (Manassas, VA).  SW480, HT-29 and Panc-28 cells were maintained 
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in Dulbecco’s modified/Ham’s F-12 (Sigma-Aldrich, St Louis, MO) with phenol red 
supplemented with 0.22% sodium bicarbonate, 0.011% sodium pyruvate, 5% fetal 
bovine serum, and 10 mL/L 100X antibiotic antimycotic solution (Sigma).  HCT-15 
cells were maintained in RPMI 1640 (Sigma) supplemented with 0.22% sodium 
bicarbonate, 0.011% sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% fetal bovine 
serum, and 10 mL/L of 100x antibiotic antimycotic solution (Sigma).  Cells were 
maintained at 37°C in the presence of 5% CO2.  Reporter lysis buffer and luciferase 
reagent for luciferase studies were supplied by Promega (Madison, WI).  β-
Galactosidase (β-Gal) reagent was obtained from Tropix (Bedford, MA), and 
LipofectAMINE reagent was purchased from Invitrogen (Carlsbad, CA).  The PPARγ 
antagonist N-(4'-aminopyridyl)-2-chloro-5-nitrobenzamide (T007) (800) was synthesized 
in this laboratory, and its identity and purity (>98%) was confirmed by gas 
chromatography-mass spectrometry.   
Synthesis of CN-BA and CN-BA-Me   
CN-BA and CN-BA-Me were prepared from betulin (Sigma-Aldrich) based on 
the previous methods (534).  The synthesis from a key intermediate, methyl lup-2-
eno[2,3-d]isoxazol-28-oate, is briefly described and only definite peaks in proton NMR 
are recorded.  Methyl Lup-2-eno[2,3-d]isoxazol-28-oate.  To a solution of methyl 
lupan-2-hydroxymethylene-3-oxo-28-oate (350 mg, 0.70 mmoL) in ethanol (20 mL) and 
water (1 mL), hydroxylamine hydrochloride (488 mg, 7.02 mmol) was added.  The 
reaction mixture was refluxed for 1 hr, cooled to room temperature and concentrated 
under vacuum.  Water was added to the reaction mixture and extracted with ethyl acetate 
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(2X).  The organic layer was then washed with brine (2X), separated, and the crude 
product was purified by a flash silica gel column using a solvent system of hexanes:ethyl 
acetate (95:5) to yield methyl lup-2-eno[2,3-d]isoxazol-28-oate as a white cream colored 
solid.  1H NMR (400 MHz, CDCl3): δ 8.00 (1H, s), 3.68 (3H, s), 1.31, 1.21, 0.99, 0.98, 
0.83 (each 3H, s), 0.89 (3H, d, J = 6.8 Hz), 0.78 (3H, d, J = 6.8 Hz). 13C NMR (100 
MHz, CDCl3): δ 177.6, 173.8, 151.1, 109.7, 57.8, 54.3, 52.0, 49.7, 49.6, 45.0, 43.4, 41.5, 
39.7, 38.9, 38.1, 36.6, 35.6, 34.2, 32.8, 30.6, 30.5, 30.4, 29.5, 27.7, 23.8, 23.6, 22.2, 
22.0, 19.6, 16.8, 16.5, 15.5, 15.4.  Methyl 2-Cyano-lup-3-hydroxy-2-en-28-oate.  To a 
solution of lup-2-eno[2,3-d]isoxazol-28-oate (250 mg, 0.50 mmol) in ether (30 mL) and 
methanol (15 mL) in an ice bath, 30% sodium methoxide in methanol (3071 mg, 56.87 
mmol) was added drop wise.  The reaction mixture was then stirred at room temperature 
for 2 hr.  After dilution with ether, the reaction mixture was washed with 5% 
hydrochloric acid (2X).  The organic layer was separated and worked up by standard 
method to yield crude methyl 2-cyano-lup-3-hydroxy-2-en-28-oate (240 mg, 96%) as a 
white solid, which was used for the next without further purification.  1H NMR (400 
MHz, CDCl3):  δ 3.90 (1H, m), 3.67 (3H, s), 1.27, 1.17, 0.98, 0.95, 0.83 (each 3H, s), 
0.89 (3H, d, J = 6.8 Hz), 0.79 (3H, d, J = 6.8 Hz).  Methyl 2-Cyano-lup-1-en-3-oxo-20-
oate (CN-BA-Me).  A mixture of 2-cyano-lup-3-hydroxy-2-en-28-oate (230 mg, 0.46 
mmol) and DDQ (117 mg, 0.52 mmol) in benzene (30 mL) was refluxed for 3 hr.  The 
reaction mixture was cooled in ice and filtered to remove reduced DDQ.  The filtrate 
was then concentrated under vacuum.  The crude product was purified by a flash silica 
gel column using a solvent system of benzene:acetone (98:2) to yield CN-BA-Me (170 
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mg, 74%) as a pale brown solid.  1H NMR (400 MHz, CDCl3):  δ 7.83 (1H, s), 3.66 (3H, 
s), 1.25, 1.18, 1.12, 1.00, 0.95 (each 3H, s), 0.87 (3H, d, J = 6.7 Hz), 0.75 (3H, d, J = 6.6 
Hz). 13C NMR (100 MHz, CDCl3): δ 199.0, 177.4, 171.6, 115.8, 114.6, 57.6, 53.3, 52.0, 
49.4, 45.7, 44.8, 44.4, 43.6, 42.6, 41.5, 38.8, 37.9, 34.2, 32.6, 30.4, 30.2, 28.5, 27.3, 
23.7, 23.5, 22.1, 22.0, 19.6, 19.1, 17.2, 15.4, 15.2.  ESI-HRMS Calcd for (C32H47NO3 + 
H): 494.3634. Found: 494.3685. Anal. (C32H47NO3) C, H.  2-Cyano-lup-1-en-3-oxo-20-
oic acid (CN-BA).  A mixture of CN-BA-Me (120 mg, 0.25 mmol) and lithiumiodide 
(720 mg) in dimethylformamide (2.4 mL) was refluxed for 2 hr.  The reaction mixture 
was cooled to room temperature and 5% hydrochloric acid was added.  The reaction 
mixture was extracted with ethyl acetate (2X).  The organic layer was then washed with 
water (2X) followed by washings with brine (2X).  The organic layer was separated and 
worked up by standard method.  The crude product was purified by a flash silica gel 
column using a solvent system of hexanes:ethyl acetate (80:20) to yield CN-BA (93 mg, 
80%) as a light yellow solid.  1H NMR (400 MHz, CDCl3): δ 10.29 (1H, broad s), 7.83 
(1H, s), 1.27, 1.14, 1.04, 0.99, 0.99 (each 3H, s), 0.91 (3H, d, J = 6.8 Hz), 0.79 (3H, d, J 
= 6.7 Hz). 13C NMR (100 MHz, CDCl3): δ 199.0, 182.1, 171.5, 115.8, 114.8, 57.5, 53.3, 
49.3, 45.8, 44.8, 44.4, 43.7, 42.7, 41.5, 39.0, 38.1, 34.3, 32.7, 32.7, 30.5, 30.3, 28.6, 
27.4, 23.8, 23.5, 22.2, 22.1, 19.6, 19.2, 17.3, 15.4, 15.3.  ESI-HRMS Calcd for 
(C31H45NO3 + H): 480.3478. Found: 480.3540. Anal. (C31H45NO3) C, H.  CN-BA and 
CN-BA-Me were > 97% pure by spectroscopic analysis. 
Cell proliferation assay   
This assay is performed in 12-well tissue culture plates at the concentration of 2 
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x 104 cells per well, using DMEM/Ham’s F-12 media containing 2.5% charcoal stripped 
FBS.  The cells were counted on the initial day using Z1 cell counter (Beckman Coulter, 
Fullerton, CA) and then the cells were treated either with vehicle (DMSO) or the 
indicated triterpenoid compounds, each sample in triplicate.  Every 48 hr, fresh medium 
was added along with the indicated compounds.  The count of the cells was taken after 2, 
4 and 6 days.  The results are expressed as means ± S.E for each set of triplicate. 
Mammalian two hybrid assay   
The GAL4 reporter construct containing 5 x GAL4 response elements (p GAL4), 
kindly provided by Dr.Marty Mayo (University of North California, Chapel Hill, NC).  
The GAL4-coactivator fusion plasmids pM-SRC1, pMSRC2, pMSRC3, pM-DRIP205, 
pM-CARM-1 and PPARγ-VP16 fusion plasmid (Vp-PPARγ) containing the DEF region 
of the PPARγ (amino acids 183 - 505) fused to the pVP16 expression vector were kindly 
provided by Dr.Shigeaki Kato (University of Tokyo, Tokyo, Japan).  SW480 colon 
cancer cells were plated in 12-well tissue culture plates at 1 x 105 cells per well in 
DMEM/Ham’s F-12 medium supplemented with 2.5% charcoal stripped FBS.  After 
allowing them to adhere for overnight, transient transfections were carried out with 
GAL4-Luc (0.4 μg), β-GAL (0.04 μg), VP-PPARγ (0.04 μg), pM-SRC1 (0.04 μg), pM-
PGC-1 (0.04 μg), pM-SMRT (0.04 μg), pM-TRAP220 (0.04 μg), pM-DRIP205 (0.04 
μg), pMCARM1 (0.04 μg) using LipofectAMINE2000 (Invitrogen) following the 
manufacturer’s guidelines.  After 6 hr of transfection, cells were treated in triplicate 
either with vehicle (DMSO) or the indicated compound suspended in complete medium 
for 20-24 hr.  One hundred μL per well of 1x Reporter Lysis Buffer ( Promega) was used 
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to lyse the cells and 30 μl of this lysate was used to perform the luciferase and β-GAL 
assays using Lumicount (Perkin-Elmer Life and Analytical Sciences, Boston, MA).  The 
luciferase activities obtained were normalized to the β-gal activity. 
Transfections   
Cells were seeded on to the 12-well plates and 0.4 μg of GAL4-Luc, 0.04 μg of 
β-GAL, 0.04 μg of GAL4DBD-PPARγ, 0.4 μg of p21-luc(FL) containing -2325 to +8 
insert, 0.4 μg of p21-luc (-124) containing -124 to +8 insert and 0.4 μg of p21-LUC (-
60) containing -60 to +8 insert were transfected using LipofectAMINE reagent 
(Invitrogen) following the manufacturer’s protocol.  Cells were treated either with 
vehicle or respective compounds suspended in complete medium after 6 hr of 
transfection.  Cell lysate is extracted after 20-22 hr by adding 100 μl of 1x reporter lysis 
buffer per well and 30 μl of this extract is used to quantitate the luciferase activity using 
Lumicount (Perkin-Elmer Life and Analytical Sciences).  Each experiment is done in 
triplicate and the results are normalized to the β-GAL activity. 
Western blot analysis   
SW480, HT-29, HCT-15 and Panc-28 (3 x 105) colon cancer cells were seeded in 
6-well tissue culture plates in DMEM/Ham’s F-12 medium containing 2.5% charcoal-
stripped FBS.  Protein is extracted from the cells treated either with vehicle or indicated 
compounds suspended for 24 hr except for caveolin-1 protein which was done for 72 hr.  
Samples were extracted in high salt buffer [50 mmol/L HEPES, 500 mmol/L NaCl, 1.5 
mmol/L MgCl2, 1 mmol/L EGTA, 10% glycerol, and 1% Triton X-100 (pH 7.5), and 5 
μL/mL protease inhibitor cocktail (Sigma-Aldrich)].  Samples were incubated at 100°C 
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for 2 min, separated on either 10% or 12% SDS-PAGE gels and then transferred to 
polyvinylidene difluoride membrane (PVDF; Bio-Rad, Hercules, CA).  The PVDF 
membrane was blocked in 5% TBST-Blotto (10mM Tris HCl, 150 mM NaCl, pH 8.0, 
0.05% Triton X-100, and 5% nonfat dry milk) for about 30 min and was then incubated 
in fresh 5% TBST-Blotto with 1:1000 for caveolin-1 [Santa Cruz Biotechnology (Santa 
Cruz, CA)], 1:1000 for p21(BD Pharmingen, Frank lakes, NJ) and 1: 10000 for β-actin 
(Sigma) primary antibody overnight with gentle shaking at 4°C.  After washing with 
TBST for 10 min, the membrane was incubated with respective secondary antibody 
(1:5000) (Santa cruz, CA) in 5% TBST-Blotto for 3 hr.  The membrane is then washed 
with TBST for 10 min, incubated with chemiluminiscence reagent from Perkin Elmer for 
one min and then exposed to Kodak X-OMAT AR autoradiography film (Eastman 
Kodak, Rochester, NY).  
Differentiation and Oil Red O staining  
 3T3-L1 preadipocytes were cultured on poly-lysine-coated coverslips with 
DMEM and 10% FBS at 5% CO2 in 24-well plates.  At 2 days post-confluence, cells 
were incubated with fresh media supplemented with 3-isobutyl-1-methylxanthine (0.5 
mM), dexamethasone (1 µM), insulin (1.7 µM), and indicated compounds (0.25 µM).  
After 48 hr, cells were changed to fresh media and treated with DMSO or indicated 
compounds for 5 days.  Cells without any treatment for the entire 7 days were used as 
control.  The cells were then fixed with 10% formalin.  Fixed cells were washed with 
60% isopropanol and stained with filtered 60% Oil Red O in deionized water.  After 
staining, cells were washed with water and photographed. 
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Semi quantitative RT-PCR   
SW480 and HT29 colon cancer cells were treated either with vehicle (DMSO) or 
indicated compounds and after 24 hr total RNA was extracted using RNeasy Mini kit 
(Qiagen, Inc., Valencia, CA).  RNA concentration was measured by UV 260:280 nm 
absorption ratio, and 2 µg RNA was used to synthesize cDNA using Reverse 
Transcription System (Promega).  PCR conditions were as follows:  initial denaturation 
at 94°C (1 min) followed by 28 cycles of denaturation for 30 s at 94°C, annealing for 60 
s at 55°C and extension at 72°C for 60 s, and a final extension step at 72°C for 5 min.  
The mRNA levels were normalized using GAPDH as an internal housekeeping gene.  
Primers obtained from IDT and used for amplification are as follows:  KLF4 (sense 5'-
CTA TGG CAG GGA GTC CGC TCC-3'; antisense 5'-ATG ACC GAC GGG CTG 
CCG TAC-3') and GAPDH (sense 5'-ACG GAT TTG GTC GTA TTG GGC G-3'; 
antisense 5'-CTC CTG GAA GAT GGT GAT GG-3').  PCR products were 
electrophoresed on 1% agarose gels containing ethidium bromide and visualized under 
UV transillumination.   
RESULTS 
Figure 6.1 illustrates the effects of BA, CN-BA and the corresponding methyl 
ester (CN-BA-Me) on growth of SW480 and Panc-28 cells.  All three compounds inhibit 
growth of both cell lines and IC50 values range from 1-5, 1-2.5 and 1-2.5 μM (Panc-28) 
and 1-5, 1.0 and 1-2.5 μM (SW480) were observed for BA, CN-BA and CN-BA-Me, 
respectively.  CN-BA was the most cytotoxic compound in both cell lines and this 
confirms results of a previous report showing that 2-cyano derivatives of BA enhanced  
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Fig. 6.1. Cell proliferation and adipocyte differentiation assays.  Panc-28 and SW480 
cells were treated with different concentrations of BA (A), CN-BA (B) or CN-BA-Me 
(C) for 6 days and the number of cells were counted after treatment for 2, 4 or 6 days as 
described in the Materials and Methods.  Results are expressed as means ± SE for three 
separate determinations for each treatment group.  (D) Effects of CN-BA and CN-BA-
Me on differentiation of 3T3-L1 adipocytes.  3T3-L1 adipocytes were treated with 0.25 
μM CN-BA, CN-BA-Me or DMSO.  Induction of fat droplets by Oil-red O staining was 
determined as described in the Materials and Methods.  Induction of intense staining for 
fat droplets was observed in replicate (3) experiments. 
 
 
 
 
  
 
207
 
CN-BA-M e  (Panc-28)
0
0.5
1
1.5
2
2.5
3
0 2 4 6
Time (Days)
C
el
l N
u
m
be
r x
 1
06
DMSO
0.5 µM
1 µ M
2.5 µM
5 µ M
C (i)
C
el
l N
u
m
be
r x
 1
06
CN-BA-M e  (SW480)
0
0.5
1
1.5
2
2.5
3
3.5
0 2 4 6
Time (Days)
DMSO
0.5 µ M
1 µM
2.5 µ M
5 µM
(ii)
DMSO CN-BA 0.25 μMCN-BA-Me 0.25  μMD
 
Fig. 6.1 continued 
 
cytotoxicity (534).  One of the hallmarks of PPARγ agonists is their induction of 
differentiation in 3T3-L1 adipocytes which is characterized by accumulation of fat 
droplets which can be detected by Oil Red O staining.  Results in Figure 6.1D show that 
both CN-BA and CN-BA-Me induce Oil Red O staining in this assay, whereas BA does 
not induce this response (data not shown).  These results suggest that these 2-cyano 
derivatives of BA exhibit activity associated with PPARγ agonists. 
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 The PPARγ agonist activity of BA and related compounds was determined in 
SW480 cells transfected with PPARγ-GAL4/pGAL4 and a PPRE3-luc construct (Fig. 
6.2A).  The results show that 2.5-10 μM CN-BA and CN-BA-Me induced 
transactivation, whereas BA was inactive in this assay.  The PPARγ agonist activities 
were also determined in SW480 cells using the same constructs but treated with CN-BA, 
CN-BA-Me alone or in combination with the PPARγ antagonist T007, and in all cases, 
the induced activities were inhibited by T007 (Fig. 6.2B).  A similar approach was used 
in Panc-28 cells transfected with PPARγ-GAL4/pGAL4 and PPRE3-luc (Fig. 6.2C), and  
CN-BA induced luciferase activity that was inhibited in cells cotreated with CN-BA plus 
T007.  Not surprisingly, BA was inactive in these assays; however, results obtained for 
CN-BA-Me were highly inconsistent in Panc-28 cells compared to the colon cancer cell 
line (Figs. 6.2A and 6.2B).  CN-BA-Me exhibited minimal induction in cells transfected 
with PPARγ-GAL4/pGAL4 and no induction was observed in Panc-28 cells transfected 
with PPRE3-luc (data not shown).  These results were observed in replicate experiments 
suggesting that there were structure-dependent differences (CN-BA vs. CN-BA-Me) for 
 activation of the PPARγ-GAL4/pGAL4 or a PPRE3-luc constructs in Panc-28 (but not 
SW480) cells.  
 PPARγ agonists are structurally-diverse and induce tissue-specific receptor-
dependent responses that are typical of selective PPARγ modulators (659, 660).  Similar  
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Fig. 6.2. Activation of PPARγ in SW480 and Panc-28 cells by BA, CN-BA and CN-BA-
Me.  SW480 cells [(A) and (B)] were transfected with PPARγ-GAL4/pGAL4 or PPRE3-
luc treated with DMSO (control) or different concentrations of the compounds, and 
luciferase activity determined as described in the Materials and Methods.  (C) Activation 
of PPARγ in Panc-28 cells.  Cells were transfected with PPARγ-GAL4/pGAL4 or 
PPRE3-luc treated with DMSO or different concentrations of CN-BA and CN-BA-Me 
alone or in combination with 10 μM T007, and luciferase activity determined as 
described in the Materials and Methods.  Results in (A) - (C) are expressed as means ± 
SE for three replicate determinations for each treatment group, and significant (p < 0.05) 
induction by the BA derivatives (*) and inhibition after cotreatment with T007 (**) are 
indicated.  For studies in Panc-28 cells, we only observed induction of luciferase activity 
using CN-BA and not with CN-BA-Me or BA over several sets of experiments.  (D) 
Mammalian two-hybrid assay in SW480 cells transfected with VP-PPARγ and GAL4-
coactivator chimeras.  SW480 cells were transfected with VP-PPARγ, coactivator-
GAL4/pGAL4, treated with different concentrations of CN-BA or CN-BA-Me and 5 μM 
β-CDODA-Me, and luciferase activity was determined as described in the Materials and 
Methods.  Results are expressed as means ± SE for three replicate determinations for 
each treatment group, and significant (p < 0.05) induction is indicated by an asterisk. 
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 Fig 6.2 Continued 
 
results have been observed for agonists that bind and activate other nuclear receptors and 
this structure-dependent effect is due, in part, to tissue-specific expression of  
coactivators and other nuclear proteins that exhibit ligand structure-dependent 
interactions with receptors.  Results in Figure 6.3D summarize the effects of CN-BA and 
CN-BA-Me on induction of luciferase activity in SW480 cells transfected VP-PPARγ 
and GAL4-co-activator and GAL4-SMRT (a co-repressor) expression plasmids.  We 
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used β-CDODA-Me, a triterpenoid methyl ester derivative which also contains a 2-
cyano-1-en-3-one function (Fig. 1.19) and activates PPARγ in colon cancer cells (312), 
as a comparative reference compound for the mammalian two-hybrid assay.  The results 
show that CN-BA, CN-BA-Me and β-CDODA-Me significantly induced luciferase 
activity in SW480 cells transfected with VP-PPARγ and GAL4-PGC-1 and GAL4-SRC-
1, but not GAL4-AIB1, GAL4-TIFII, GAL4-TRAP220 and GAL4-SMRT.  In contrast, 
only CN-BA-Me also activated GAL4-CARM1 indicating differences between CN-BA  
and CN-BA-Me in the mammalian two-hybrid assay, suggesting that even among these 
two acid-ester analogs, some tissue-specific selective PPARγ modulator activity might 
be expected.  The data are consistent with the differences observed for CN-BA and CN-
BA-Me in activation of transfected constructs in Panc-28 cells (Fig. 6.2C). 
 Previous studies in this laboratory have shown that PPARγ agonists induce p21 
and p27 and decrease cyclin D1 expression in Panc-28 cells, and only the former 
response is receptor dependent (297).  Results in Figure 6.3 C show that both CN-BA 
and CN-BA-Me induce p21 protein expression in Panc-28 cells, and this is also 
accompanied by induction of p27 and downregulation of cyclin D1 (data not shown) as 
previously reported for a series of PPARγ-active methylene-substituted 
diindolylmethanes (C-DIM) analogs in this cell line (297).  Cotreatment of Panc-28 cells 
with 5 μM CN-BA and CN-BA-Me plus the 10 μM T007 significantly inhibited 
induction of p21, confirming that induction of p21 was PPARγ-dependent (Fig. 6.3A).  
In contrast, induction of p21 by BA was not inhibited after cotreatment with T007 and 
this was consistent with results of transactivation studies showing that BA does not 
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activate PPARγ in Panc-28 or SW480 (Fig. 6.2).  Figure 6.3B shows that BA, CN-BA 
and CN-BA-Me induce transactivation in Panc-28 cells transfected with p21-luc(Fl)  
DMSO 2.5 5 7.51
CN-BA(µM)
Panc -28
p21
β-Actin
DMSO 2.5 5 7.51
CN-BA-Me (µM)
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A
 
     Fig. 6.3. Induction of p21 by BA, CN-BA and CN-BA-Me in Panc-28 cells.  (A)  
Induction of p21 protein.  Panc-28 cells were treated with the different compounds as 
indicated for 24 hr, and whole cell lysates were obtained and analyzed by immunoblots 
as described in the Materials and Methods.  Induction of p21-luc (B) and p21 deletion 
constructs (C) in Panc-28 cells.  Cells were transfected with the various constructs, 
treated with DMSO, BA, CN-BA, CN-BA-Me alone or in combination with T007, and 
luciferase activity determined as described in the Materials and Methods.  Results of all 
transactivation studies in this Figure are presented as means ± SE for at least three 
separate determinations for each treatment group.  Significant (p < 0.05) induction 
compared to solvent (DMSO) control (*) and inhibition by cotreatment with T007 (**) 
are indicated.  (D) Chromatin immunoprecipitation assays.  Primers designed for the 
proximal region of the p21 promoter (i) were used for a ChIP assay in Panc-28 cells (ii) 
treated with DMSO, 5 μM BA, 5 μM CN-BA, and 5 μM CN-BA-Me for 1 or 2 hr.  
Analysis of interactions of Sp1 and PPARγ with the p21 promoter were carried out in the 
ChIP assay as described in the Materials and Methods.  The ChIP assay was also used to 
examine binding of TFIIB to the GAPDH promoter (positive control) (iii) and to exon 1 
of CNAP1 (negative control) as described in the Materials and Methods. 
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which contains the -2325 to +8 region of the p21 promoter.  In cells cotreated with BA 
and related compounds plus the PPARγ antagonist T007, the induction of luciferase 
activity by CN-BA and CN-BA-Me was inhibited, whereas BA-induced activity was 
unaffected by T007.  The results complement the immunoblot data confirming that 
induction of p21 by CN-BA/CN-BA-Me was PPARγ-dependent, whereas induction of 
p21 by BA was PPARγ-independent.  We further investigated induction of luciferase 
activity in Panc-28 cells transfected with constructs containing -2325 to +8 [p21-Luc 
(Fl)], -124 to +8 [p21-Luc (-124)], -101 to +8 [p21-Luc (-101)], and -60 to +8 [p21-Luc 
(-60)] p21 promoter inserts.  The latter three constructs contain the 6 proximal GC rich 
sites (1 - 6) and the results of the transfection studies suggest that these GC-rich sites are 
necessary for CN-BA- and CN-BA-Me-induced transactivation.  Deletion analysis of the 
p21 promoter indicated that loss of inducibility [i.e. p21-luc(60)] was associated with 
loss of GC-rich sites 3 and 4, whereas CN-BA significantly induced activity but only at 
the 7.5 μM concentration, suggesting sites 3 and 4 were also important for this 
compound but induction could also be observed using constructs containing only GC-
rich sites 1 and 2.  Previous studies show that PPARγ-dependent activation of p21 by 
other PPARγ agonists is also dependent on GC-rich sites 3 and 4 and involves 
PPARγ/Sp-dependent activation of p21.  The ligand-dependent recruitment of PPARγ to 
the p21 promoter by CN-BA and CN-BA-Me was further investigated in a ChIP assay in 
Panc-28 cells treated with the BA, CN-BA and CN-BA-Me for 1 or 2 hr.  The results 
  
 
215
(Fig. 6.3D) show that both CN-BA and CN-BA-Me recruited PPARγ to the proximal 
GC-rich region of the p21 promoter and this was also accompanied by enhanced binding 
 experiment, transcription factor TFIIb bound to the proximal region of the GAPDH 
gene promoter but not to exon-1 of the CNAP1 gene. 
 PPARγ agonists such as CDDO, β-CDODA and related esters and PPARγ-active 
C-DIMs also induce receptor-dependent expression of caveolin-1 in colon cancer cells 
(300-302, 312).  Figure 6.4A shows that CN-BA, CN-BA-Me but not BA induce 
caveolin-1 in HT-29 cells and similar results were observed in HCT-15 cells (Fig. 6.4B).  
In contrast, BA, CN-BA and CN-BA-Me did not induce caveolin-1 expression in 
SW480 cells, and the latter two compounds decreased expression of this protein (Fig. 
6.4C).  Cotreatment of HT-29 and HCT-15 cells with CN-BA/CN-BA-Me plus the 
PPARγ antagonist T007 resulted in inhibition of the induced caveolin-1 response, 
confirming that induction was PPARγ-dependent (Fig. 6.4D).  Thus, receptor-dependent 
activation of caveolin-1 by CN-BA and CN-BA-Me was dependent on cell context and 
this of Sp1.  In contrast, BA did not induce PPARγ interactions with the p21 promoter in 
the ChIP assay.  This is consistent with receptor-independent activation of p21 by BA 
and the mechanism of this response is currently being investigated.  As a control for this 
correlated with results of previous studies with CDDO and the 18α and 18β-isomers of 
CDODA-Me where CDDO and α-CDODA-Me but not β-CDODA-Me induced 
caveolin-1 in HT-29 and SW480 cells, whereas like CN-BA/CN-BA-Me, β-CDODA 
induced caveolin-1 in HT-29 but not in SW480 cells. Previous studies showed that α- 
and β-CDODA-Me induced the tumor suppressor gene KLF-4 in HT-29 and SW480 
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colon cancer cells (312), and the results in Figure 6.5 summarize the effects of CN-BA 
and CN-BA-Me on KLF4 expression in HT-29 and SW480 cells.  In the former cell line, 
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Fig. 6.4. Induction of caveolin-1 expression in colon cancer cells.  HT-29 (A), HCT-15 
(B) and SW480 (C) cells were treated with DMSO, different concentrations of BA, CN-
BA or CN-BA-Me for 72 hr.  Caveolin-1 expression was determined by Western blot 
analysis as described in the Materials and Methods.  Similar results were observed in 
replicate experiments.  (D) Effects of T007 on induction of caveolin-1.  HCT-15 or HT-
29 cells were treated with DMSO or different concentrations of CN-BA and CN-BA-Me 
alone or in combination with 5 μM T007 and caveolin-1 expression was determined by 
Western blot analysis as described in the Materials and Methods. 
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CN-BA and CN-BA-Me induced KLF4 mRNA levels and similar results were observed 
for β-CDODA-Me which was used as a positive control for this cell line.  However, in 
HT-29 cells cotreated with CN-BA, CN-BA-Me and β-CDODA-Me plus the PPARγ 
antagonist T007, induction of KLF4 was significantly decreased only for β-CDODA-
Me.  In contrast, CN-BA and CN-BA-Me did not induce KLF4 expression in SW480 
cells, whereas β-CDODA-Me treatment  enhanced KLF4 mRNA as previously described 
(312).  The differences between CN-BA/CN-BA-Me and β-CDODA-Me as inducers of 
KLF4 mRNA levels in colon cancer cells clearly distinguished between two classes of 
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Fig. 6.5. Induction of KLF4 gene expression apoptosis by BA and related compounds.  
Induction of KLF4 in HT-29 (A) and SW480 (B) cells.  Cells were treated with different 
concentrations of CDODA isomers or T007 alone or in combination, and KLF4 mRNA 
levels were determined by real time PCR as described in the Materials and Methods.  
Each experiment was replicated (> 3X) and T007 did not inhibit KLF4 mRNA induction 
by BA, CN-BA and CN-BA-Me, whereas 60-80% of the response induced by β-
CDODA-Me was inhibited by T007.  KLF4 mRNA levels were not induced in SW480 
cells by BA derivatives.  (C) Induction of apoptosis.  Cells were treated for 24 hr with 
BA and related compounds, and whole cell lysates were examined by Western blot 
analysis as described in the Materials and Methods. 
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 structurally related PPARγ agonists derived from triterpenoid acids and confirm that 
CN-BA/CN-BA-Me are a novel class of PPARγ antagonists.  In addition, we also 
confirmed that BA/CN-BA induced apoptosis in SW480 and Panc28 cells, and results in 
Figure 6.5C show that both compounds induced caspase-dependent PARP cleavage in 
these cell lines. 
  
 
220
DISCUSSION 
 PPARγ is overexpressed in tumors from multiple tissues and cell lines (283) and 
PPARγ agonists are being developed as mechanism-based drugs for cancer 
chemotherapy.  PPARγ agonists typically inhibit cancer cell growth and this is 
associated with induction of p21 and/or p27 and downregulation of cyclin D1 and cells 
treated with these compounds also exhibit morphological and biochemical features of 
apoptosis.  The mechanisms of the growth inhibitory/pro-apoptotic responses induced by 
different structural classes of PPARγ agonists are cell context and gene-dependent, and 
induction of both receptor-dependent and -independent responses are observed.  For 
example, the thiazolidinedione troglitazone induces non-steroidal inflammatory drug-
activated gene-1 (NAG-1) in HCT-116 colon cancer cells through receptor-independent 
activation of kinase pathways, whereas induction of NAG-1 by 15-deoxy-Δ12,14-
prostaglandin J2 in HCT-116 cells is PPARγ-dependent and inhibited by PPARγ 
antagonist (278, 665, 694).  PPARγ-active C-DIMs induce caveolin-1 expression in HT-
29 and HCT-15 colon cancer cells, whereas rosiglitazone induced caveolin-1 only in the 
former cell lines (300).  The induction responses by both compounds were inhibited by 
PPARγ antagonists and cell context-dependent differences of C-DIMs and rosiglitazone 
in HCT-15 cells were associated with expression of mutant PPARγ (K422Q) in this cell 
line  and the mutant receptor was insensitive to rosiglitazone (301). 
 CDDO and its related methyl ester and imidazole derivatives are PPARγ agonists 
(234, 302) and are potent anticancer drugs currently undergoing clinical trials.  These 
triterpenoid acid derivatives of oleanolic acid, a phytochemical used in  traditional 
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medicine induce multiple receptor-independent and some receptor-dependent responses 
including the receptor-dependent induction of caveolin-1 in colon cancer cells (302).  
Although oleanolic acid is only weakly cytotoxic to cancer cells, the introduction of the 
2-cyano-substituted 1-en-3-oxo moiety into the A-ring of oleanolic acid greatly 
enhanced the cytotoxicity of the resulting 2-cyano derivatives including CDDO which 
also has an enone system in the C-ring (655) (463, 464) and similar results were 
observed for the corresponding 2-cyano derivatives of glycyrrhetinic acid, namely α-
CDODA and β-CDODA-Me (312).  Moreover, in studies with glycyrrhetinic acid 
analogs, it was shown that the 2-cyano group was required for PPARγ agonist activity.   
 The major structural differences between betulinic acid and oleanolic and 
glycyrrhetinic acids are their 5 and 6-member E-rings, respectively, and the position of 
substituents in this ring.  However, despite these structural differences, introduction of 
the 2-cyano-1-ene-3-oxo system into the A-ring of betulinic acid gave CN-BA which 
activated PPARγ in both SW480 and Panc-28 cell lines (Figs. 6.1 and 6.2) and enhanced 
the cytotoxicity of these compounds compared to BA (1.19).  Surprisingly, CN-BA-Me 
activated PPARγ-GAL4/pGAL4 and PPRE-luc in SW480 but was much less effective in 
activating these constructs in Panc-28 cells, and these cell context-dependent differences 
in CN-BA and CN-BA-Me suggest that these compounds may be selective PPARγ 
agonists.   
 Selective receptor modulators exhibit tissue-selective receptor agonist activities 
and differences between diverse structural classes of these compounds can be discerned 
in mammalian two-hybrid assays using VP-PPAR and GAL4-coactivator chimeras (300, 
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302, 312).  This assay has some relevance for identifying selective receptor modulators 
since differences between selective receptor modulators may be due, in part, to their 
interaction with coactivator proteins.  Induction of luciferase activity in colon cancer 
cells transfected with VP-PPARγ/GAL4-coactivator constructs is dependent on the 
coactivator and structure of the PPARγ agonist (300, 302, 312).  C-DIM PPARγ agonists 
induce transactivation in cells transfected with GAL4-PGC-1 (300), whereas CDDO and 
CDDO-Me are active in cells transfected with GAL4-chimeras containing SRC-1, SRC-
2 (TIFII), SRC-3 (A1B1), TRAP220, PGC-1 and CARM-1 (302).  β-CDODA and α-
CDODA-Me activate GAL4-chimeras containing PGC-1 and SRC-1 and PGC-1 and 
SRC-2, respectively (312).  CN-BA activates GAL4-chimeras containing PGC-1 and 
SRC-1 in SW480 cells and resembles β-CDODA-Me, whereas CN-BA-Me activates 
PGC-1, SRC-1 and CARM-2 (Fig. 6.2D), whereas these compounds did not activate 
GAL4 chimeras containing SRC-2, TRAP220 or SMRT (data not shown).  The unique 
pattern for CN-BA-Me in the mammalian two-hybrid assay highlights differences that 
are dependent only on methylation of the 20-carboxyl group in the E-ring, and these 
results are consistent with differences between CN-BA and CN-BA-Me in their 
activation of transfected PPARγ-responsive constructs in Panc-28 cells (Fig.6.2C). 
 The PPARγ agonist activities of CN-BA and CN-BA-Me and their role as 
selective receptor modulators were further investigated using four receptor-mediated 
responses, namely (i) the induced differentiation of 3T3-L1 adipocytes, (ii) induction of 
the cyclin-dependent kinase inhibitor p21 in Panc-28 cells, and the induction of (iii) 
caveolin-1 and (iv) KLF4 in colon cancer cells.  Both CN-BA and CN-BA-Me induced 
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differentiation of 3T3-L1 adipocytes and this was characterized by accumulation of fat 
droplets which are visualized by Oil-red O staining (Fig. 6.1D).  Previous studies 
showed that PPARγ-active C-DIMs induced p21 expression in Panc-28 cells and this 
response was associated with interactions of PPARγ with the proximal GC-rich region of 
the p21 promoter (297).  Similar results were obtained for both CN-BA and CN-BA-Me 
which induced p21 expression in Panc-28 cells and reporter gene activity in cells 
transfected with p21-luc(F1), and both responses were inhibited after cotreatment with 
PPARγ antagonist T007 (Fig. 6.3A).  Deletion analysis of the p21 promoter suggested 
that for CN-BA-Me, GC-rich sites 3 and 4 were required for activation of p21, whereas 
CN-BA also induced activity with p21-luc (60) which only contained GC-rich sites 1 
and 2.  Nevertheless, sites 3 and 4 appear to play an important role for both CN-BA-Me 
and CN-BA, and these same sites were also required for PPARγ-dependent activation of 
p21 by C-DIMs (297).  It has also previously been reported that progesterone receptor 
and androgen receptor agonists induce p21 through receptor-Sp protein interactions with 
GC-rich sites 3 and 4 and site 3, respectively (801, 802), suggesting that these GC-rich 
sites in the p21 promoter are important targets for nuclear receptors.  We also showed 
that BA induced PPARγ-independent activation of p21, and the differences between BA 
vs. CN-BA/CN-BA-Me are evident not only after treatment with the PPARγ antagonist 
T007 (Figs. 6.3A and 6.3B), but also in the recruitment of PPARγ to the p21 promoter 
by CN-BA/CN-BA-Me but not BA in a ChIP assay in Panc-28 cells (Fig. 6.3D).   
 In a recent study with the 18α and 18β isomers of CDODA, we showed that both 
compounds induced caveolin-1 in HT-29 and HCT-15 cells, whereas only α-CDODA-
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Me induced caveolin-1 in SW480 cells (312).  These results suggested that in SW480 
cells the stereochemistry at C-18 of CDODA which influences the confirmation of the E-
ring also differentially affected PPARγ-dependent activation of caveolin-1.  CN-BA and 
CN-BA-Me but not BA induced caveolin-1 in HT-29 and HCT-15 cells and cotreatment 
with the PPARγ antagonist T007 inhibited the induction response (Fig. 6.5).  In contrast, 
CN-BA and CN-BA-Me do not induce caveolin-1 in SW480 cells as previously 
observed for 18β isomer of CDODA; however, the stereochemistry at C-18 for the BA 
derivatives is α, suggesting that the cell context-dependent activation of caveolin-1 by 
the cyano-substituted triterpenoid acids is not only dependent on the stereochemistry at 
C-18 but also the structure of the E-ring.  The presence of the 5-membered E-ring with 
carboxy and isopropyl substituents (Fig. 1.19) resulted in loss of PPARγ-dependent 
induction of caveolin-1 in SW480 cells by CN-BA and CN-BA-Me and this cell context-
dependent response was consistent with the activity of these compounds as selective 
receptor modulators.  The cytotoxicity of BA and CN-BA derivatives (Fig. 6.1) was due 
not only to growth inhibition but also to induction of apoptosis (Fig. 6.5C) which was 
not inhibited by PPARγ antagonists (data not shown), suggesting a receptor-independent 
proapoptotic pathway which is currently being investigated. 
 The CDODA-Me compound induced the tumor suppressor gene KLF4 in SW480 
and HT-29 colon cancer cells, and this response was inhibited by T007 (312).  In 
contrast, CN-BA/CN-BA-Me did not induce KLF4 mRNA in SW480 cells and induction 
of this gene in HT-29 cells was receptor independent.  These data, coupled with the 
effects of the cyano-substituted compounds on transactivation in the mammalian two-
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hybrid and reporter gene assays, adipocyte differentiation, p21 and caveolin-1 
expression demonstrate that CN-BA and CN-BA-Me represent a novel class of selective 
PPARγ agonists in colon an pancreatic cancer cells.  The concentration-dependent 
differences in the activation of p21 and PPARγ-GAL4/PPRE3-luc (≥ 2.5 μM) and 
induction of Oil Red O staining and caveolin-1 (≤ 0.5 μM) may be due, in part, to 
relatively short (24 hr) and longer (72 - 120 hr) treatment times, respectively.  However, 
differences in gene-responsiveness may also be due to other nuclear proteins and 
competition by receptor complexes bound to response elements on different gene 
promoters for common nuclear cofactors.  The activities of CN-BA and CN-BA-Me 
coupled with their cytotoxicity (Fig. 6.1) suggest that the receptor-dependent and -
independent responses induced by these compounds will be advantageous for further 
development of these compounds for clinical applications in the treatment of colon and 
pancreatic cancer. 
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CHAPTER VII 
SUMMARY 
 Glycyrrhizin, a pentacyclic triterpene glycoside, is the major phytochemical in 
licorice and this compound and its hydrolysis product glycyrrhetinic acid (GA) have 
been associated with the multiple therapeutic properties of licorice extracts. We have 
investigated the effects of 2-cyano substituted analogs of GA on their cytotoxicities and 
activity as selective peroxisome proliferator-activated receptor γ (PPARγ) agonists.  
Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (β-CDODA-Me) and methyl 
2-cyano-3,11-dioxo-18α-olean-1,12-dien-30-oate (α-CDODA-Me ) were more cytotoxic 
to colon cancer cells than their des-cyano analogs and introduction of the 2-cyano group 
into the pentacyclic ring system was necessary for the PPARγ agonist activity of α- and 
β-CDODA-Me isomers.  However, in mammalian two-hybrid assays, both compounds 
differentially induced interactions of PPARγ with coactivators, suggesting that these 
isomers, which differ only in the stereochemistry at C18 (D/E ring junction), are 
selective receptor modulators.  This selectivity in colon cancer cells was demonstrated 
for the induction of two proapoptotic proteins, namely caveolin-1 and the tumor 
suppressor gene Krüppel-like factor-4 (KLF-4).  β-CDODA-Me but not α-CDODA-Me 
induced caveolin-1 in SW480 colon cancer cells, whereas caveolin-1 was induced by 
both compounds in HT-29 and HCT-15 colon cancer cells.  The CDODA-Me isomers 
induced KLF-4 mRNA levels in HT-29 and SW480 cells but had minimal effects on 
KLF-4 expression in HCT-15 cells.  These induced responses were inhibited by 
cotreatment with a PPARγ antagonist.  This demonstrates for the first time that PPARγ 
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agonists derived from GA induced cell-dependent caveolin-1 and KLF-4 expression 
through receptor-dependent pathways.   
 β-CDODA-Me inhibited growth of RKO and SW480 colon cancer cells and this 
was accompanied by decreased expression of Sp1, Sp3 and Sp4 protein and mRNA and 
several Sp-dependent genes including survivin, VEGF, and VEGFR receptor 1 
(VEGFR1 or Flt-1).  β-CDODA-Me also induced apoptosis, arrested RKO and SW480 
cells at G2/M, and inhibited tumor growth in athymic nude mice bearing RKO cells as 
xenografts.  β-CDODA-Me decreased expression of microRNA-27a (miR-27a), and this 
was accompanied by increased expression of two miR-27a-regulated mRNAs, namely 
ZBTB10 (an Sp repressor) and Myt-1 which catalyzes phosphorylation of cdc2 to inhibit 
progression of cells through G2/M.  Both β-CDODA-Me and antisense miR-27a induced 
comparable responses in RKO and SW480 cells, suggesting that the potent 
anticarcinogenic activity of β-CDODA-Me is due to downregulation of oncogenic miR-
27a. 
β-CDODA-Me was also a potent inhibitor of LNCaP prostate cancer cell growth 
(IC50 ~ 1 μM) and activated peroxisome proliferator-activated receptor γ (PPARγ), β-
CDODA-Me induced p21 and p27 and downregulated cyclin D1 protein expression and 
also induced two other proapoptotic proteins, namely NAG-1 and ATF-3.  However, 
induction of these responses by β-CDODA-Me was PPARγ-independent and due to 
activation of phosphatidylinositol-3-kinase (PI3K), mitogen activated protein kinase 
(MAPK), and jun N-terminal kinase (JNK) pathways by this compound.  In contrast, β-
CDODA-Me also decreased androgen receptor (AR) and prostate specific antigen (PSA) 
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mRNA and protein levels through kinase-independent pathways.  β-CDODA-Me 
repressed AR mRNA transcription, whereas decreased PSA mRNA levels were 
dependent on protein synthesis and was reversed by cycloheximide.  Thus, potent 
inhibition of LNCaP cell survival by β-CDODA-Me is due to PPARγ-independent 
activation of multiple pathways that selectively activate growth inhibitory and 
proapoptotic responses. 
Betulinic acid (BA) is a pentacyclic triterpene natural product  initially identified 
as a melanoma-specific cytotoxic agent which exhibits low toxicity in animal models.  
Subsequent studies show that BA induces apoptosis and antiangiogenic responses in 
tumors derived from multiple tissues; however, the underlying mechanism of action is 
unknown.  Using LNCaP prostate cancer cells as a model, we now show that BA 
decreases expression of vascular endothelial growth (VEGF) and the antiapoptotic 
protein survivin.  The mechanism of these BA-induced antiangiogenic and proapoptotic 
responses in both LNCaP cells and in tumors is due to activation of selective 
proteasome-dependent degradation of the specificity protein 1 (Sp1), Sp3 and Sp4 
transcription factors which regulate VEGF and survivin expression.  Thus, BA acts as a 
novel anticancer agent through targeted degradation of Sp proteins which are highly 
overexpressed in tumors. We modified the A-ring of BA to give a 2-cyano-1-en-3-one 
moiety and the effects of the 2-cyano derivative of BA (CN-BA) and its methyl ester 
(CN-BA-Me) were investigated in colon and pancreatic cancer cells.  Both CN-BA and 
CN-BA-Me were highly cytotoxic to Panc-28 pancreatic and SW480 colon cancer cells.  
CN-BA and CN-BA-Me also induced differentiation in 3T3-L1 adipocytes which 
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exhibited a characteristic fat droplet accumulation induced by peroxisome proliferator-
activated receptor γ (PPARγ) agonists.  Based on these results, we investigated the 
activities of CN-BA and CN-BA-Me as PPARγ agonists using several receptor-mediated 
responses including activation of transfected PPARγ-responsive constructs, induction of 
p21 in Panc-28 cells, and induction of caveolin-1 and Krüppel-like factor 4 in colon 
cancer cells.  The results clearly demonstrated that both CN-BA and CN-BA-Me 
activated PPARγ-dependent responses in colon (caveolin-1) and pancreatic (p21) cells, 
whereas induction of KLF4 by these compounds in colon cancer cells was PPARγ-
independent and also dependent on cell context.  The PPARγ agonist activities of CN-
BA and CN-BA-Me were structure-, response-/gene- and cell context-dependent 
suggesting that these compounds are a novel class of selective PPARγ modulators with 
potential for clinical treatment of colon and pancreatic cancer. 
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